CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</title><meta name="description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta property="og:url" content="https://www.ajmc.com/compendium/cll "/><meta property="og:title" content="Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"/><meta property="og:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta property="og:site_name" content="AJMC"/><meta property="og:description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"/><meta name="twitter:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta name="twitter:site" content="@@AJMC_Journal"/><meta name="twitter:description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.ajmc.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", dimension9: "compendium/cll", dimension11: "", dimension12: "", dimension13: "", dimension14: "", dimension15: "compendium/cll", dimension18: "", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NK5KQXS'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.ajmc.com/compendium/cll"/><meta name="next-head-count" content="10"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <link rel="preload" href="/_next/static/css/93f9ef4c3d7e4e35.css" as="style"/><link rel="stylesheet" href="/_next/static/css/93f9ef4c3d7e4e35.css" data-n-g=""/><link rel="preload" href="/_next/static/css/88b2d00f7c97cf96.css" as="style"/><link rel="stylesheet" href="/_next/static/css/88b2d00f7c97cf96.css" data-n-p=""/><link rel="preload" href="/_next/static/css/73c00cd95dc66651.css" as="style"/><link rel="stylesheet" href="/_next/static/css/73c00cd95dc66651.css" data-n-p=""/><link rel="preload" href="/_next/static/css/0f1de527bcd6b2b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0f1de527bcd6b2b3.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-ad8343792a395beb.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-27978c591df7a592.js" defer=""></script><script src="/_next/static/chunks/8eec4907-3e083fdcb8f62d72.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/72585f70-d02c41699ad6afb6.js" defer=""></script><script src="/_next/static/chunks/59b4e022-07228b5f1b83aaf8.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e893f787-08b93252db7fc864.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/c8eae200-9f0c2beb62006a40.js" defer=""></script><script src="/_next/static/chunks/a29ae703-70c961c34719afa8.js" defer=""></script><script src="/_next/static/chunks/4592-37f767f9d2e595fc.js" defer=""></script><script src="/_next/static/chunks/1212-e69ee8c76b24c02a.js" defer=""></script><script src="/_next/static/chunks/4179-91956f2d2c4bf724.js" defer=""></script><script src="/_next/static/chunks/9879-c84885d45ee98d34.js" defer=""></script><script src="/_next/static/chunks/9355-c793747e2dd7fab4.js" defer=""></script><script src="/_next/static/chunks/3499-b4daf1c9382343af.js" defer=""></script><script src="/_next/static/chunks/6063-bbb1fdc15e518c3d.js" defer=""></script><script src="/_next/static/chunks/8421-a4cb4c694745bc83.js" defer=""></script><script src="/_next/static/chunks/3320-350cc08e721d74f9.js" defer=""></script><script src="/_next/static/chunks/430-ec5773e97694cd78.js" defer=""></script><script src="/_next/static/chunks/2480-79475d7513ce93a1.js" defer=""></script><script src="/_next/static/chunks/7707-1da2c55d66608b06.js" defer=""></script><script src="/_next/static/chunks/475-8933b8b0e2730387.js" defer=""></script><script src="/_next/static/chunks/9323-fbb62165c37c2d73.js" defer=""></script><script src="/_next/static/chunks/8965-8b53cc894e020425.js" defer=""></script><script src="/_next/static/chunks/2773-a05d436f7b457fd1.js" defer=""></script><script src="/_next/static/chunks/pages/%5B...slug%5D-88ccbf8d6ba56d13.js" defer=""></script><script src="/_next/static/br828rKgKfSPtzyqAf35K/_buildManifest.js" defer=""></script><script src="/_next/static/br828rKgKfSPtzyqAf35K/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-1215160397">.bottomDiv.jsx-1215160397{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1215160397::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1215160397::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1215160397{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1215160397{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1215160397{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0undefined.jsx-1215160397:hover{background:var(--secondary)}.view-more-wrap0undefined.jsx-1215160397{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0undefined.jsx-1215160397:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1215160397{background-position:right bottom}.text-white.jsx-1215160397{color:var(--primary)}</style><style id="__jsx-1637274924">.bottomDiv.jsx-1637274924{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1637274924::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1637274924::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1637274924{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1637274924{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1637274924{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore1undefined.jsx-1637274924:hover{background:var(--secondary)}.view-more-wrap1undefined.jsx-1637274924{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap1undefined.jsx-1637274924:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1637274924{background-position:right bottom}.text-white.jsx-1637274924{color:var(--primary)}</style><style id="__jsx-286612495">.bottomDiv.jsx-286612495{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-286612495::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-286612495::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-286612495{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-286612495{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-286612495{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2undefined.jsx-286612495:hover{background:var(--secondary)}.view-more-wrap2undefined.jsx-286612495{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2undefined.jsx-286612495:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-286612495{background-position:right bottom}.text-white.jsx-286612495{color:var(--primary)}</style><style id="__jsx-2915913710">.bottomDiv.jsx-2915913710{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2915913710::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2915913710::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2915913710{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2915913710{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2915913710{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore3undefined.jsx-2915913710:hover{background:var(--secondary)}.view-more-wrap3undefined.jsx-2915913710{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap3undefined.jsx-2915913710:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2915913710{background-position:right bottom}.text-white.jsx-2915913710{color:var(--primary)}</style><style id="__jsx-2363373513">.bottomDiv.jsx-2363373513{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2363373513::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2363373513::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2363373513{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2363373513{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2363373513{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore4undefined.jsx-2363373513:hover{background:var(--secondary)}.view-more-wrap4undefined.jsx-2363373513{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap4undefined.jsx-2363373513:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2363373513{background-position:right bottom}.text-white.jsx-2363373513{color:var(--primary)}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-2785488040">.bottomDiv.jsx-2785488040{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2785488040::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2785488040::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2785488040{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2785488040{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2785488040{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore5undefined.jsx-2785488040:hover{background:var(--secondary)}.view-more-wrap5undefined.jsx-2785488040{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap5undefined.jsx-2785488040:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2785488040{background-position:right bottom}.text-white.jsx-2785488040{color:var(--primary)}</style><style id="__jsx-1434825611">.bottomDiv.jsx-1434825611{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1434825611::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1434825611::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1434825611{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1434825611{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1434825611{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore6undefined.jsx-1434825611:hover{background:var(--secondary)}.view-more-wrap6undefined.jsx-1434825611{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap6undefined.jsx-1434825611:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1434825611{background-position:right bottom}.text-white.jsx-1434825611{color:var(--primary)}</style><style id="__jsx-4064126826">.bottomDiv.jsx-4064126826{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-4064126826::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-4064126826::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-4064126826{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-4064126826{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-4064126826{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore7undefined.jsx-4064126826:hover{background:var(--secondary)}.view-more-wrap7undefined.jsx-4064126826{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap7undefined.jsx-4064126826:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-4064126826{background-position:right bottom}.text-white.jsx-4064126826{color:var(--primary)}</style><style id="__jsx-187450181">.bottomDiv.jsx-187450181{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-187450181::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-187450181::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-187450181{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-187450181{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-187450181{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore8undefined.jsx-187450181:hover{background:var(--secondary)}.view-more-wrap8undefined.jsx-187450181{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap8undefined.jsx-187450181:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-187450181{background-position:right bottom}.text-white.jsx-187450181{color:var(--primary)}</style><style id="__jsx-609564708">.bottomDiv.jsx-609564708{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-609564708::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-609564708::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-609564708{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-609564708{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-609564708{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore9undefined.jsx-609564708:hover{background:var(--secondary)}.view-more-wrap9undefined.jsx-609564708{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap9undefined.jsx-609564708:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-609564708{background-position:right bottom}.text-white.jsx-609564708{color:var(--primary)}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 z-[999999]"><div class="h-full w-full"><nav role="navigation" class=" w-full mx-auto hidden lg:block bg-white shadow-md relative"><div class="bg-primary" id="topnav"><div class="container px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto "><div class="h-full flex items-center flex-1 justify-between mr-4"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></a><div class="hidden md:block"><div class="bg-primary py-2 whitespace-nowrap"><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 items-end"><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">News<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/news" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All News</a><a href="/press-release" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Press Releases</a><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Video<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/video-hub" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Video Types</a><a href="/interviews" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC TV</a><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a><a href="/insights" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insights</a><a href="/onlocation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">OnLocation</a><a href="/payer-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Payer Perspectives</a><a href="/peer-exchange" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Peer Exchange</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a><a href="/stakeholder-summit" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Stakeholder Summit</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/podcasts">Podcasts</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/latest-conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Coverage</a><a href="/conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Listing</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Journals<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/publications" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Journals</a><a href="/publications/issue" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">The American Journal of Managed Care</a><a href="/publications/ajac" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health, Equity & Outcomes</a><a href="/publications/evidence-based-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Evidence-Based Oncology</a><a href="/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">About Supplements and Featured Publications</a><a href="/publications/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Supplements and Featured Publications Issues</a><a href="/submit-a-manuscript" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Submit a Manuscript</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Events<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/ivbmevents" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Institute for Value-Based Medicine</a><a href="https://pcoc.ajmc.com/" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Patient-Centered Oncology Care</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/interactive-tools" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Interactive Tools</a><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary Central</a><a href="/clinical-spotlight" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Clinical Spotlight</a><a href="/custom-email" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Microsites</a><a href="/sponsored" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sponsored Content</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/continuing-education">CE</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">About AJMC<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/editorial" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC Staff</a><a href="/anniversary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Anniversary</a><a href="/about/seema-sonnad-nomination" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Seema Sonnad Award</a><a href="/partners" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Strategic Alliance Partners</a></div></div></div></div></div></div></div><div class="md:flex items-center justify-end hidden"><div class="flex items-center"><div class="md:pr-10 lg:pr-0 h-full flex items-center"><button class="w-6 h-6 relative"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button><div class="hidden bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center z-[99999] "><form method="GET" action="/search"><div class="relative"><div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg" class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search"/></div></form></div></div></div><a href="https://one.ajmc.com/subscribe" class="bg-subscribe-btn rounded text-white py-1.5 px-3 text-[14px] ml-4 uppercase font-semibold">Subscribe</a></div></div></div><div class="bg-white" id="bottomnav"><div style="max-height:60px" class="px-4 transition-all container justify-between h-14 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-row gap-2 mr-4"><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/allergy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Allergy</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a><a href="/compendium/rheumatoid-arthritis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatoid Arthritis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div><div class="flex flex-1 items-center gap-3 overflow-hidden justify-start"><span class="text-md font-semibold whitespace-pre !text-primary filter brightness-75">Spotlight</span><ul id="spotlight-links" class="flex gap-2 h-4 overflow-hidden flex-wrap"><li class="text-xs pt-0.5 whitespace-pre cursor-pointer hover:underline text-gray-800"><a href="/ivbmevents?display=home">Free In-Person Regional Events Focused on Oncology and Population Health</a></li></ul></div></div></div></div></nav><nav class="lg:hidden"><div class="w-full shadow-md bg-primary sticky top-0 z-40"><div class="flex mx-auto container"><div class=" py-4 flex items-stretch justify-between mx-4 items-center w-full"><div class="flex items-center justify-end"><div class="flex items-center"><div class="h-full flex items-center"><button id="menu" aria-label="open menu" aria-expanded="false" class="focus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md text-white"><svg width="30" height="30" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M21 10H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 6H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 14H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 18H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path></svg></button></div></div></div><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-10 w-40"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center" loading="lazy"/></noscript></span></a></div><div class="relative w-8 h-8 my grid items-center"><a class="absolute lg:hidden inset-0 mt-1" href="/search"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></a></div></div></div><div style="max-height:50px" class="bg-white px-4 transition-all h-12 md:items-stretch mx-auto" id="bottomnav-mobile"><div class="container justify-between h-12 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-1 justify-center xs:justify-start items-center relative group h-full z-50 gap-2"><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/allergy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Allergy</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a><a href="/compendium/rheumatoid-arthritis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatoid Arthritis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div></div></div></div></div><div class="fixed top-0 w-[85vw] h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg" id="mobile-nav"><div class="w-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out"><div class="px-5 h-full"><div class="flex flex-col justify-between h-full w-full"><div><div class="mt-6 flex w-full items-center justify-between"><div class="border-b border-gray-200 pb-2 flex items-center justify-between w-full"><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-16 w-40 "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></div><button aria-label="close menu" class="focus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold"><svg width="18" height="18" viewBox="0 0 14 14" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M13 1L1 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path><path d="M1 1L13 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path></svg></button></div></div><ul role="list" class="flex flex-1 flex-col gap-y-7 mt-6"><li><ul role="list" class="-mx-2 space-y-1"><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Spotlight</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>News</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Video</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/podcasts"><span>Podcasts</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Conferences</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Journals</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Events</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Resources</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/continuing-education"><span>CE</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>About AJMC</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="https://one.ajmc.com/subscribe"><span>Subscribe</span></a></li></ul></li></ul><div class="flex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t"><a rel="noreferrer noopener" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="21" height="21" viewBox="12.65 12.65 118.02 118.02"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z" fill="#FFFFFF"></path></g></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="27" width="27" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.instagram.com/ajmcjournal/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="/rss"></a></div></div></div></div></div></div></nav></div></div><div class="container top-ad-div px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><hr class="mt-8 pt-8 -mb-4 pb-0 customPageTopMargin"/><div id="cll" class="study-hall customPageFullWidthClass container mx-auto flex m-1 min-h-[57vh] px-4"><div class="customPageFullWidthClass flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="pb-24 my-2"><div class="flex"><h1 class="text-[19px] mt-1 md:mt-0 md:text-3xl mb-2">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h1><div class="flex justify-center px-0 -mt-1 sm:-mt-2 align-center"></div></div><div class="w-full mb-2 border border-secondary"></div><div id="description-summary" class="text-sm text-gray-500"><div class="blockText_blockContent__TbCXh"></div><div class="clear-both"></div></div><div class="border-b-[2px] border-[#EEE] "><div class="m-2"><div class="hidden xs:flex justify-between items-center"><h2 class="text-3xl">Latest News</h2></div><div class="xs:my-6 my-4 xs:block hidden"><div class="flex"><div class="flex sm:pr-[35px] pr-[20px] flex-col w-[40%] border-r-[2px] border-[#EEE]"><div class="lg:h-[220px] h-[170px] relative bg-default-logo-background "><a class="0 w-full" href="/view/immune-microenvironment-a-key-target-in-cll"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-contain" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-contain" loading="lazy"/></noscript></span></a></div><div class="border-t-gray-100 border-t-2 flex-auto py-2 "><span class="text-sm text-gray-500 py-2">April 8th 2025</span><div class="py-3"><a class="lg:text-[20px] text-[19px] font-[500]" href="/view/immune-microenvironment-a-key-target-in-cll">Immune Microenvironment a Key Target in CLL</a></div><div class="pb-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jared-kaltwasser"><i>Jared Kaltwasser</i></a></span></div></div><a href="/view/immune-microenvironment-a-key-target-in-cll"><a href="/view/immune-microenvironment-a-key-target-in-cll"><p class="mt-1 text-gray-800 text-[13px] line-clamp-6 text-hidden">A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). </p></a></a></div></div><div class="flex-wrap w-[60%] flex "><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/pharmacist-led-model-reduces-tumor-lysis-risk-in-cll-venetoclax-therapy"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/pharmacist-led-model-reduces-tumor-lysis-risk-in-cll-venetoclax-therapy"><span class="text-sm text-gray-500">April 3rd 2025</span></a><div><a class="text-[14px]" href="/view/pharmacist-led-model-reduces-tumor-lysis-risk-in-cll-venetoclax-therapy"><p class="line-clamp-4 text-hidden font-[500]">Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/in-cll-zanubrutinib-shows-better-safety-profile-than-ibrutinib"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/in-cll-zanubrutinib-shows-better-safety-profile-than-ibrutinib"><span class="text-sm text-gray-500">March 20th 2025</span></a><div><a class="text-[14px]" href="/view/in-cll-zanubrutinib-shows-better-safety-profile-than-ibrutinib"><p class="line-clamp-4 text-hidden font-[500]">In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/newer-cll-therapies-show-superior-long-term-disease-control"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/newer-cll-therapies-show-superior-long-term-disease-control"><span class="text-sm text-gray-500">March 19th 2025</span></a><div><a class="text-[14px]" href="/view/newer-cll-therapies-show-superior-long-term-disease-control"><p class="line-clamp-4 text-hidden font-[500]">Newer CLL Therapies Show Superior Long-Term Disease Control</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/modulating-cholesterol-metabolism-could-open-therapeutic-pathways-in-cll"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/modulating-cholesterol-metabolism-could-open-therapeutic-pathways-in-cll"><span class="text-sm text-gray-500">March 11th 2025</span></a><div><a class="text-[14px]" href="/view/modulating-cholesterol-metabolism-could-open-therapeutic-pathways-in-cll"><p class="line-clamp-4 text-hidden font-[500]">Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jared-kaltwasser"><i>Jared Kaltwasser</i></a></span></div></div></div></a></div></div></div><div class="xs:hidden block"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-full xs:my-6 my-4 #000 text-3xl">Latest News</div></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/immune-microenvironment-a-key-target-in-cll"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">April 8th 2025</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Immune Microenvironment a Key Target in CLL</p></div><div class="jsx-1215160397 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jared-kaltwasser"><i>Jared Kaltwasser</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/pharmacist-led-model-reduces-tumor-lysis-risk-in-cll-venetoclax-therapy"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">April 3rd 2025</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy</p></div><div class="jsx-1637274924 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/in-cll-zanubrutinib-shows-better-safety-profile-than-ibrutinib"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fde33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">March 20th 2025</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib</p></div><div class="jsx-286612495 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/newer-cll-therapies-show-superior-long-term-disease-control"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F93a174337b137846bb88ca7522afba78209a16dd-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">March 19th 2025</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Newer CLL Therapies Show Superior Long-Term Disease Control</p></div><div class="jsx-2915913710 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/hayden-e-klein"><i>Hayden E. Klein</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/modulating-cholesterol-metabolism-could-open-therapeutic-pathways-in-cll"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fe83905430236d6800bb84d2a61fb00c3bf27af05-1037x673.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">March 11th 2025</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL</p></div><div class="jsx-2363373513 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/jared-kaltwasser"><i>Jared Kaltwasser</i></a></span></div></div></div></div></a></div></div></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Series</div><a href="/video-series" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/future-directions-of-btk-inhibitors-in-leukemia-and-lymphoma"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">August 19th 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Future Directions of BTK Inhibitors in Leukemia and Lymphoma</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/patient-access-advocacy-for-btk-inhibitors"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">August 19th 2024</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Patient Access Advocacy for BTK Inhibitors</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/the-inflation-reduction-act-implications-for-patient-access-in-cl"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">August 12th 2024</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">The Inflation Reduction Act: Implications for Patient Access in CL </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/navigating-access-challenges-in-cll-treatment-strategies-for-overcoming-barriers"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">August 12th 2024</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers  </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/financial-challenges-of-btk-inhibitor-therapy-in-cll-impact-on-access-and-utilization"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">August 5th 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/combination-regimens-with-btk-inhibitors-new-frontiers-in-cll-treatment"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">August 5th 2024</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/decision-making-in-cll-the-role-of-real-world-evidence"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">July 29th 2024</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Decision-Making in CLL: The Role of Real-World Evidence </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/leveraging-maics-for-decision-making-in-cll-btk-inhibitor-selection"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">July 29th 2024</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-187450181 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/optimizing-therapy-sequencing-in-cll"><div class="jsx-187450181 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-187450181 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-187450181 content-wrap"><span class="jsx-187450181 py-3 text-sm text-gray-500 text-left"><i class="jsx-187450181">July 23rd 2024</i></span><div class="jsx-187450181 w-full h-fit mb-4"><p class="jsx-187450181 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Optimizing Therapy Sequencing in CLL </p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-609564708 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/empowering-patients-key-considerations-for-btk-inhibitor-adherence"><div class="jsx-609564708 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-609564708 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png%2FAJMC%2520wide.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-609564708 content-wrap"><span class="jsx-609564708 py-3 text-sm text-gray-500 text-left"><i class="jsx-609564708">July 23rd 2024</i></span><div class="jsx-609564708 w-full h-fit mb-4"><p class="jsx-609564708 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Empowering Patients: Key Considerations for BTK Inhibitor Adherence </p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Interviews</div><a href="/interviews" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/advancing-hematologic-care-and-the-future-of-shared-decision-making"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">January 24th 2025</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Advancing Hematologic Care and the Future of Shared Decision-Making</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/insights-on-allogeneic-hematopoietic-cell-transplantation-values-of-older-adult-patients"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">January 17th 2025</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/insights-on-multiple-myeloma-treatment-real-world-data-on-survivorship-burden-and-patient-preferences"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">January 10th 2025</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/insights-on-cll-and-sll-treatment-with-btk-inhibitors-patient-preferences-and-shared-decision-making"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">January 3rd 2025</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/unmet-needs-and-emerging-trends-in-hematologic-cancer-management-around-ash-2024"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png%2Fmarketing%2520image%2520(62).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">December 20th 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/exploring-the-efficacy-and-safety-of-ibrutinib-and-venetoclax-in-cll"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg%2FCLL%2520Video%2520-%2520Ryan%2520Jacobs%2520-%2520TN.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">July 23rd 2024</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-ann-lacasce-discusses-potentially-game-changing-treatments-for-lymphoma"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">February 11th 2024</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-ann-lacasce-looks-to-the-year-ahead-in-the-lymphoma-treatment-landscape"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">February 2nd 2024</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-187450181 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-jennifer-brown-discusses-zanubrutinib-uptake-in-cll-sll"><div class="jsx-187450181 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-187450181 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png%2FScreen%2520Shot%25202023-06-09%2520at%25206.06.50%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-187450181 content-wrap"><span class="jsx-187450181 py-3 text-sm text-gray-500 text-left"><i class="jsx-187450181">August 23rd 2023</i></span><div class="jsx-187450181 w-full h-fit mb-4"><p class="jsx-187450181 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Podcasts</div><a href="/podcasts" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/diving-into-patient-preferences-for-blood-cancer-treatments-with-dr-sikander-ailawadhi"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">December 17th 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi</p></div></div></div></a></div></div></div><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">More News</h2></div><div class="flex flex-wrap w-full pb-4"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/liso-cel-prolongs-responses-pfs-and-os-in-pretreated-high-risk-r-r-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/25522052a2c51d8713921072b1256a81c1576daf-1200x800.jpg?fit=crop&auto=format" alt="CLL Cells | Image Credit: © Laszlo - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 7th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/liso-cel-prolongs-responses-pfs-and-os-in-pretreated-high-risk-r-r-cll">Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk R/R CLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ashling-wahner">Ashling Wahner</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/liso-cel-prolongs-responses-pfs-and-os-in-pretreated-high-risk-r-r-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-benefits-r-r-cll-but-combo-therapy-works-better"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/dcc970cc0e88a2d1082c03f90fffac7a882f7264-5139x3426.jpg?fit=crop&auto=format" alt="Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 5th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-benefits-r-r-cll-but-combo-therapy-works-better">Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-benefits-r-r-cll-but-combo-therapy-works-better"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/academic-cancer-centers-see-longer-survival-in-cll-mcl-than-community-centers"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/c47d1001b06db553ad12b402fa8d787f080c3245-3600x2057.jpg?fit=crop&auto=format" alt="Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 10th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/academic-cancer-centers-see-longer-survival-in-cll-mcl-than-community-centers">Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/academic-cancer-centers-see-longer-survival-in-cll-mcl-than-community-centers"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/personalized-cll-therapy-with-mrd-guidance-improves-survival-outcomes"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cc6ced98d5b353302d9801257a99e66403d946f7-1200x738.jpg?fit=crop&auto=format" alt="CLL | Image credit: Saiful52 – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 6th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/personalized-cll-therapy-with-mrd-guidance-improves-survival-outcomes">Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/personalized-cll-therapy-with-mrd-guidance-improves-survival-outcomes"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/targeted-therapy-in-cll-may-impact-blood-cell-behavior"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/b1ee2df4225a6664d5e63acaef1d16318eb00901-5093x2853.jpg?fit=crop&auto=format" alt="Red blood cells | Image credit: wanchalerm – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 31st 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/targeted-therapy-in-cll-may-impact-blood-cell-behavior">Targeted Therapy in CLL May Impact Blood Cell Behavior</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/targeted-therapy-in-cll-may-impact-blood-cell-behavior"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/john-burke-md-discusses-survey-on-venetoclax-uptake-among-community-physicians"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8109a01173520de1840d640d8e4837fe43f0883c-200x200.jpg?fit=crop&auto=format" alt="John Burke, MD | Image credit: Navigating Cancer" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 22nd 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/john-burke-md-discusses-survey-on-venetoclax-uptake-among-community-physicians">John Burke, MD, Discusses Survey on Venetoclax Uptake Among Community Physicians</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/john-burke-md">John Burke, MD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/john-burke-md-discusses-survey-on-venetoclax-uptake-among-community-physicians"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-7"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/venetoclax-shows-good-results-even-in-short-telomere-patients-with-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/3515117e6a864d50d9bf5dbf07c655b884d50d06-6700x3300.jpg?fit=crop&auto=format" alt="Chromosomes with Telomere floating on blue background | Image credit: peterschreiber.media – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 21st 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/venetoclax-shows-good-results-even-in-short-telomere-patients-with-cll">Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/venetoclax-shows-good-results-even-in-short-telomere-patients-with-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/btki-resistance-mechanisms-solutions-probed-at-ash"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/e9cc14ef4e90a78e114b001df670a92229b0212e-1920x1267.jpg?fit=crop&auto=format" alt="chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 15th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/btki-resistance-mechanisms-solutions-probed-at-ash">BTKi Resistance Mechanisms, Solutions Probed at ASH</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/btki-resistance-mechanisms-solutions-probed-at-ash"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-safe-and-effective-in-patients-with-cll-sll-real-world-data-show"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/dcc970cc0e88a2d1082c03f90fffac7a882f7264-5139x3426.jpg?fit=crop&auto=format" alt="Ibrutinib packaging | Image credit: CLShebley – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 10th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-safe-and-effective-in-patients-with-cll-sll-real-world-data-show">Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ibrutinib-safe-and-effective-in-patients-with-cll-sll-real-world-data-show"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/patient-reported-qol-outcomes-of-initial-cll-treatments-ash-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/2c0c80a8d8015483642cad22fa013c85973e6fcc-4000x2662.jpg?fit=crop&auto=format" alt="Patient with leukemia receiving treatment | Image credit: tonefotografia – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 8th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/patient-reported-qol-outcomes-of-initial-cll-treatments-ash-2024">Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/patient-reported-qol-outcomes-of-initial-cll-treatments-ash-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/new-generation-of-car-t-may-elicit-improved-cr-rates-in-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/870dc4d0d66f515ef74ad8e359f869e372efda1d-5824x3264.jpg?fit=crop&auto=format" alt="New Generation of CAR T May Elicit Improved CR Rates in CLL" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 3rd 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/new-generation-of-car-t-may-elicit-improved-cr-rates-in-cll">New Generation of CAR T May Elicit Improved CR Rates in CLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ajmc-contributor">AJMC Contributor</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/new-generation-of-car-t-may-elicit-improved-cr-rates-in-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/beigene-s-mehrdad-mobasher-md-mph-discusses-cll-data-pipeline-following-ash-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/22e60e3b550af9c763788aaa1a5bbe0cdbbdfbcd-1200x1200.png?fit=crop&auto=format" alt="Mehrdad Mobasher, MD, MPH | Image credit: BeiGene" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 2nd 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/beigene-s-mehrdad-mobasher-md-mph-discusses-cll-data-pipeline-following-ash-2024">BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/beigene-s-mehrdad-mobasher-md-mph-discusses-cll-data-pipeline-following-ash-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change January 2, 2025.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-13"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/top-5-most-read-cll-sll-articles-of-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cc853809632b92ceefafe62b7af787d6451fb5fd-3187x1625.png?fit=crop&auto=format" alt="Top 5 CLL of 2024" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 26th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/top-5-most-read-cll-sll-articles-of-2024">Top 5 Most-Read CLL/SLL Articles of 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/christina-mattina">Christina Mattina</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/top-5-most-read-cll-sll-articles-of-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/infection-rate-more-than-double-in-cll-sll-accompanied-by-secondary-immunodeficiency-disease"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/f0c5d4ea0717f266f567a6a19f049cf7ff272c85-7500x4076.jpg?fit=crop&auto=format" alt="A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 19th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/infection-rate-more-than-double-in-cll-sll-accompanied-by-secondary-immunodeficiency-disease">Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/infection-rate-more-than-double-in-cll-sll-accompanied-by-secondary-immunodeficiency-disease"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/different-btk-inhibitors-bring-distinct-changes-to-full-length-btk"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/baa43745aa5408bc2ee3f75b86c2aab17c718dbe-1200x675.jpg?fit=crop&auto=format" alt="doctor and patient - Sebra - stock.adobe.com.jpg" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/different-btk-inhibitors-bring-distinct-changes-to-full-length-btk">Different Bruton Tyrosine Kinase Inhibitors Bring Distinct Changes to Full-Length BTK</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/different-btk-inhibitors-bring-distinct-changes-to-full-length-btk"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/6-year-data-support-fixed-duration-ven-obi-for-untreated-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8b532ed92234b55d19339ba1cd96b319212188cf-6000x4000.jpg?fit=crop&auto=format" alt="CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 10th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/6-year-data-support-fixed-duration-ven-obi-for-untreated-cll">6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/6-year-data-support-fixed-duration-ven-obi-for-untreated-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/new-guidelines-clarify-eortc-quality-of-life-scores-for-chronic-lymphocytic-leukemia"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/29f50a50749d5b42870bfbf652a620b3fce97dcb-1200x738.jpg?fit=crop&auto=format" alt="Guidelines folder-tashatuvango-stock.adobe.com.jpeg" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/new-guidelines-clarify-eortc-quality-of-life-scores-for-chronic-lymphocytic-leukemia">New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/new-guidelines-clarify-eortc-quality-of-life-scores-for-chronic-lymphocytic-leukemia"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/tattoos-may-be-associated-with-increased-risk-of-rare-nhls"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/d68a0ae1f89cececa803c05ff5632ab318098f1c-5472x3648.jpg?fit=crop&auto=format" alt="New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 29th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/tattoos-may-be-associated-with-increased-risk-of-rare-nhls">Tattoos May Be Associated With Increased Risk of Rare NHLs </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ajmc-contributor">AJMC Contributor</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/tattoos-may-be-associated-with-increased-risk-of-rare-nhls"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-19"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-confirm-ibrutinib-s-role-in-relapsed-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/fd617092164d84c81add47518d2c67d8dc91de53-1200x738.jpg?fit=crop&auto=format" alt="Big Data | Image Credit: © Friends Stock-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 26th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-confirm-ibrutinib-s-role-in-relapsed-cll">Real-World Data Confirm Ibrutinib's Role in Relapsed CLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-confirm-ibrutinib-s-role-in-relapsed-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/b276506cb9fe42e52165074a6e038a4b99789dcb-5622x3622.jpg?fit=crop&auto=format" alt="Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 23rd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles">Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/treating-double-exposed-patients-with-cll-a-continued-unmet-need"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cc6ced98d5b353302d9801257a99e66403d946f7-1200x738.jpg?fit=crop&auto=format" alt="CLL over the image of a stethoscope and red blood cells | Image credit: Saiful52 - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 21st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/treating-double-exposed-patients-with-cll-a-continued-unmet-need">Treating Double-Exposed Patients With CLL: A Continued Unmet Need</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/treating-double-exposed-patients-with-cll-a-continued-unmet-need"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/386a8d9de05e073b8c8e281bd8b54ba21d2c0fc4-6000x4000.jpg?fit=crop&auto=format" alt="Health care costs and fees | Image Credit: © everythingpossible - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 9th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world">Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ajmc-contributor">AJMC Contributor</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/kir2ds2-nk-cells-show-potential-in-hcc-and-leukemia-treatment"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8eccbe2e0fbcb0daf334fb38c368a1a559ae8af0-1200x738.jpg?fit=crop&auto=format" alt="NK Cell test | Image Credit: © jarun011-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 6th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/kir2ds2-nk-cells-show-potential-in-hcc-and-leukemia-treatment">KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ajmc-contributor">AJMC Contributor</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/kir2ds2-nk-cells-show-potential-in-hcc-and-leukemia-treatment"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/review-emphasizes-potential-infection-risks-with-btk-inhibitors"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/962ea5111c87d03bf0c9862e1749ebeecd4f5905-5376x3584.jpg?fit=crop&auto=format" alt="Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/review-emphasizes-potential-infection-risks-with-btk-inhibitors">Review Emphasizes Potential Infection Risks With BTK Inhibitors </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/review-emphasizes-potential-infection-risks-with-btk-inhibitors"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-25"></div></div></div><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-more-effective-than-ibrutinib-in-treating-patients-with-relapsed-refractory-cll-sll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/e825022f10d04a8c8b873d06455d4327ec5a3449-1200x800.jpg?fit=crop&auto=format" alt="Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-more-effective-than-ibrutinib-in-treating-patients-with-relapsed-refractory-cll-sll">Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-more-effective-than-ibrutinib-in-treating-patients-with-relapsed-refractory-cll-sll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/understanding-ibrutinib-relapse-in-cll-immune-profiles-of-responders-vs-relapsing-patients"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/9d0d21b5e56292278fdfee526605374241258910-6000x5248.jpg?fit=crop&auto=format" alt="Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 23rd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/understanding-ibrutinib-relapse-in-cll-immune-profiles-of-responders-vs-relapsing-patients">Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/understanding-ibrutinib-relapse-in-cll-immune-profiles-of-responders-vs-relapsing-patients"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-not-cost-effective-in-china-against-fixed-duration-r-bendamustine-in-1l-cll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4964e17cc7785a4c0fc3b158e3dadf41c44b050a-6016x4016.jpg?fit=crop&auto=format" alt="money and stethoscope | Image Credit: © pla2na - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-not-cost-effective-in-china-against-fixed-duration-r-bendamustine-in-1l-cll">Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/ajmc-contributor">AJMC Contributor</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/zanubrutinib-not-cost-effective-in-china-against-fixed-duration-r-bendamustine-in-1l-cll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/melanoma-risk-doubled-for-monoclonal-b-cell-lymphocytosis"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/739c7a6180c80ee48c24f41b112dab5177075f4e-5184x3456.jpg?fit=crop&auto=format" alt="Skin Cancer Potential | Image Credit: © Monstar Studio-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/melanoma-risk-doubled-for-monoclonal-b-cell-lymphocytosis">Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/melanoma-risk-doubled-for-monoclonal-b-cell-lymphocytosis"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-acalabrutinib-safety-profile-superior-in-cll-sll"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/89ce8146b16a95750ea182db263745b7a16b6ec5-8064x5376.jpg?fit=crop&auto=format" alt="Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 9th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-acalabrutinib-safety-profile-superior-in-cll-sll">Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-acalabrutinib-safety-profile-superior-in-cll-sll"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-support-tki-discontinuation-after-cp-cml-remission"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/00f63d1a9fdd06b3f99a5e908a01ac22ec5b25ea-1200x728.jpg?fit=crop&auto=format" alt="diagnosis leukemia | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 4th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-support-tki-discontinuation-after-cp-cml-remission">Real-World Data Support TKI Discontinuation After CP-CML Remission</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/real-world-data-support-tki-discontinuation-after-cp-cml-remission"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div><div class="w-full text-center flex justify-center pb-24"><a class="px-4 py-2 border-y border-r bg-primary text-white" href="/compendium/cll?page=1">1</a><a class="px-4 py-2 border-y border-r " href="/compendium/cll?page=2">2</a><a class="px-4 py-2 border-y border-r " href="/compendium/cll?page=3">3</a><a class="px-4 py-2 border-y border-r " href="/compendium/cll?page=4">4</a><a class="px-4 py-2 border-y border-r " href="/compendium/cll?page=5">5</a><a class="px-4 py-2 border-y border-r" href="/compendium/cll?page=2">></a></div></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK5KQXS" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class=" mx-auto flex"><div class="bg-[#00598D] xl:w-[70%] w-[70%] py-12 pl-auto"><div class="xxl:w-[75%] w-[90%] ml-auto"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27300%27%20height=%2744%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=384&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div><div class="flex"><div class="flex justify-between pt-6"><div class="w-[40%]"><div class="text-footer-text-color text-xs"><p>2 Commerce Drive<br/>Suite 100<br/>Cranbury, NJ 08512</p></div><div class="self-start py-6" style="display:flex;flex-wrap:wrap"><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="25" height="25" viewBox="1.41 1.41 252.9 252.9"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><polygon points="24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)"></polygon><path d="M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)" stroke-linecap="round"></path></g></svg></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.instagram.com/ajmcjournal/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='instagram' fill='#FFFFFF' fillRule='nonzero'> <path d='M305,256 C305,283.0625 283.0625,305 256,305 C228.9375,305 207,283.0625 207,256 C207,228.9375 228.9375,207 256,207 C283.0625,207 305,228.9375 305,256 Z' id='Path' /> <path d='M370.59375,169.304688 C368.238281,162.921875 364.480469,157.144531 359.597656,152.402344 C354.855469,147.519531 349.082031,143.761719 342.695312,141.40625 C337.515625,139.394531 329.734375,137 315.402344,136.347656 C299.898438,135.640625 295.25,135.488281 256,135.488281 C216.746094,135.488281 212.097656,135.636719 196.597656,136.34375 C182.265625,137 174.480469,139.394531 169.304688,141.40625 C162.917969,143.761719 157.140625,147.519531 152.402344,152.402344 C147.519531,157.144531 143.761719,162.917969 141.402344,169.304688 C139.390625,174.484375 136.996094,182.269531 136.34375,196.601562 C135.636719,212.101562 135.484375,216.75 135.484375,256.003906 C135.484375,295.253906 135.636719,299.902344 136.34375,315.40625 C136.996094,329.738281 139.390625,337.519531 141.402344,342.699219 C143.761719,349.085938 147.515625,354.859375 152.398438,359.601562 C157.140625,364.484375 162.914062,368.242188 169.300781,370.597656 C174.480469,372.613281 182.265625,375.007812 196.597656,375.660156 C212.097656,376.367188 216.742188,376.515625 255.996094,376.515625 C295.253906,376.515625 299.902344,376.367188 315.398438,375.660156 C329.730469,375.007812 337.515625,372.613281 342.695312,370.597656 C355.515625,365.652344 365.648438,355.519531 370.59375,342.699219 C372.605469,337.519531 375,329.738281 375.65625,315.40625 C376.363281,299.902344 376.511719,295.253906 376.511719,256.003906 C376.511719,216.75 376.363281,212.101562 375.65625,196.601562 C375.003906,182.269531 372.609375,174.484375 370.59375,169.304688 L370.59375,169.304688 Z M256,331.484375 C214.308594,331.484375 180.511719,297.691406 180.511719,256 C180.511719,214.308594 214.308594,180.515625 256,180.515625 C297.6875,180.515625 331.484375,214.308594 331.484375,256 C331.484375,297.691406 297.6875,331.484375 256,331.484375 Z M334.46875,195.171875 C324.726562,195.171875 316.828125,187.273438 316.828125,177.53125 C316.828125,167.789062 324.726562,159.890625 334.46875,159.890625 C344.210938,159.890625 352.109375,167.789062 352.109375,177.53125 C352.105469,187.273438 344.210938,195.171875 334.46875,195.171875 Z' id='Shape' /> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M402.113281,316.605469 C401.402344,332.253906 398.914062,342.9375 395.28125,352.289062 C387.644531,372.035156 372.035156,387.644531 352.289062,395.28125 C342.941406,398.914062 332.253906,401.398438 316.609375,402.113281 C300.933594,402.828125 295.925781,403 256.003906,403 C216.078125,403 211.074219,402.828125 195.394531,402.113281 C179.75,401.398438 169.0625,398.914062 159.714844,395.28125 C149.902344,391.589844 141.019531,385.804688 133.675781,378.324219 C126.199219,370.984375 120.414062,362.097656 116.722656,352.289062 C113.089844,342.941406 110.601562,332.253906 109.890625,316.609375 C109.167969,300.929688 109,295.921875 109,256 C109,216.078125 109.167969,211.070312 109.886719,195.394531 C110.597656,179.746094 113.082031,169.0625 116.714844,159.710938 C120.40625,149.902344 126.195312,141.015625 133.675781,133.675781 C141.015625,126.195312 149.902344,120.410156 159.710938,116.71875 C169.0625,113.085938 179.746094,110.601562 195.394531,109.886719 C211.070312,109.171875 216.078125,109 256,109 C295.921875,109 300.929688,109.171875 316.605469,109.890625 C332.253906,110.601562 342.9375,113.085938 352.289062,116.714844 C362.097656,120.40625 370.984375,126.195312 378.328125,133.675781 C385.804688,141.019531 391.59375,149.902344 395.28125,159.710938 C398.917969,169.0625 401.402344,179.746094 402.117188,195.394531 C402.832031,211.070312 403,216.078125 403,256 C403,295.921875 402.832031,300.929688 402.113281,316.605469 L402.113281,316.605469 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a></div><div class="text-footer-text-color text-xs"><p>© 2025 MJH Life Sciences<sup>®</sup> and AJMC®.<br/> All rights reserved.</p></div></div><div class="flex flex-row flex-wrap self-start w-[60%]"><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about-us">About</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contactus">Contact</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-boards">Editorial Boards</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com">Do Not Sell My Information</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms & Conditions</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div></div><div class="flex items-start mr-6 lg:mr-10"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2768%27/%3e"/></span><img alt="AJMC Managed Markets Network Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="AJMC Managed Markets Network Logo" srcSet="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=256&q=75 1x, /_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75 2x" src="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div></div></div></div><div class="w-[30%] bg-[#003767] flex items-center justify-center "><div class="flex flex-col justify-between "><a target="_self" rel="noopener noreferrer" class="my-2 px-8" href="/topic/center-on-health-equity-and-access"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="CH Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="CH Logo" srcSet="/_next/image?url=%2FCHA_Logo.png&w=384&q=75 1x, /_next/image?url=%2FCHA_Logo.png&w=640&q=75 2x" src="/_next/image?url=%2FCHA_Logo.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a><a target="_blank" rel="noopener noreferrer" class="my-2 px-8" href="https://www.centerforbiosimilars.com/"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="Center for Biosimilars Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Center for Biosimilars Logo" srcSet="/_next/image?url=%2FCB.png&w=384&q=75 1x, /_next/image?url=%2FCB.png&w=640&q=75 2x" src="/_next/image?url=%2FCB.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"_createdAt":"2020-04-14T13:26:14Z","_rev":"Yw6MEKZDMdk6hC2JCRdGN7","is_active":true,"sortOrder":1,"name":"News","subQuery":[{"_updatedAt":"2020-04-14T13:30:35Z","is_active":true,"navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_createdAt":"2020-04-14T13:30:35Z","name":"All News","url":"/news","_type":"mainNavigation","_id":"1376963d-32e8-4647-bb5e-59c984e35893","_rev":"sBk7YzjWMuBuhiatU3YIhQ","children":[]},{"name":"Press Releases","_updatedAt":"2020-04-14T13:30:57Z","navParent":{"_type":"reference","_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b"},"_type":"mainNavigation","url":"/press-release","_createdAt":"2020-04-14T13:30:57Z","_id":"2af5da5e-78c2-42c8-90b8-3900f8c89889","children":[],"is_active":true,"_rev":"QxOJBWa4XErmibN6Cb5OcA"},{"_type":"mainNavigation","_createdAt":"2021-07-29T12:15:49Z","name":"Product Approvals and Launches","_id":"854a1ad1-9831-4387-bda9-ffb93a074ace","_updatedAt":"2022-01-07T20:44:44Z","url":"/approvals-launches","is_active":true,"navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_rev":"jvOgZ3KZdbRHfWlt9ePmOA","children":[]}],"_id":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"mainNavigation","_updatedAt":"2020-04-14T13:26:21Z","navParent":null},{"_updatedAt":"2024-05-24T16:36:15Z","_type":"mainNavigation","name":"Video","_id":"821e259a-db55-4862-985a-5cd089bbf894","navParent":null,"is_active":true,"_createdAt":"2020-04-14T13:26:30Z","_rev":"rcwwj6TiN2Q0ymhqDzIFjO","sortOrder":2,"subQuery":[{"_rev":"rcwwj6TiN2Q0ymhqDzJ8ty","_createdAt":"2024-05-24T16:37:06Z","_type":"mainNavigation","name":"All Video Types","url":"/video-hub","children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"sortOrder":1,"_updatedAt":"2024-05-24T16:52:54Z","_id":"f51d85fa-cabc-4c7d-85d0-11301088b7f6","is_active":true},{"_id":"a99a3683-5173-46b3-94b0-21b7d6b06a24","_updatedAt":"2024-05-28T19:38:54Z","url":"/interviews","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","name":"AJMC TV","is_active":true,"_createdAt":"2024-05-24T16:38:14Z","_rev":"LJrwYxwtzLC9JsOYMk8TBr","children":[]},{"_type":"mainNavigation","name":"Guidelines","children":[],"url":"/guidelines","_createdAt":"2025-02-14T19:40:54Z","_rev":"4IWvQAHLC63503PAHcJfUU","_id":"9affe463-8f89-4d72-b806-62281069ebba","is_active":true,"_updatedAt":"2025-02-14T19:41:11Z","navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"}},{"url":"/insights","_createdAt":"2020-04-14T13:43:45Z","children":[],"_rev":"Yw6MEKZDMdk6hC2JCRda8Z","_type":"mainNavigation","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_updatedAt":"2020-04-14T13:43:45Z","is_active":true,"name":"Insights","_id":"b03ccbf6-6387-48de-8edc-4f1f23debe40"},{"_type":"mainNavigation","_id":"f3d69d10-636b-4927-8ff4-4f54fabc940a","url":"/onlocation","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2020-04-14T13:44:19Z","_rev":"k6N5FycA5UhVnvpzSEa3Rp","children":[],"name":"OnLocation","_updatedAt":"2020-04-14T13:44:19Z","is_active":true},{"url":"/payer-perspectives","children":[],"_id":"d4e3d69c-8a07-4191-af89-27d7e838af08","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2022-10-05T15:29:11Z","_type":"mainNavigation","name":"Payer Perspectives","_updatedAt":"2022-10-05T15:29:11Z","_rev":"37PW14Mg02p9z7FTF1SGE9"},{"url":"/peer-exchange","_id":"8f602f1e-1840-4c32-8cdb-9a26d6c0e873","is_active":true,"_type":"mainNavigation","name":"Peer Exchange","_updatedAt":"2020-04-14T13:44:43Z","_createdAt":"2020-04-14T13:44:43Z","_rev":"VdTcsTJkAuZveXGf2i9Pes","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"children":[]},{"is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"url":"/post-conference-perspectives","_type":"mainNavigation","name":"Post Conference Perspectives","_updatedAt":"2024-05-24T18:27:43Z","_createdAt":"2024-05-24T18:27:43Z","_id":"0f532685-cd4c-4350-89cd-b8a388e6495b","_rev":"Jz2W7keLhiw1UYkGHgA51N","children":[]},{"_id":"bbc55ff8-1532-475e-9f51-f9d5eb39e369","_updatedAt":"2020-12-01T22:43:26Z","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"url":"/stakeholder-summit","children":[],"_rev":"y3lsbm3yQTliOnC9CU5TiR","_type":"mainNavigation","is_active":true,"_createdAt":"2020-12-01T22:43:10Z","name":"Stakeholder Summit"}]},{"_createdAt":"2024-05-24T16:40:58Z","_type":"mainNavigation","name":"Podcasts","_id":"4939ee15-ae6f-4aba-8481-9ee27ce729d3","url":"/podcasts","_updatedAt":"2024-05-24T16:41:18Z","navParent":null,"subQuery":[],"is_active":true,"sortOrder":3,"_rev":"rcwwj6TiN2Q0ymhqDzIUb7"},{"subQuery":[{"sortOrder":1,"_type":"mainNavigation","is_active":true,"navParent":{"_type":"reference","_ref":"6841664a-93f2-4f56-8760-836ec9c7b483"},"name":"Conference Coverage","_id":"f45b532b-23e3-4b44-8d7f-2f3c13c9ae81","children":[],"_rev":"pI9SawGKsTP14Lioy589Kx","_updatedAt":"2020-08-21T22:11:23Z","url":"/latest-conference","_createdAt":"2020-06-12T15:17:29Z"},{"sortOrder":2,"_rev":"FxFuWbqTkFGbPWgBBSR6xp","_type":"mainNavigation","_id":"004461ae-46cb-45ef-916e-f03c6d99d6d3","url":"/conference","_createdAt":"2020-06-12T15:18:28Z","name":"Conference Listing","_updatedAt":"2020-06-12T15:19:26Z","children":[],"is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"}},{"_type":"mainNavigation","_id":"a006d0df-0cc9-4386-abfb-b1931a3918d4","navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_createdAt":"2024-07-03T19:00:13Z","name":"Post Conference Perspectives","is_active":true,"sortOrder":3,"children":[],"_rev":"ZU3dXbR1BZtBbbPuRGxz53","_updatedAt":"2024-07-03T19:00:13Z","url":"/post-conference-perspectives"}],"is_active":true,"_createdAt":"2020-04-14T13:27:01Z","_updatedAt":"2024-05-24T16:41:40Z","_rev":"rcwwj6TiN2Q0ymhqDzIVAU","_id":"6841664a-93f2-4f56-8760-836ec9c7b483","sortOrder":4,"_type":"mainNavigation","name":"Conferences","navParent":null},{"_rev":"uJbbwQWkLESsncBrcLL0hr","_type":"mainNavigation","_id":"94f13109-c3cc-47b5-bf49-96ed727c8150","is_active":true,"_updatedAt":"2024-05-24T16:41:49Z","sortOrder":5,"name":"Journals","_createdAt":"2020-04-14T13:27:20Z","navParent":null,"subQuery":[{"sortOrder":1,"children":[],"_rev":"rcwwj6TiN2Q0ymhqDzIVyQ","_id":"48193abd-ecf4-4c90-b0ae-984ca2be88c9","_type":"mainNavigation","_updatedAt":"2024-05-24T16:42:23Z","name":"All Journals","url":"/publications","is_active":true,"_createdAt":"2020-05-04T21:06:00Z","navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"}},{"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_updatedAt":"2024-05-24T16:42:39Z","url":"/publications/issue","children":[],"_createdAt":"2020-04-14T13:55:29Z","_rev":"rcwwj6TiN2Q0ymhqDzIWug","_type":"mainNavigation","_id":"08081ddf-ffd8-4b17-a2ff-dfe6a0ac64a3","sortOrder":2,"name":"The American Journal of Managed Care"},{"_rev":"4fso9RuTzczLhlxmnMQ1bu","_updatedAt":"2024-09-16T13:23:11Z","url":"/publications/ajac","_type":"mainNavigation","_createdAt":"2020-04-14T13:56:01Z","name":"Population Health, Equity \u0026 Outcomes","_id":"47782239-2714-4bd1-99e6-750443bd39ea","children":[],"is_active":true,"navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"sortOrder":3},{"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"sortOrder":4,"_type":"mainNavigation","children":[],"_rev":"uJbbwQWkLESsncBrcLL4uf","_id":"b99cc54f-5801-46e9-bd20-e690623ed12c","_createdAt":"2020-04-14T13:56:21Z","name":"Evidence-Based Oncology","_updatedAt":"2024-05-24T16:43:12Z","url":"/publications/evidence-based-oncology"},{"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2024-05-23T20:59:41Z","sortOrder":5,"url":"/supplement","children":[],"_type":"mainNavigation","_id":"6e7e3485-ef8b-40e3-8320-3c434df6bbb5","_updatedAt":"2024-05-24T16:43:26Z","_rev":"rcwwj6TiN2Q0ymhqDzIY1L","name":"About Supplements and Featured Publications"},{"_id":"a2112c87-8e92-4b64-b42d-3117117f67a3","_updatedAt":"2024-05-24T16:43:32Z","name":"Supplements and Featured Publications Issues","_rev":"uJbbwQWkLESsncBrcLL5w0","children":[],"is_active":true,"url":"/publications/supplement","navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"_createdAt":"2020-04-14T13:56:51Z","sortOrder":6,"_type":"mainNavigation"},{"sortOrder":7,"children":[],"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"name":"Submit a Manuscript","_id":"fa8c9edc-3d32-4e9e-b68b-47d5c15694a5","_createdAt":"2023-03-14T13:29:11Z","_rev":"rcwwj6TiN2Q0ymhqDzIYDp","_type":"mainNavigation","url":"/submit-a-manuscript","is_active":true,"_updatedAt":"2024-05-24T16:43:38Z"}]},{"_updatedAt":"2020-05-08T20:03:10Z","navParent":null,"_createdAt":"2020-04-14T13:27:17Z","sortOrder":6,"_type":"mainNavigation","_id":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","url":"/events","subQuery":[{"_type":"mainNavigation","_updatedAt":"2024-05-24T18:26:23Z","navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"name":"Institute for Value-Based Medicine","children":[],"_rev":"Jz2W7keLhiw1UYkGHgA4Yf","url":"/ivbmevents","is_active":true,"_id":"de4fe195-3db9-4d12-842d-f26100fbea5b","_createdAt":"2024-05-24T16:44:43Z"},{"is_active":true,"navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"_type":"mainNavigation","_rev":"Jz2W7keLhiw1UYkGHgA4eP","name":"Patient-Centered Oncology Care","_updatedAt":"2024-05-24T18:26:42Z","_createdAt":"2024-05-24T16:45:02Z","_id":"dddfc37d-8958-4e0a-91e3-0634bb6502a3","url":"https://pcoc.ajmc.com/","children":[]}],"is_active":true,"_rev":"8ZvheBjSwe5Dc4gCmgsR0M","name":"Events"},{"_rev":"rcwwj6TiN2Q0ymhqDzIdco","_type":"mainNavigation","name":"Resources","_id":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_updatedAt":"2024-05-24T16:45:37Z","is_active":true,"_createdAt":"2020-04-14T13:29:34Z","sortOrder":7,"navParent":null,"subQuery":[{"is_active":true,"_createdAt":"2020-04-14T13:51:39Z","sortOrder":1,"name":"Interactive Tools","url":"/interactive-tools","_rev":"rcwwj6TiN2Q0ymhqDzIfXP","_type":"mainNavigation","_updatedAt":"2024-05-24T16:46:13Z","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_id":"4a08b5fc-379c-4952-bec1-0d9dacb11170","children":[]},{"name":"Formulary Central","_id":"db1214fd-aa4d-4f12-a6f5-72d7e3927ce9","_updatedAt":"2025-02-14T19:42:02Z","url":"/formulary","is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_createdAt":"2025-02-14T19:41:37Z","sortOrder":3,"_rev":"4IWvQAHLC63503PAHcJhJi","_type":"mainNavigation","children":[]},{"children":[],"_createdAt":"2020-10-16T13:03:47Z","_rev":"rcwwj6TiN2Q0ymhqDyFVrf","name":"Clinical Spotlight","_id":"43960f88-0c8d-404b-b9d9-d90432c2c516","url":"/clinical-spotlight","is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2024-05-23T20:32:07Z"},{"_updatedAt":"2024-05-24T16:46:44Z","url":"/custom-email","_type":"mainNavigation","_id":"38aa3af0-8a34-4ae6-898c-37214580d384","children":[],"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_createdAt":"2024-05-24T16:46:44Z","_rev":"rcwwj6TiN2Q0ymhqDzIhDR","is_active":true,"name":"Microsites"},{"_type":"mainNavigation","_createdAt":"2024-05-24T16:47:05Z","children":[],"name":"Sponsored Content","_id":"d0b0683f-18e1-4e75-89fd-fb4e578a562f","_updatedAt":"2024-05-24T16:47:05Z","url":"/sponsored","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDzIiDr"}]},{"_createdAt":"2020-04-14T14:00:08Z","_id":"621fccf5-dcdb-40a9-af70-9bf3ccf79278","_updatedAt":"2024-08-27T15:31:04Z","url":"/continuing-education","is_active":true,"name":"CE","navParent":null,"subQuery":[],"sortOrder":8,"_rev":"LtkInV1jlQdtEIFjVpi9sG","_type":"mainNavigation"},{"_createdAt":"2024-05-24T16:48:11Z","_type":"mainNavigation","_id":"c14e4637-909c-4bf6-bf81-64eeb6005352","_updatedAt":"2024-05-24T16:48:11Z","_rev":"rcwwj6TiN2Q0ymhqDzIlc0","is_active":true,"sortOrder":9,"name":"About AJMC","navParent":null,"subQuery":[{"is_active":true,"_id":"be637b3b-f72a-4049-91b8-409809b2d815","navParent":{"_type":"reference","_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352"},"_rev":"Jz2W7keLhiw1UYkGHgBp6D","_type":"mainNavigation","children":[],"name":"AJMC Staff","url":"/editorial","_createdAt":"2024-05-24T19:05:57Z","_updatedAt":"2024-05-24T19:05:57Z"},{"_updatedAt":"2024-05-24T16:48:30Z","url":"/anniversary","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"children":[],"name":"Anniversary","_id":"5298152f-5135-4c2c-a46e-a14ad0300bf4","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDzIn5Y","_type":"mainNavigation","_createdAt":"2024-05-24T16:48:30Z"},{"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"name":"Seema Sonnad Award","_updatedAt":"2024-07-23T13:38:48Z","_type":"mainNavigation","url":"/about/seema-sonnad-nomination","children":[],"is_active":true,"_rev":"AGf4LvcO2r7q1La1cjR7dD","_id":"28d33143-d9a9-45bd-af63-bed8d2198118","_createdAt":"2024-05-24T18:24:23Z"},{"url":"/partners","_createdAt":"2024-05-24T16:49:00Z","_type":"mainNavigation","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_id":"acb7dc53-dfab-462a-b2e9-b0cfc8675da4","_updatedAt":"2024-05-24T16:49:00Z","is_active":true,"children":[],"_rev":"uJbbwQWkLESsncBrcLLVEZ","name":"Strategic Alliance Partners"}]},{"is_active":true,"sortOrder":9,"_type":"mainNavigation","_updatedAt":"2024-03-11T14:58:15Z","url":"https://one.ajmc.com/subscribe","navParent":null,"subQuery":[],"_rev":"gFXie0Ldruy1o91XppbLLd","_id":"1e279576-0b33-4e57-8782-b6b1edbf68da","blank":true,"_createdAt":"2020-06-22T20:56:33Z","name":"Subscribe"}],"sub_menu":[{"_id":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_updatedAt":"2024-05-24T05:08:37Z","sortOrder":1,"subQuery":[{"children":[],"is_active":true,"_updatedAt":"2024-05-24T05:06:44Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_createdAt":"2024-05-24T05:06:44Z","_rev":"Jz2W7keLhiw1UYkGHfbM3A","name":"Biosimilars","_id":"aa3904f3-c0d8-495d-a77f-afcc41f27045","url":"/compendium/biosimilars"},{"name":"Cardiorenalmetabolic","url":"/compendium/cardiorenalmetabolic","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_updatedAt":"2025-01-17T17:17:34Z","_rev":"aW9ZvtW6d5z6x1Negj6Jxc","children":[{"is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:30:54Z","_rev":"Jz2W7keLhiw1UYkGHfbquf","_updatedAt":"2024-05-24T05:30:54Z","url":"/compendium/cardiovascular","_type":"subNavigation","name":"Cardiovascular","_id":"c3566f20-e7c6-4b38-bf9f-7d52055698b1"},{"_updatedAt":"2024-05-24T05:32:42Z","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_type":"subNavigation","url":"/compendium/ckd","_createdAt":"2024-05-24T05:32:42Z","_rev":"Jz2W7keLhiw1UYkGHfbumO","name":"Chronic Kidney Disease","_id":"f3a69e16-dc38-4135-886e-d70e18532bf4"},{"_type":"subNavigation","url":"/compendium/diabetes","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:31:14Z","name":"Diabetes","_id":"79c02dc8-3c2d-451b-9797-008b25d61d4d","_updatedAt":"2024-05-24T05:31:14Z","_rev":"Jz2W7keLhiw1UYkGHfbrEl"},{"_updatedAt":"2024-05-24T05:31:38Z","url":"/compendium/heart-failure","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbrQF","name":"Heart Failure","_id":"84c7dd54-fb21-4bc5-86bc-9bbf39a7f836","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:31:38Z","_type":"subNavigation"},{"is_active":true,"_createdAt":"2024-05-24T05:32:00Z","name":"Type 1 Diabetes","_updatedAt":"2024-05-24T05:32:00Z","navParent":{"_type":"reference","_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab"},"_rev":"Jz2W7keLhiw1UYkGHfbsbS","_type":"subNavigation","_id":"aadd9bdc-4dd1-4ac1-be4f-2afb4315b6cb","url":"/compendium/type1diabetes"}],"is_active":true,"_type":"subNavigation","_id":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_createdAt":"2024-05-24T05:30:27Z"},{"url":"/compendium/dermatology","_rev":"Jz2W7keLhiw1UYkGHfbSVf","_createdAt":"2024-05-24T05:10:35Z","name":"Dermatology","_type":"subNavigation","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-23T21:42:49Z","_id":"04523862-a8a1-4626-b288-95b3d4114267","_rev":"Jz2W7keLhiw1UYkGHfbTPe","_type":"subNavigation","name":"Alopecia","_updatedAt":"2024-05-24T05:12:43Z","url":"/compendium/alopecia"},{"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_type":"subNavigation","name":"Atopic Dermatitis","_id":"637a0b1e-1b12-42bf-81a3-e6db5a997021","url":"/compendium/atopic-dermatitis","_createdAt":"2024-05-24T05:12:02Z","_rev":"Jz2W7keLhiw1UYkGHfbSvV","_updatedAt":"2024-05-24T05:12:02Z","is_active":true},{"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:30Z","_type":"subNavigation","name":"Psoriasis","_updatedAt":"2024-05-24T05:12:36Z","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbTJu","_id":"a9dcce80-4f29-488e-b7ef-51f0fb562a5a","url":"/compendium/psoriasis"}],"_id":"7599f50b-36ff-42a5-8d72-82814db9b988","_updatedAt":"2024-05-24T05:10:35Z"},{"_rev":"I64rexdokWxpEDPZsg5Lox","url":"/compendium/gastroenterology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_updatedAt":"2024-11-25T15:12:43Z","_id":"3c425964-bf72-4f93-bfbc-4d44d42dc2fe","name":"Gastroenterology","children":[],"is_active":true,"_createdAt":"2024-11-25T15:12:24Z"},{"_createdAt":"2024-05-24T05:13:48Z","_rev":"Jz2W7keLhiw1UYkGHfbU3q","name":"Hematology","_id":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"url":"/compendium/hematology","children":[{"_rev":"Iat2IZiT321TmGHwkF66wB","_type":"subNavigation","name":"ALL/AML","_id":"d79f2b30-e7f2-4915-bef8-1a73a9190a91","_updatedAt":"2024-05-29T15:28:26Z","_createdAt":"2024-05-29T15:28:26Z","url":"/compendium/all","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"}},{"_createdAt":"2024-05-29T15:26:57Z","_rev":"Iat2IZiT321TmGHwkF65Md","_type":"subNavigation","name":"CLL/SLL","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_id":"664a6ece-64dd-41f8-87a0-7f5a47323c3b","_updatedAt":"2024-05-29T15:27:46Z","url":"/compendium/cll"},{"is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:28:51Z","_rev":"Iat2IZiT321TmGHwkF67tn","name":"GVHD","_id":"32cf626c-1ce6-4fb5-9dd7-088522dc46e6","_updatedAt":"2024-05-29T15:28:51Z","_type":"subNavigation","url":"/compendium/gvhd"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:14:15Z","_updatedAt":"2024-05-24T05:14:15Z","url":"/compendium/hemophilia","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbUDt","_type":"subNavigation","name":"Hemophilia","_id":"4dd2ce64-8f4d-4285-bc1a-ec40ffc99b51"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Iat2IZiT321TmGHwkF6NtX","name":"Multiple Myeloma","_id":"84e2d674-0fe1-4bd1-9d97-2f8bc8589ba0","_updatedAt":"2024-05-29T15:35:07Z","url":"/compendium/multiple-myeloma","is_active":true,"_createdAt":"2024-05-24T05:45:17Z","_type":"subNavigation"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:45:36Z","_type":"subNavigation","name":"Myelodysplastic Syndromes","is_active":true,"_rev":"Iat2IZiT321TmGHwkF6a5X","_id":"3a327f90-a5fc-4d87-9a18-02f54cb40b8e","_updatedAt":"2024-05-29T15:35:22Z","url":"/compendium/myelodysplastic-syndromes"},{"is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:29:21Z","_type":"subNavigation","_updatedAt":"2024-06-05T20:02:27Z","_rev":"Up1TL5YPo1fhI8V2tpNnMb","name":"Myeloproliferative Neoplasms","_id":"a6003c4f-e7f0-422a-8129-49a2d78eb113","url":"/compendium/mpn"},{"_id":"fc247a6b-0b33-4e18-ae78-56e677c6bb18","_updatedAt":"2024-06-25T17:42:12Z","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"rmdpbbz4U7GL9ExaGp96DY","name":"Non-Hodgkin Lymphoma","url":"/compendium/nhl","is_active":true,"_createdAt":"2024-05-24T05:43:54Z","_type":"subNavigation"},{"name":"Rare Blood","_id":"85e2fc3e-ac5c-4b47-8b14-411d730d20d9","_updatedAt":"2024-05-24T05:14:40Z","url":"/compendium/rareblood","_createdAt":"2024-05-24T05:14:40Z","_rev":"Jz2W7keLhiw1UYkGHfbUPN","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_type":"subNavigation"}],"is_active":true,"_type":"subNavigation","_updatedAt":"2024-05-24T05:13:48Z"},{"_updatedAt":"2025-01-17T17:19:10Z","url":"/compendium/hepatology","is_active":true,"_rev":"IZ4ZA8avncRcTDvyuUbX0o","name":"Hepatology","_id":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"_createdAt":"2024-05-24T05:34:54Z","url":"/compendium/liver-cancer","_rev":"Jz2W7keLhiw1UYkGHfbwkP","_type":"subNavigation","name":"Liver","_id":"2aefee8c-db97-4e7d-b600-efb48e6bcb6c","_updatedAt":"2024-05-24T05:34:54Z","is_active":true,"navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"}},{"is_active":true,"_createdAt":"2025-01-15T14:59:47Z","name":"MASH","_id":"28c2b871-3034-43e1-b2b3-613ceefea3f1","_updatedAt":"2025-03-11T17:44:39Z","navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"},"_rev":"eeMGZbS7LW7ixyJqiosQnW","_type":"subNavigation","url":"/compendium/mash"}],"_createdAt":"2024-05-24T05:34:29Z","_type":"subNavigation"},{"_rev":"Jz2W7keLhiw1UYkGHfbkam","_type":"subNavigation","children":[{"_updatedAt":"2025-03-26T15:50:07Z","url":"/compendium/allergy","_createdAt":"2025-03-26T15:49:52Z","_rev":"HgejcbDQPm4c9MTbpNzlSc","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_type":"subNavigation","name":"Allergy","_id":"35f1dd25-2978-4597-b32e-611e7e6a7b99"},{"_updatedAt":"2024-05-24T05:23:39Z","url":"/compendium/autoimmune","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbkp8","_id":"b3daefd0-0ac3-4be2-ad23-f9c3fa37cf37","navParent":{"_type":"reference","_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797"},"_createdAt":"2024-05-24T05:23:39Z","_type":"subNavigation","name":"Autoimmune"},{"name":"Inflammation","_id":"6016d41d-9d43-49fa-99b6-7caca304f30d","url":"/compendium/Inflammation","_type":"subNavigation","_updatedAt":"2024-05-24T05:23:59Z","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:23:59Z","_rev":"Jz2W7keLhiw1UYkGHfbkzB"},{"is_active":true,"name":"Lupus","_updatedAt":"2024-05-24T05:24:47Z","url":"/compendium/lupus","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:24:47Z","_rev":"Jz2W7keLhiw1UYkGHfbmd6","_type":"subNavigation","_id":"b537fcea-aea3-40ca-83c1-0907fdc9ccb5"},{"_id":"ef6c4efc-5932-4148-b626-cbf42e1c49c3","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:25:23Z","_updatedAt":"2024-05-24T05:25:23Z","url":"/compendium/myasthenia-gravis","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbn7F","_type":"subNavigation","name":"Myasthenia Gravis"},{"name":"Rheumatoid Arthritis","url":"/compendium/rheumatoid-arthritis","is_active":true,"_id":"d5805074-645d-4a98-80cd-31c3e1321555","_updatedAt":"2025-03-31T20:55:37Z","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2025-03-31T20:55:16Z","_rev":"8qXc6rI0pNzm8KCf6Hia3L","_type":"subNavigation"}],"url":"/compendium/immunology","is_active":true,"name":"Immunology","_id":"1b1e3727-8b82-42da-9a62-b20472b9c797","_updatedAt":"2024-05-24T05:23:19Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:23:19Z"},{"url":"/compendium/infectious-disease","name":"Infectious Disease","_id":"b62af616-818b-4bda-b606-bd64287f9a85","_updatedAt":"2024-05-24T05:35:38Z","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:36:03Z","_rev":"rcwwj6TiN2Q0ymhqDyeyP3","_type":"subNavigation","name":"COVID-19","_id":"ffcd30d0-169f-4a8f-9f01-616142f33712","url":"/compendium/covid-19","is_active":true,"_updatedAt":"2024-05-24T05:36:03Z"},{"is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcAxn","name":"HIV","url":"/compendium/hiv","_createdAt":"2024-05-24T05:36:22Z","_type":"subNavigation","_id":"a53004c6-9fe2-4b9c-a86a-ad74f9204b3a","_updatedAt":"2024-05-24T05:36:29Z"},{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyezNO","_type":"subNavigation","name":"RSV","_updatedAt":"2024-05-24T05:37:06Z","is_active":true,"_createdAt":"2024-05-24T05:37:06Z","_id":"ca70e9ab-a981-4629-a766-81f7890b3977","url":"/compendium/rsv"},{"_createdAt":"2024-05-24T05:37:53Z","url":"/compendium/vaccines","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcFFM","_type":"subNavigation","name":"Vaccines","_id":"a0ec0591-b4a1-4723-b984-b681c957523f","_updatedAt":"2024-05-24T05:37:53Z"}],"_rev":"Jz2W7keLhiw1UYkGHfcA9Y","_type":"subNavigation","_createdAt":"2024-05-24T05:35:38Z"},{"_id":"db67ff69-2c58-4931-ad3d-767a636e38b0","is_active":true,"name":"Mental Health","url":"/compendium/mental-health","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","children":[{"_id":"efcab5a8-97d8-4f5a-ba99-0a0555531f5a","_updatedAt":"2024-05-24T05:38:58Z","url":"/compendium/mdd","is_active":true,"_createdAt":"2024-05-24T05:38:58Z","_type":"subNavigation","navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyf7Qk","name":"Major Depressive Disorder"},{"navParent":{"_type":"reference","_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0"},"name":"Sleep","url":"/compendium/sleep","is_active":true,"_createdAt":"2024-05-24T05:39:18Z","_rev":"rcwwj6TiN2Q0ymhqDyf96m","_type":"subNavigation","_id":"f52dbfa9-aefe-4d21-b432-7052a136ae98","_updatedAt":"2024-05-24T05:39:18Z"}],"_updatedAt":"2024-05-24T05:38:33Z","_rev":"rcwwj6TiN2Q0ymhqDyf4PU","_createdAt":"2024-05-24T05:38:33Z"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_id":"bafe1c52-a8b5-4786-bcee-668409d14a11","_updatedAt":"2025-01-17T17:18:32Z","url":"/compendium/neurology","children":[{"_createdAt":"2024-05-24T05:40:18Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:40:18Z","url":"/compendium/dmd","is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfERb","name":"Duchenne Muscular Dystrophy","_id":"3e24f5af-027e-4f0b-a7e2-a3ffaf756a35"},{"_rev":"rcwwj6TiN2Q0ymhqDyfIhq","_type":"subNavigation","_id":"d4e270df-2a59-4109-a7be-9c10f80722a7","url":"/compendium/epilepsy","is_active":true,"name":"Epilepsy","_updatedAt":"2024-05-24T05:40:38Z","navParent":{"_type":"reference","_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11"},"_createdAt":"2024-05-24T05:40:30Z"},{"_id":"7539f9b5-8f2a-4e1b-a10f-8cc748cd1489","_updatedAt":"2024-05-24T05:41:07Z","url":"/compendium/multiple-sclerosis","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:07Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfJRc","_type":"subNavigation","name":"Multiple Sclerosis"},{"name":"Parkinson Disease","_id":"90ebd8e7-e6d1-4128-8010-0b205fedb430","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:29Z","_rev":"rcwwj6TiN2Q0ymhqDyfJiG","_type":"subNavigation","_updatedAt":"2024-05-24T05:41:29Z","url":"/compendium/parkinson","is_active":true}],"_rev":"wsljz10lCZachwUMK3D8Fg","_type":"subNavigation","_createdAt":"2024-05-24T05:39:38Z","name":"Neurology"},{"url":"/compendium/obesity","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"B2kOGngERQtEUh1WG5WXvd","_updatedAt":"2024-09-04T14:25:34Z","children":[],"is_active":true,"_createdAt":"2024-09-04T14:25:34Z","name":"Obesity","_type":"subNavigation","_id":"fe48de19-78d2-4ed0-83fa-8884fb340de2"},{"_createdAt":"2024-05-24T05:41:55Z","_type":"subNavigation","name":"Oncology","_rev":"rcwwj6TiN2Q0ymhqDyfKov","children":[{"_updatedAt":"2024-05-24T05:42:17Z","is_active":true,"_createdAt":"2024-05-24T05:42:17Z","url":"/compendium/breast-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfMpl","_type":"subNavigation","name":"Breast Cancer","_id":"03ea9371-55cd-42e2-b300-7078b94ff467"},{"_id":"8b57fc91-4191-420c-a224-cb869f8fa0d7","url":"/compendium/cholangiocarcinoma","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_updatedAt":"2024-05-24T05:42:35Z","is_active":true,"_createdAt":"2024-05-24T05:42:35Z","_rev":"rcwwj6TiN2Q0ymhqDyfatY","_type":"subNavigation","name":"Cholangiocarcinoma"},{"is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"_createdAt":"2024-05-24T05:43:23Z","name":"Colorectal Cancer","_id":"e45ff858-e1bc-4b4a-9398-e12877b61607","_updatedAt":"2024-05-24T05:43:23Z","url":"/compendium/colorectal-cancer","_rev":"Jz2W7keLhiw1UYkGHfcTh6","_type":"subNavigation"},{"_id":"289f747b-dffd-4006-a27d-4933a46fd7c1","_updatedAt":"2024-05-24T13:25:09Z","url":"/compendium/immuno-oncology","is_active":true,"_createdAt":"2024-05-24T05:44:17Z","_rev":"Jz2W7keLhiw1UYkGHfsKT5","name":"Immuno-Oncology","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_type":"subNavigation"},{"is_active":true,"_createdAt":"2024-05-29T15:32:02Z","_rev":"Iat2IZiT321TmGHwkF6F4B","_type":"subNavigation","_updatedAt":"2024-05-29T15:32:02Z","url":"/compendium/liver-cancer","navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"name":"Liver Cancer","_id":"9d17bccc-3f33-4793-90e3-0adecfa71fa1"},{"_rev":"Jz2W7keLhiw1UYkGHfsIwL","_type":"subNavigation","_updatedAt":"2024-05-24T13:24:22Z","url":"/compendium/nsclc","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:45:56Z","name":"Non–Small Cell Lung Cancer","_id":"85d30c37-d6a1-4028-9c0f-ecdf36de220d"},{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:46:17Z","_rev":"Jz2W7keLhiw1UYkGHfcbF4","_type":"subNavigation","name":"Ovarian Cancer","_id":"5a67adcb-11d8-48a6-8c39-b2956f5f3e86","_updatedAt":"2024-05-24T05:46:17Z","url":"/compendium/ovarian-cancer"},{"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfmoB","_type":"subNavigation","name":"Prostate Cancer","_id":"bcfe0d88-7498-4268-95e6-875c94a2dab5","_updatedAt":"2024-05-24T05:47:42Z","url":"/compendium/prostate-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:47:42Z"},{"url":"/compendium/skincancer","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:48:18Z","name":"Skin Cancer","_id":"a3a04e72-c707-450d-b9d3-f9ebacc9f997","_updatedAt":"2024-05-24T05:48:18Z","_rev":"rcwwj6TiN2Q0ymhqDyfpKE","_type":"subNavigation"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:44:58Z","name":"Small Cell Lung Cancer","_id":"89f99f56-72a9-4dcd-9d8c-3d717d66a5f0","_updatedAt":"2025-01-14T18:47:45Z","is_active":true,"_rev":"36ELbxF4To1FbIa7xZVI3e","_type":"subNavigation","url":"/compendium/lung-cancer"},{"_type":"subNavigation","name":"Soft Tissue Sarcoma","_id":"6d1dc4b4-1be8-41ee-9bba-90ad4ce546b3","url":"/compendium/soft-tissue-sarcoma","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-29T15:30:06Z","_rev":"Iat2IZiT321TmGHwkF69Qd","_updatedAt":"2024-05-29T15:30:06Z"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"url":"/compendium/oncology","is_active":true,"_id":"90b398eb-3349-4b6a-b205-780a34cb4717","_updatedAt":"2024-05-24T05:41:55Z"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:48:54Z","_updatedAt":"2024-05-24T05:48:54Z","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfcePj","url":"/compendium/ophthalmology","children":[],"_type":"subNavigation","name":"Ophthalmology","_id":"eee19078-eb50-46e7-a97c-8f16d79eea97"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:49:11Z","_id":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"subNavigation","_updatedAt":"2025-01-17T17:19:27Z","url":"/compendium/pulmonology","children":[{"_type":"subNavigation","name":"COPD","_updatedAt":"2024-05-24T05:49:28Z","navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:28Z","_id":"3a19d535-d61e-43b1-bf6a-d6ced486a0b9","url":"/compendium/copd","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfrwW"},{"is_active":true,"navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:52Z","_rev":"rcwwj6TiN2Q0ymhqDyfuBv","_id":"474080cd-4295-4a70-907d-e1fc93c435cc","_updatedAt":"2024-05-24T05:49:52Z","url":"/compendium/pah","_type":"subNavigation","name":"Pulmonary Arterial Hypertension"}],"is_active":true,"_rev":"IZ4ZA8avncRcTDvyuUbYi3","name":"Pulmonology"},{"_updatedAt":"2024-05-24T05:50:50Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyg1Ah","_type":"subNavigation","url":"/compendium/raredisease","children":[{"navParent":{"_ref":"de690920-3cdc-4c43-a27e-ba4e38a62059","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyg1k4","_updatedAt":"2024-05-24T05:51:19Z","url":"/compendium/sma","is_active":true,"_createdAt":"2024-05-24T05:51:19Z","_type":"subNavigation","name":"Spinal Muscular Atrophy","_id":"9e780f76-2008-441b-ab5f-00d3a6d1a5b0"}],"_createdAt":"2024-05-24T05:50:50Z","name":"Rare Disease","is_active":true,"_id":"de690920-3cdc-4c43-a27e-ba4e38a62059"},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfcjSf","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_id":"f2a34114-0396-44cb-b241-11ef7b175500","url":"/compendium/respiratory","_createdAt":"2024-05-24T05:50:22Z","name":"Respiratory","_updatedAt":"2024-05-24T05:50:22Z","children":[{"is_active":true,"_type":"subNavigation","_id":"b2b2802f-2918-4431-8f4f-3bc7e6e6042f","_updatedAt":"2024-05-24T05:52:02Z","navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_createdAt":"2024-05-24T05:52:02Z","_rev":"rcwwj6TiN2Q0ymhqDyg2wy","name":"Asthma","url":"/compendium/asthma"},{"name":"Idiopathic Pulmonary Fibrosis","_id":"4dac47d5-8dd1-4e90-b4be-b6b5e605f6f5","url":"/compendium/ipf","navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_createdAt":"2024-06-03T18:31:07Z","_rev":"5DUHcaiKRKj5c8wHOPKtuf","_updatedAt":"2024-06-03T18:31:07Z","is_active":true,"_type":"subNavigation"}],"_type":"subNavigation"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcm6J","_createdAt":"2024-05-24T05:52:28Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:52:28Z","url":"/compendium/rheumatology","_id":"3ecb2952-6710-46b1-ab05-36997bfb4a33","is_active":true,"name":"Rheumatology","children":[]},{"_id":"ead467ba-7c17-4a1b-9deb-a7af56a7366e","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","name":"Women's Health","_updatedAt":"2024-05-24T05:52:51Z","url":"/compendium/womens-health","children":[],"is_active":true,"_createdAt":"2024-05-24T05:52:51Z","_rev":"Jz2W7keLhiw1UYkGHfcmDU"}],"_createdAt":"2020-04-14T14:04:25Z","name":"Specialty Area","url":"/compendium","is_active":true,"navParent":null,"_rev":"Jz2W7keLhiw1UYkGHfbRHa","_type":"subNavigation"},{"_id":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_updatedAt":"2024-05-23T21:04:52Z","sortOrder":2,"_type":"subNavigation","name":"Spotlight","navParent":null,"subQuery":[{"_createdAt":"2024-05-23T21:04:56Z","_rev":"uJbbwQWkLESsncBrcJSd1N","_type":"subNavigation","_id":"f5b2c97b-d6d4-468b-8a9a-4814364994c8","is_active":true,"_updatedAt":"2024-05-23T21:05:49Z","name":"Free In-Person Regional Events Focused on Oncology and Population Health","url":"/ivbmevents?display=home","children":[],"navParent":{"_ref":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_type":"reference"}}],"_rev":"rcwwj6TiN2Q0ymhqDyHDJ3","is_active":true,"_createdAt":"2024-05-23T20:47:34Z"},{"url":"/topic","subQuery":[{"sortOrder":1,"_rev":"Jz2W7keLhiw1UYkGHfbHQ4","children":[],"_type":"subNavigation","is_active":true,"_id":"43207521-4e5f-42d2-b013-34763a4d964c","_updatedAt":"2024-05-24T05:05:19Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Biosimilars","url":"/compendium/biosimilars","_createdAt":"2024-05-24T05:05:19Z"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"N7mKycgLbGtEq6btkPIW3d","_updatedAt":"2024-06-12T13:58:35Z","url":"/topic/center-on-health-equity-and-access","_createdAt":"2022-12-23T21:04:41Z","_id":"4161ff97-2901-4526-80ee-3749b6dc6345","children":[],"_type":"subNavigation","is_active":true,"name":"Center on Health Equity \u0026 Access"},{"_createdAt":"2024-05-24T05:56:42Z","_rev":"rcwwj6TiN2Q0ymhqDygl51","_type":"subNavigation","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Digital Health","_id":"232e30a0-2f7d-4ce1-9e4d-cc0cee73b20a","url":"/compendium/digital-health","_updatedAt":"2024-05-24T05:56:42Z","children":[],"is_active":true},{"_rev":"Jz2W7keLhiw1UYkGHfdAmX","_createdAt":"2024-05-24T05:57:01Z","_id":"3887cee2-5461-4cb3-b54f-297fcceb11ee","url":"/formulary","children":[],"_type":"subNavigation","is_active":true,"name":"Formulary","_updatedAt":"2024-05-24T05:57:01Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"_rev":"rcwwj6TiN2Q0ymhqDygmDl","name":"Gene Therapy","_id":"56aff93b-4f24-48fc-9dda-2d394397f956","_type":"subNavigation","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"children":[],"_updatedAt":"2024-05-24T05:57:41Z","url":"/compendium/gene-therapy","is_active":true,"_createdAt":"2024-05-24T05:57:41Z"},{"_createdAt":"2024-05-24T06:00:55Z","_updatedAt":"2024-05-24T06:00:55Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDygv9D","_type":"subNavigation","children":[],"url":"/guidelines","is_active":true,"name":"Guidelines","_id":"69723346-76b2-4896-b2d9-2db53ed5da96"},{"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDz7eaC","url":"/","_createdAt":"2024-05-24T13:53:24Z","name":"Health Care Administration","_updatedAt":"2024-05-24T14:10:39Z","_type":"subNavigation","_id":"cd6edcff-faa3-4bee-9071-042f8186052d","children":[{"_rev":"rcwwj6TiN2Q0ymhqDz6EMB","_type":"subNavigation","name":"Employers","_id":"83fca4ec-4ff0-4766-9e49-0376d44179e8","_updatedAt":"2024-05-24T13:53:42Z","url":"/compendium/employers","is_active":true,"navParent":{"_type":"reference","_ref":"cd6edcff-faa3-4bee-9071-042f8186052d"},"_createdAt":"2024-05-24T05:58:26Z"},{"_createdAt":"2024-05-24T05:58:44Z","name":"Medicare","url":"/compendium/medicare","_rev":"rcwwj6TiN2Q0ymhqDz6F3s","_type":"subNavigation","_id":"5647b438-aca9-4b57-9d4d-2df660b5a6ce","_updatedAt":"2024-05-24T13:53:53Z","is_active":true,"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"}},{"name":"Reimbursement","_updatedAt":"2024-05-24T13:54:23Z","url":"/compendium/reimbursement","navParent":{"_type":"reference","_ref":"cd6edcff-faa3-4bee-9071-042f8186052d"},"_type":"subNavigation","_id":"2c8ff713-9c43-4afc-aaca-e33ceb98f00c","is_active":true,"_createdAt":"2024-05-24T05:59:16Z","_rev":"rcwwj6TiN2Q0ymhqDz6G8S"}]},{"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"wx7I38TXtYeZdHCfn60Syn","_type":"subNavigation","name":"Health Care Cost","url":"/topic/healthcare-cost","_createdAt":"2020-04-14T14:06:29Z","_id":"c9a8f6fd-0ad0-4a82-a385-13c03fe688d0","children":[],"_updatedAt":"2021-02-25T17:30:59Z"},{"name":"Health Care Delivery","_updatedAt":"2021-02-25T17:29:58Z","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:06:43Z","_type":"subNavigation","url":"/topic/healthcare-delivery","is_active":true,"_rev":"YN5IiYQkhJ3hq0R7jM8DQW","_id":"d01b9875-6e51-42d1-bdf5-93fd8771855c"},{"_createdAt":"2020-04-14T14:07:01Z","_rev":"lslStCipHxtG437RQOGJ7p","name":"Insurance","url":"/topic/insurance","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_updatedAt":"2022-12-21T19:05:52Z","children":[],"_type":"subNavigation","_id":"d8eab058-f5ec-4c42-a95a-941c0a506543","is_active":true},{"url":"/topic/policy","_updatedAt":"2020-04-14T14:07:15Z","is_active":true,"_id":"fd066f36-78ee-4112-a121-4e02f8e45b0b","_createdAt":"2020-04-14T14:07:15Z","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"T035zdq5xruIFPyK3OzgdQ","_type":"subNavigation","name":"Policy"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDygvgV","_id":"d7893fef-5eb0-4b2d-b13d-a0bec73b2c14","is_active":true,"_createdAt":"2024-05-24T05:59:24Z","_type":"subNavigation","name":"Population Health","_updatedAt":"2024-05-24T06:01:29Z","url":"/compendium/population","children":[]},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T06:01:51Z","_id":"6188ac2f-7ec8-4cbb-a154-5822f606f3fa","url":"/approvals-launches","children":[],"_updatedAt":"2024-05-24T13:24:58Z","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfsKLu","_type":"subNavigation","name":"Product Approvals and Launches"},{"_id":"4e2fe99b-3ac4-4b48-89ed-774dd51675df","_type":"subNavigation","children":[],"is_active":true,"_updatedAt":"2020-04-14T14:07:28Z","url":"/topic/technology","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:07:28Z","_rev":"QxOJBWa4XErmibN6Cb5bN0","name":"Technology"},{"is_active":true,"_id":"22bd1bd6-88a6-4278-a846-e086cf30b141","_createdAt":"2020-04-14T14:07:42Z","_rev":"T035zdq5xruIFPyK3OzhkC","_type":"subNavigation","name":"Value-Based Care","_updatedAt":"2020-04-14T14:07:42Z","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"url":"/topic/value-based-care"}],"is_active":true,"_createdAt":"2020-04-14T14:05:54Z","_type":"subNavigation","name":"Topics","_rev":"iEeBpgQLYwZXMeCflboLMu","navParent":null,"_id":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","sortOrder":2,"_updatedAt":"2020-08-21T22:11:57Z"},{"sortOrder":3,"_rev":"N0LuVAjtHhQSyVgQyS0Kyv","_id":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_updatedAt":"2020-04-27T18:48:23Z","url":"/ivbm","_type":"subNavigation","is_active":true,"_createdAt":"2020-04-27T18:48:09Z","name":"Institute for Value-Based Medicine","navParent":null,"subQuery":[{"_rev":"cyKVTGb2fpu5E4X0UMrv4p","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_createdAt":"2020-05-06T13:11:16Z","_type":"subNavigation","children":[],"is_active":true,"name":"All Coverage","_id":"f7379c68-40be-45e4-9747-484dcec584d3","_updatedAt":"2020-05-06T13:11:16Z","url":"/ivbm"},{"_type":"subNavigation","children":[],"_id":"cc8a827f-3e94-413a-aa0c-0d8b40eb5f18","_updatedAt":"2020-04-27T18:49:41Z","url":"/ivbm/event-coverage","name":"Event Coverage","is_active":true,"_createdAt":"2020-04-27T18:49:41Z","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_rev":"k2D4PisPM2pBS5NIl95QbN"},{"_id":"aa3f3bb8-9e8c-457d-aeb6-7b94b968395a","_type":"subNavigation","name":"Interviews","children":[],"_updatedAt":"2020-04-27T18:50:03Z","url":"/ivbm/interviews","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_createdAt":"2020-04-27T18:50:03Z","is_active":true,"_rev":"k2D4PisPM2pBS5NIl95RlO"},{"_id":"1be7e99c-8d37-4d70-a009-67eb03fae5ba","_updatedAt":"2020-04-27T18:50:34Z","_rev":"XtnP0djhkej33kSTbdUgmN","_type":"subNavigation","children":[],"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_createdAt":"2020-04-27T18:50:34Z","url":"/ivbm/news","is_active":true,"name":"News"}]},{"navParent":null,"_id":"9a07b754-3383-43ac-9d2d-a370d44406d1","is_active":true,"_rev":"lsW1cEPdRFwwIdupAS8Stb","_type":"subNavigation","name":"About AJMC","_updatedAt":"2020-04-27T18:48:27Z","_createdAt":"2020-04-14T14:09:11Z","subQuery":[{"_rev":"NGYpFwzJghlKjBIAt48VzS","_updatedAt":"2020-05-07T17:05:52Z","is_active":true,"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2020-05-07T17:05:52Z","url":"/about","children":[],"name":"AJMC Journals","_id":"4e10ead3-6a42-43df-b251-b93b912a24cb","_type":"subNavigation"},{"_createdAt":"2020-04-14T14:09:38Z","name":"Anniversary","_id":"4451f4fa-a919-45b4-b6e5-282668cd792e","_rev":"rHX8vIEJKWyjgUO02y82fe","_type":"subNavigation","children":[],"url":"/anniversary","is_active":true,"_updatedAt":"2020-04-14T14:09:38Z","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"}},{"_type":"subNavigation","_id":"99bccc8e-9329-496f-b588-ec3d080f0859","url":"/authorshipforms","_createdAt":"2020-04-14T14:10:37Z","name":"Author Forms","_updatedAt":"2020-06-09T11:44:06Z","is_active":true,"_rev":"VmKMEDy0rHs5jzhO3eZVVM","children":[],"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"}},{"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"name":"Authors","_rev":"0JTsteyxJPdyCvciQ9yBPv","_type":"subNavigation","url":"/authors","children":[],"is_active":true,"_createdAt":"2020-04-14T14:10:19Z","_updatedAt":"2020-05-06T12:53:11Z","_id":"518317a5-297f-4c4f-9d2a-6da7b8c98d9c"},{"_type":"subNavigation","name":"Nominate a Rising Leader","_id":"a96a44c9-4d51-47c6-8f81-4263bd2f58b4","is_active":true,"_createdAt":"2020-06-15T17:13:51Z","children":[],"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_rev":"m6BzyPIGe9IGx2bV3pSCbq","_updatedAt":"2020-06-15T17:13:51Z","url":"/seema-sonnad-nomination"},{"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2023-03-14T13:29:28Z","_rev":"TctAtfg0qER1kILh39bPC4","_id":"4420e458-acb4-4edb-9f33-c4fc4504ff41","name":"Submit a Manuscript","is_active":true,"_type":"subNavigation","_updatedAt":"2023-03-14T13:29:28Z","url":"/submit-a-manuscript","children":[]}],"sortOrder":4}],"site_setting":{"siteURL":"www.ajmc.com","salesforceDMPId":"tr3xsudox","_createdAt":"2020-04-14T14:14:32Z","description":"The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.","alternateName":"The American Journal of Managed Care","socialLinks":[{"title":"Facebook","url":"https://www.facebook.com/TheAmericanJournalOfManagedCare","blank":true,"_type":"urlArray","_key":"5a09ae68c48c"},{"_type":"urlArray","_key":"ad6b3d250e0b","title":"Twitter","url":"https://twitter.com/AJMC_Journal","blank":true},{"blank":true,"_type":"urlArray","_key":"7d1e53fa7d09","title":"LinkedIn","url":"https://www.linkedin.com/company/american-journal-of-managed-care/"},{"title":"Instagram","url":"https://www.instagram.com/ajmcjournal/","blank":true,"_type":"urlArray","_key":"2478204aa05c"},{"blank":true,"_type":"urlArray","_key":"0ba4cf990c2f","title":"RSS","url":"/rss"}],"creativeLayout":null,"contactPoint":{"email":"info@ajmc.com"},"keywords":["American Journal of Managed Care","AJMC"],"enableSanity2":true,"gaID":"UA-155582410-5,UA-11140057-3","_rev":"qEABtfO2fuUtkjkDrKfCaP","address":{"addressRegion":"New Jersey","addressCountry":"United States of America","streetAddress":"2 Commerce Drive, Suite 100","postalCode":"08512","addressLocality":"Cranbury"},"_type":"siteSettings","orangizationName":"AJMC","name":"AJMC - Managed Care News, Research, and Expert Insights","creativeLayoutLatestNews":null,"_id":"siteSettings","copyRightText":"AJMC®","footerLinks":[{"_type":"urlArray","_key":"6170fdefc8129a5a7ef9dfdd78a2573e","title":"About","url":"/about-us"},{"_type":"urlArray","_key":"281c240875d5","title":"Contact","url":"/contactus"},{"url":"/editorial-boards","_type":"urlArray","_key":"25e9e6fb7b4422cd0ac20e1a1d993228","title":"Editorial Boards"},{"_type":"urlArray","_key":"20a44c137e8d","title":"Advertise","url":"/advertise"},{"_key":"21b84fcc9b6e","title":"Do Not Sell My Information","url":"https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com","blank":true,"_type":"urlArray"},{"_type":"urlArray","_key":"2f35307aab1f","title":"Terms \u0026 Conditions","url":"/terms"},{"_type":"urlArray","_key":"50ecd8627d01","title":"Privacy Policy","url":"/privacy"}],"_updatedAt":"2025-03-26T14:23:02Z"},"clinicalData":[{"_id":"4ee49086-e720-4a65-883e-4efc24de53bb","name":"Center on Health Equity \u0026 Access","identifier":"center-on-health-equity-and-access","sortOrder":null,"children":[]},{"_id":"topic_clinical","name":"Clinical","identifier":"clinical","sortOrder":null,"children":[]},{"identifier":"healthcare-cost","sortOrder":null,"children":[],"_id":"topic_healthcare-cost","name":"Health Care Cost"},{"_id":"topic_healthcare-delivery","name":"Health Care Delivery","identifier":"healthcare-delivery","sortOrder":null,"children":[]},{"_id":"topic_insurance","name":"Insurance","identifier":"insurance","sortOrder":null,"children":[]},{"identifier":"policy","sortOrder":null,"children":[],"_id":"topic_policy","name":"Policy"},{"_id":"topic_technology","name":"Technology","identifier":"technology","sortOrder":null,"children":[]},{"identifier":"value-based-care","sortOrder":null,"children":[],"_id":"topic_value-based-care","name":"Value-Based Care"}],"seo_data":[],"recent_news":[{"thumbnail":{"asset":{"_ref":"image-cc66dd5d25e32e7810e821815897e40ae141d674-6720x4480-jpg","_type":"reference"},"_type":"mainImage","alt":"Man rubbing his eyes | Image credit: Prostock-studio - stock.adobe.com","caption":"Man rubbing his eyes | Image credit: Prostock-studio - stock.adobe.com"},"url":{"_type":"slug","current":"sleep-disruptions-contribute-to-likelihood-of-dry-eye-syndrome"},"authorMapping":{"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"_key":"8a55e07516550","_type":"span","marks":[],"text":"Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®."}],"_type":"block","style":"normal","_key":"106fd454900b"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"marks":[],"text":"She has a BA in English language and literature from Rutgers University. You can connect with Julia on ","_key":"c2ef3167786d","_type":"span"},{"_key":"8a55e07516551","_type":"span","marks":["d45285824c6f"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"8a55e07516552"}],"_type":"block","style":"normal","_key":"769839c11518"}],"profileImage":{"_type":"mainImage","alt":"Julia Bonavitacola","asset":{"_ref":"image-fa6d7df41e3dda6f2ed66b65f3313ff5869748c2-430x430-png","_type":"reference"}},"url":{"current":"julia-bonavitacola","_type":"slug"},"firstName":"Julia","_rev":"sgy4yN0CjmArmRDnE2Khrz","_type":"author","_updatedAt":"2024-05-20T19:27:55Z","lastName":"Bonavitacola","displayName":"Julia Bonavitacola","_createdAt":"2022-02-23T21:42:42Z","_id":"15b1de57-6a71-4655-ba17-eeaa1c733634"},"factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"83c47a61-69ea-4368-84a8-f0a54e22226b","title":"Sleep Disruptions Contribute to Likelihood of Dry Eye Syndrome","summary":"Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.","published":"2025-04-09T16:33:00.000Z"},{"url":{"current":"nccn-data-find-racial-socioeconomic-disparities-in-quality-of-care-for-metastatic-pancreatic-cancer","_type":"slug"},"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"985109ca-1ea9-4fbd-abee-d084a3ec8fe7","title":"NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer","published":"2025-04-09T16:08:39.933Z","authorMapping":{"_type":"author","_updatedAt":"2025-02-24T18:36:26Z","firstName":"Giuliana","_createdAt":"2023-06-23T19:52:20Z","_rev":"j14L132AMqRQ5agq21Fxkz","_id":"8e597e29-c3ad-470c-8174-00c81b563f81","biography":[{"style":"normal","_key":"7644d0957596","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/topic/center-on-health-equity-and-access","_key":"324bbc17fbcd"}],"children":[{"_type":"span","marks":[],"text":"Giuliana Grossi is an editor for ","_key":"0179b0541e0b"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"d7871694e50e"},{"_key":"3173808ea48d","_type":"span","marks":["sup"],"text":"®"},{"text":", overseeing the publication's ","_key":"1c074ec7251f","_type":"span","marks":[]},{"_type":"span","marks":["324bbc17fbcd"],"text":"Center on Health Equity \u0026 Access","_key":"e68159433236"},{"_type":"span","marks":[],"text":". Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.","_key":"c2e2da920bfb"}],"_type":"block"},{"style":"normal","_key":"cf123c823686","markDefs":[],"children":[{"_key":"cd7292039254","_type":"span","marks":[],"text":"Before Giuliana joined "},{"text":"AJMC","_key":"ad727be45f99","_type":"span","marks":["em"]},{"_key":"c140cf0f19d0","_type":"span","marks":[],"text":", she delved into rare disease coverage at HCPLive"},{"marks":["sup"],"text":"®","_key":"39ac8edb75a8","_type":"span"},{"_type":"span","marks":[],"text":", a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in ","_key":"6a1265a483a0"},{"_type":"span","marks":["em"],"text":"Population Health, Equity \u0026 Outcomes","_key":"cf2d12c38dca"},{"_type":"span","marks":["sup"],"text":"®","_key":"aa763d202117"},{"_type":"span","marks":[],"text":" (formerly ","_key":"61f88e04956e"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"17e5c52377f8"},{"_type":"span","marks":["sup"],"text":"®","_key":"5504bfff7017"},{"_type":"span","marks":[],"text":"), ","_key":"19512dc0b299"},{"_key":"3cb7d49a81f9","_type":"span","marks":["em"],"text":"Evidence-Based Oncology"},{"_type":"span","marks":["sup"],"text":"®","_key":"22ab5aeaa59a"},{"_type":"span","marks":[],"text":",","_key":"b1d13339e368"},{"text":" ","_key":"fcd8255a68b5","_type":"span","marks":["sup"]},{"text":"NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.","_key":"e4e8d0128520","_type":"span","marks":[]}],"_type":"block"},{"children":[{"_key":"5f3ea2ee587e","_type":"span","marks":[],"text":"She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications."}],"_type":"block","style":"normal","_key":"59a199fedfec","markDefs":[]},{"children":[{"text":"\n","_key":"e7fe8691814f","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"cd682b512e51","markDefs":[]}],"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","caption":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","asset":{"_ref":"image-6ce94d112b3a5df5bd05dc2b689a0720adadcc62-400x400-jpg","_type":"reference"}},"url":{"current":"giuliana-grossi","_type":"slug"},"lastName":"Grossi","authorType":"author","displayName":"Giuliana Grossi"},"factCheckAuthorMapping":null,"summary":"New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.","thumbnail":{"asset":{"_ref":"image-059ff9256b03d464e82497337deb6513e0bb71b1-5909x4000-jpg","_type":"reference"},"_type":"mainImage","alt":"Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg"}},{"_id":"7cda4ace-7f96-4201-a12e-0b219f4bac70","title":"Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD","url":{"current":"addressing-unmet-needs-emerging-treatment-for-atopic-dermatitis-raj-chovatiya-md-phd","_type":"slug"},"published":"2025-04-09T16:00:00.000Z","authorMapping":{"biography":[{"_key":"3da8fced8696","markDefs":[],"children":[{"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd","_type":"span","marks":[]},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal"}],"url":{"current":"cameron-santoro","_type":"slug"},"_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","profileImage":{"asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Cameron Santoro"},"_updatedAt":"2024-05-20T19:28:22Z","firstName":"Cameron","lastName":"Santoro","displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z","_type":"author"},"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"summary":"Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.","thumbnail":{"_type":"mainImage","alt":"Raj Chovatiya, MD, PhD, MSCI","caption":"Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission. ","asset":{"_ref":"image-39c897af8850d2f2fab9da3bd06453a01d7c5e5d-1200x640-png","_type":"reference"}},"factCheckAuthorMapping":null},{"published":"2025-04-09T15:01:00.000Z","factCheckAuthorMapping":null,"summary":"US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers to accessing health care.","authorMapping":{"_type":"author","biography":[{"_key":"3da8fced8696","markDefs":[],"children":[{"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd","_type":"span","marks":[]},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal"}],"url":{"current":"cameron-santoro","_type":"slug"},"_rev":"sgy4yN0CjmArmRDnE2KiNm","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","profileImage":{"asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Cameron Santoro"},"_updatedAt":"2024-05-20T19:28:22Z","firstName":"Cameron","lastName":"Santoro","displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z"},"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"_id":"9996ba50-4244-4dca-8b6f-5236d0cc6854","title":"Review Explores Skin Health Risks of US Migrant Populations","thumbnail":{"alt":"Migrant Populations. | Image Credit: wladimir1804 - stock.adobe.com ","caption":"US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers in accessing health care. | Image Credit: wladimir1804 - stock.adobe.com ","asset":{"_ref":"image-23de5ad902bbd3cf2c300150ae495972f15fe176-6000x4000-jpg","_type":"reference"},"_type":"mainImage"},"url":{"_type":"slug","current":"review-explores-skin-health-risks-of-us-migrant-populations"}}],"latest_publications":[{"_id":"1ecbd295-09c6-4fa2-89fa-72cd97f8c0af","issueGroup":{"_ref":"04f96f28-a532-45fc-b381-a16d1b79bd77","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"}},"authorDetails":[{"lastName":"Ouayogodé","url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou"},{"displayName":"Xiaodan Liang, MS","firstName":"Xiaodan","lastName":"Liang","url":{"_type":"slug","current":"xiaodan-liang-ms"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Sancia K. Ferguson, MD, MPH","firstName":"Sancia","lastName":"Ferguson","url":{"current":"sancia-k-ferguson-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"title":"Organizational Factors Associated With Variation in Primary Care Providers in ACOs","summary":"A higher percentage of accountable care organization (ACO) primary care providers was associated with physician leadership, upside financial risk, and financial compensation of physicians tied to performance measures.","url":"organizational-factors-associated-with-variation-in-primary-care-providers-in-acos","published":"2025-04-08T13:00:00.000Z","factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou","lastName":"Ouayogodé","url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null},{"firstName":"Xiaodan","lastName":"Liang","url":{"current":"xiaodan-liang-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Xiaodan Liang, MS"},{"biography":null,"showSocialShare":null,"displayName":"Sancia K. Ferguson, MD, MPH","firstName":"Sancia","lastName":"Ferguson","url":{"current":"sancia-k-ferguson-md-mph","_type":"slug"},"profileImage":null}]},{"title":"The Role of Advanced Technologies in Improving Diabetes Outcomes","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAKCAYAAAC0VX7mAAAACXBIWXMAABYlAAAWJQFJUiTwAAABxklEQVQoka2STW/aQBCG+f/qLZdeqkrpoQqpWiIlCk2BhKCEErAxRXGMnQ8wJoAxGMyX7fX6rWbSpqXnWlrN7M7sszPvOAMAaZrif32Z3zCySSKRSIlYJFhtQgTrLVbbCNsohpQSUqYIY8ErigU2YYxNGPGe7hHjFUiHjutj6C0w8ZfQLAeK0UPTtKF2bEwXK8yCNZ+3LAd6d4iOPcbjYIKB63MBO0BvvkSxYaDctHDvuCg0DJzd3OHsRsd+voaG0UP7YYAP+Rren1RxVGnxfjDxMZousN5GL0CCiSRhSLakIFtU0DT7DL9QTVy1HxiQLan4WtPxNlfBm48FHBQVPHtzloIkIvsLmMIP1tzWafUWh+cqCnUD+e+3KCkd1PQnfC5reHd8zRCye58u+IHucMoaU7ukP7EyJHR/PENd76J173CrhyUVuUsN52oH1fYjyk2TK6b1pazhqPKDH9OsPkx7zPfDKH6ZMpVK+tnjGVw/YGjusoVv9TsYvRG6Q48vTOZL1srqu1wZ+aQfDZKGRbJxhdS3SCSESFiL0TRgsZ+ePRaaziiZ8qgbyqP2yCdLMfIpvjPl139RSkRCcPK/sT/7v/3d+E98j+pE3hWucAAAAABJRU5ErkJggg==","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778}},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png"}},"url":"the-role-of-advanced-technologies-in-improving-diabetes-outcomes","published":"2025-04-07T17:00:00.000Z","factCheckBy":[{"firstName":"David","lastName":"Marrero","url":{"current":"david-g-marrero-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"David G. Marrero, PhD"},{"lastName":"Parkin","url":{"current":"christopher-g-parkin-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Christopher G. Parkin, MS","firstName":"Christopher"},{"firstName":"Grazia","lastName":"Aleppo","url":{"current":"grazia-aleppo-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Grazia Aleppo, MD"},{"url":{"current":"irl-b-hirsch-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Irl B. Hirsch, MD","firstName":"Irl","lastName":"Hirsch"},{"lastName":"McGill","url":{"current":"janet-mcgill-md-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Janet McGill, MD, MA","firstName":"Janet"},{"firstName":"Rodolfo","lastName":"Galindo","url":{"current":"rodolfo-j-galindo-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rodolfo J. Galindo, MD"},{"firstName":"Davida","lastName":"Kruger","url":{"_type":"slug","current":"davida-f-kruger-msn-aprn-bc-bc-adm"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Davida F. Kruger, MSN, APRN-BC, BC-ADM"},{"biography":null,"showSocialShare":null,"displayName":"Carol J. Levy, MD, CDE","firstName":"Carol","lastName":"Levy","url":{"current":"carol-j-levy-md-cde","_type":"slug"},"profileImage":null},{"url":{"current":"anders-l-carlson-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Anders L. Carlson, MD","firstName":"Anders","lastName":"Carlson"},{"url":{"current":"guillermo-e-umpierrez-md-cde","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Guillermo E. Umpierrez, MD, CDE","firstName":"Guillermo","lastName":"Umpierrez"}],"summary":"This article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.","authorDetails":[{"displayName":"David G. Marrero, PhD","firstName":"David","lastName":"Marrero","url":{"_type":"slug","current":"david-g-marrero-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Christopher G. Parkin, MS","firstName":"Christopher","lastName":"Parkin","url":{"current":"christopher-g-parkin-ms","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Grazia Aleppo, MD","firstName":"Grazia","lastName":"Aleppo","url":{"current":"grazia-aleppo-md","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Irl B. Hirsch, MD","firstName":"Irl","lastName":"Hirsch","url":{"current":"irl-b-hirsch-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Janet McGill, MD, MA","firstName":"Janet","lastName":"McGill","url":{"current":"janet-mcgill-md-ma","_type":"slug"},"profileImage":null},{"firstName":"Rodolfo","lastName":"Galindo","url":{"current":"rodolfo-j-galindo-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rodolfo J. Galindo, MD"},{"displayName":"Davida F. Kruger, MSN, APRN-BC, BC-ADM","firstName":"Davida","lastName":"Kruger","url":{"_type":"slug","current":"davida-f-kruger-msn-aprn-bc-bc-adm"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Carol J. Levy, MD, CDE","firstName":"Carol","lastName":"Levy","url":{"current":"carol-j-levy-md-cde","_type":"slug"},"profileImage":null},{"firstName":"Anders","lastName":"Carlson","url":{"current":"anders-l-carlson-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Anders L. Carlson, MD"},{"firstName":"Guillermo","lastName":"Umpierrez","url":{"current":"guillermo-e-umpierrez-md-cde","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Guillermo E. Umpierrez, MD, CDE"}],"_id":"1be59b1d-5594-4f9f-8f89-f0b48ae684a4","issueGroup":{"_ref":"04f96f28-a532-45fc-b381-a16d1b79bd77","_type":"reference"}},{"url":"comparing-breast-cancer-treatment-outcomes-between-fee-for-service-and-medicare-advantage","factCheckBy":[{"lastName":"Shearn-Nance","url":{"current":"galen-shearn-nance-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Galen Shearn-Nance, BS","firstName":"Galen"},{"showSocialShare":null,"displayName":"Rishi R. Sachdev, BS","firstName":"Rishi","lastName":"Sachdev","url":{"current":"rishi-r-sachdev-bs","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Long Vu, MS","firstName":"Long","lastName":"Vu","url":{"current":"long-vu-ms","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Weichuan Dong, PhD","firstName":"Weichuan","lastName":"Dong","url":{"_type":"slug","current":"weichuan-dong-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Alberto J. Montero, MD, MBA","firstName":"Alberto","lastName":"Montero","url":{"current":"alberto-j-montero-md-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Siran M. Koroukian, PhD","firstName":"Siran","lastName":"Koroukian","url":{"_type":"slug","current":"siran-m-koroukian-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Johnie","lastName":"Rose","url":{"current":"johnie-rose-md-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Johnie Rose, MD, PhD"}],"issueGroup":{"_ref":"04f96f28-a532-45fc-b381-a16d1b79bd77","_type":"reference"},"thumbnail":{"asset":{"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"}},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"},"_type":"mainImage","alt":"AJMC"},"published":"2025-04-04T13:00:00.000Z","authorDetails":[{"lastName":"Shearn-Nance","url":{"current":"galen-shearn-nance-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Galen Shearn-Nance, BS","firstName":"Galen"},{"displayName":"Rishi R. Sachdev, BS","firstName":"Rishi","lastName":"Sachdev","url":{"current":"rishi-r-sachdev-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Long","lastName":"Vu","url":{"current":"long-vu-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Long Vu, MS"},{"displayName":"Weichuan Dong, PhD","firstName":"Weichuan","lastName":"Dong","url":{"current":"weichuan-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Alberto J. Montero, MD, MBA","firstName":"Alberto","lastName":"Montero","url":{"current":"alberto-j-montero-md-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"siran-m-koroukian-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Siran M. Koroukian, PhD","firstName":"Siran","lastName":"Koroukian"},{"firstName":"Johnie","lastName":"Rose","url":{"current":"johnie-rose-md-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Johnie Rose, MD, PhD"}],"_id":"d9ff5f51-04d8-4aab-a8b3-7962bb157995","title":"Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage","summary":"This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare."},{"issueGroup":{"_type":"reference","_ref":"ec950d3a-3b95-408b-962c-2c66473de271"},"title":"Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most","summary":"On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum \nfrom prevention to treatment.","url":"value-based-care-is-key-to-bringing-cardiology-breakthroughs-to-those-who-will-benefit-most","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"marks":["em"],"text":"AJMC","_key":"b773bee92455","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_key":"14118ee858d3","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" (","_key":"a25757970c62","_type":"span"},{"marks":["em"],"text":"AJAC","_key":"6353c3a02e0f","_type":"span"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d"}],"children":[{"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span","marks":[]},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"}}],"factCheckBy":[{"lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_key":"b9461d308bc8","_type":"span","marks":[],"text":") and "},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block"},{"_type":"block","style":"normal","_key":"a90d7ab4c801","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}]}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina"}],"_id":"3631f7ee-c7d0-43ef-8560-9d8c17140e87","thumbnail":{"_type":"mainImage","alt":"Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com","asset":{"_rev":"5vytRcQQMhLIHBYX6HcWVW","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/017d98cc686b8591cedb8628f1284c6333f99de9-1200x801.jpg","size":736846,"mimeType":"image/jpeg","_id":"image-017d98cc686b8591cedb8628f1284c6333f99de9-1200x801-jpg","assetId":"017d98cc686b8591cedb8628f1284c6333f99de9","metadata":{"isOpaque":true,"blurHash":"V.HoU%adoMaysmlCWXoLofWBI]WBoKWXazM{aeR*WXj]","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":0.52,"background":"#b7bbd4","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#2387d4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.47},"dominant":{"title":"#fff","population":6.83,"background":"#59413e","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":6.83,"background":"#59413e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"title":"#fff","population":1.07,"background":"#a6704f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":4.64,"background":"#90bbf0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.32,"background":"#2e4e69"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.4981273408239701,"height":801}},"uploadId":"KmfRqAMxsqXqMxiMu0EQv841rfMptKR8","_type":"sanity.imageAsset","sha1hash":"017d98cc686b8591cedb8628f1284c6333f99de9","path":"images/0vv8moc6/ajmc/017d98cc686b8591cedb8628f1284c6333f99de9-1200x801.jpg","originalFilename":"Dallas Texas - SeanPavonePhoto - stock.adobe.com.jpeg","_createdAt":"2025-03-06T20:35:51Z","_updatedAt":"2025-03-06T20:35:51Z","extension":"jpg"}},"published":"2025-03-13T17:00:00.000Z"},{"summary":"Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.","thumbnail":{"_type":"mainImage","alt":"Pittsburgh, Pennsylvania | Image Credit: © SeanPavonePhoto - stock.adobe.com","asset":{"_type":"sanity.imageAsset","mimeType":"image/jpeg","size":393515,"originalFilename":"Pittsburgh Pennsylvania - SeanPavonePhoto - stock.adobe.com.jpeg","metadata":{"_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#3b2424","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.43},"muted":{"background":"#636f9f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.83},"lightVibrant":{"background":"#6c8cf4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.05},"darkVibrant":{"background":"#5a3429","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.03},"lightMuted":{"foreground":"#000","title":"#fff","population":2.39,"background":"#d4b0ad","_type":"sanity.imagePaletteSwatch"},"vibrant":{"population":1.13,"background":"#da8327","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"foreground":"#fff","title":"#fff","population":8.05,"background":"#6c8cf4","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7777777777777777,"height":675},"exif":{"PixelYDimension":675,"ExposureBiasValue":0,"FocalLength":28,"SceneCaptureType":0,"DateTimeOriginal":"2012-08-07T20:53:36.000Z","ExposureTime":30,"ColorSpace":1,"ExposureProgram":1,"SubSecTime":"8","_type":"sanity.imageExifMetadata","SensitivityType":2,"FocalLengthIn35mmFormat":42,"WhiteBalance":1,"CustomRendered":1,"FNumber":18,"GainControl":0,"Saturation":0,"Sharpness":0,"LensModel":"16-28mm f/2.8","ISO":100,"SubSecTimeDigitized":"8","SubSecTimeOriginal":"8","Contrast":0,"LightSource":10,"MaxApertureValue":2.9708536585365852,"DigitalZoomRatio":1,"SubjectDistanceRange":0,"SensingMethod":2,"MeteringMode":5,"ExposureMode":1,"PixelXDimension":1200,"DateTimeDigitized":"2012-08-07T20:53:36.000Z","BodySerialNumber":"3067398"},"isOpaque":true,"blurHash":"MqF#-3XAWXs+Wrx|obj^WVoIE;j]axf6ay"},"sha1hash":"6644908b569760ee031bc73457d4ebf2d7685b23","assetId":"6644908b569760ee031bc73457d4ebf2d7685b23","uploadId":"0n62DXfYU8uxfZ8kQgahB9JdkXq48wk9","_rev":"5vytRcQQMhLIHBYX6HYPPY","_updatedAt":"2025-03-06T20:24:43Z","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/6644908b569760ee031bc73457d4ebf2d7685b23-1200x675.jpg","path":"images/0vv8moc6/ajmc/6644908b569760ee031bc73457d4ebf2d7685b23-1200x675.jpg","_createdAt":"2025-03-06T20:24:43Z","_id":"image-6644908b569760ee031bc73457d4ebf2d7685b23-1200x675-jpg","extension":"jpg"}},"url":"reducing-care-fragmentation-to-boost-ckm-disease-outcomes","authorDetails":[{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}],"_type":"block","style":"normal","_key":"643be033259e"},{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}],"_type":"block","style":"normal","_key":"f4070c315fab"}],"showSocialShare":null,"displayName":"Maggie L. Shaw","firstName":"Maggie","lastName":"Shaw","url":{"current":"maggie-l-shaw","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}}}],"_id":"78ac3d38-2f82-4daa-9ae9-5a5c97c42f26","issueGroup":{"_ref":"ec950d3a-3b95-408b-962c-2c66473de271","_type":"reference"},"title":"Reducing Care Fragmentation to Boost CKM Disease Outcomes","published":"2025-03-13T13:00:00.000Z","factCheckBy":[{"firstName":"Maggie","lastName":"Shaw","url":{"current":"maggie-l-shaw","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_key":"abc0e18a29ce0","_type":"span","marks":[],"text":"Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor."}],"_type":"block","style":"normal","_key":"643be033259e"},{"style":"normal","_key":"f4070c315fab","markDefs":[{"_key":"159c764717fb","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/"}],"children":[{"marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2","_type":"span"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_key":"abc0e18a29ce2","_type":"span","marks":[],"text":"."}],"_type":"block"}],"showSocialShare":null,"displayName":"Maggie L. Shaw"}]},{"published":"2025-03-12T17:00:00.000Z","_id":"befd4246-6c9e-4a26-929b-67f32ed6d0ea","issueGroup":{"_type":"reference","_ref":"ec950d3a-3b95-408b-962c-2c66473de271"},"summary":"Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.","url":"closing-the-gaps-in-cardiac-care-with-technology-collaboration","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"marks":["em"],"text":"AJMC","_key":"b773bee92455","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_key":"14118ee858d3","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" (","_key":"a25757970c62","_type":"span"},{"marks":["em"],"text":"AJAC","_key":"6353c3a02e0f","_type":"span"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true}],"children":[{"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span","marks":[]},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"}}],"factCheckBy":[{"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_key":"b9461d308bc8","_type":"span","marks":[],"text":") and "},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null}],"title":"Closing the Gaps in Cardiac Care With Technology, Collaboration","thumbnail":{"_type":"mainImage","alt":"Phoenix Arizona | Image Credit: © Kevin Ruck - stock.adobe.com","asset":{"_id":"image-f254913b4d2b82f5f4b9ef36991f19f9af1a4a76-1200x741-jpg","uploadId":"HaCML4BSTw1U7FPuL2oTj3cXlu8OLTCq","_type":"sanity.imageAsset","sha1hash":"f254913b4d2b82f5f4b9ef36991f19f9af1a4a76","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f254913b4d2b82f5f4b9ef36991f19f9af1a4a76-1200x741.jpg","assetId":"f254913b4d2b82f5f4b9ef36991f19f9af1a4a76","_createdAt":"2025-03-06T20:11:55Z","originalFilename":"Phoenix Arizona - Kevin Ruck - stock.adobe.com.jpeg","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"aspectRatio":1.6194331983805668,"height":741,"_type":"sanity.imageDimensions","width":1200},"exif":{"PixelYDimension":741,"_type":"sanity.imageExifMetadata","DateTimeDigitized":"2022-03-13T15:30:18.000Z","ColorSpace":1,"PixelXDimension":1200},"isOpaque":true,"blurHash":"VPJ6ysIrV@s:Nb|zNfV[j[WX0.X8W.WrW;1QxWX6Nboe","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#eec28a","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":4.96},"_type":"sanity.imagePalette","darkMuted":{"population":4.39,"background":"#64503d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"title":"#fff","population":1.14,"background":"#606ca0","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":4.96,"background":"#eec28a","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.71,"background":"#6f551f"},"lightMuted":{"background":"#b4b6c8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.25},"vibrant":{"background":"#f27f3c","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.96}}},"_rev":"64U6pdV7i6019NRal6r2LF","path":"images/0vv8moc6/ajmc/f254913b4d2b82f5f4b9ef36991f19f9af1a4a76-1200x741.jpg","_updatedAt":"2025-03-06T20:11:55Z","extension":"jpg","mimeType":"image/jpeg","size":679526}}},{"published":"2025-03-07T18:00:00.000Z","authorDetails":[{"lastName":"Lyles","url":{"current":"courtney-r-lyles-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Courtney R. Lyles, PhD","firstName":"Courtney"}],"factCheckBy":[{"displayName":"Courtney R. Lyles, PhD","firstName":"Courtney","lastName":"Lyles","url":{"current":"courtney-r-lyles-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"title":"The Health Information Technology Special Issue: Evolving Tech, Fundamental Methods","summary":"A letter from the guest editor highlights how the findings in this special issue touch on timely themes in health technology research and yield real-world considerations for practice.","url":"the-health-information-technology-special-issue-evolving-tech-fundamental-methods","_id":"eb57b416-6a3d-4242-a2d6-fda82acee64c","issueGroup":{"_ref":"ad60ee1b-e6bc-45d8-ab64-543e89017343","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"palette":{"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"}}},{"_id":"1290ac17-73e9-4ba3-94e4-04281bd8b1d7","summary":"A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.","url":"demographic-disparities-in-video-visit-telemetry-understanding-telemedicine-utilization","published":"2025-03-07T14:00:00.000Z","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Daniel Stein, MS","firstName":"Daniel","lastName":"Stein","url":{"_type":"slug","current":"daniel-stein-ms"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Mark L. Moubarek, MD","firstName":"Mark","lastName":"Moubarek","url":{"current":"mark-l-moubarek-md","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Jeffrey Fine, MPH","firstName":"Jeffrey","lastName":"Fine","url":{"current":"jeffrey-fine-mph","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Jeffery Wajda, DO","firstName":"Jeffery","lastName":"Wajda","url":{"current":"jeffery-wajda-do","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Mark Avdalovic, MD","firstName":"Mark","lastName":"Avdalovic","url":{"current":"mark-avdalovic-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"url":{"current":"daniel-stein-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Daniel Stein, MS","firstName":"Daniel","lastName":"Stein"},{"firstName":"Mark","lastName":"Moubarek","url":{"current":"mark-l-moubarek-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mark L. Moubarek, MD"},{"lastName":"Fine","url":{"current":"jeffrey-fine-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jeffrey Fine, MPH","firstName":"Jeffrey"},{"lastName":"Wajda","url":{"current":"jeffery-wajda-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jeffery Wajda, DO","firstName":"Jeffery"},{"lastName":"Avdalovic","url":{"current":"mark-avdalovic-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mark Avdalovic, MD","firstName":"Mark"}],"issueGroup":{"_ref":"ad60ee1b-e6bc-45d8-ab64-543e89017343","_type":"reference"},"title":"Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization","thumbnail":{"asset":{"size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"_type":"sanity.imageMetadata","palette":{"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj"},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"},"_type":"mainImage","alt":"AJMC"}},{"title":"The “New” New Normal: Changes in Telemedicine Utilization Since COVID-19","authorDetails":[{"url":{"current":"soumik-mandal-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Soumik Mandal, PhD","firstName":"Soumik","lastName":"Mandal"},{"displayName":"Batia M. Wiesenfeld, PhD","firstName":"Batia","lastName":"Wiesenfeld","url":{"current":"batia-m-wiesenfeld-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Devin M. Mann, MD","firstName":"Devin","lastName":"Mann","url":{"current":"devin-m-mann-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Oded Nov, PhD","firstName":"Oded","lastName":"Nov","url":{"current":"oded-nov-phd","_type":"slug"}}],"factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Soumik Mandal, PhD","firstName":"Soumik","lastName":"Mandal","url":{"current":"soumik-mandal-phd","_type":"slug"}},{"url":{"current":"batia-m-wiesenfeld-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Batia M. Wiesenfeld, PhD","firstName":"Batia","lastName":"Wiesenfeld"},{"firstName":"Devin","lastName":"Mann","url":{"current":"devin-m-mann-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Devin M. Mann, MD"},{"displayName":"Oded Nov, PhD","firstName":"Oded","lastName":"Nov","url":{"current":"oded-nov-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"e0d1bb13-f2e5-445d-8529-4c95016228a1","summary":"Telemedicine utilization has declined since the peak of the COVID-19 pandemic, but non–primary care specialties continue to see an increase in moderate- and high-complexity telemedicine visits.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"the-new-new-normal-changes-in-telemedicine-utilization-since-covid-19","published":"2025-03-06T18:00:00.000Z","issueGroup":{"_ref":"ad60ee1b-e6bc-45d8-ab64-543e89017343","_type":"reference"}},{"_id":"9aad20b6-a311-4652-8fa6-7991baa92ef1","issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"summary":"To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.","url":"managed-care-reflections-insights-from-richard-j-gilfillan-md-and-donald-m-berwick-md-mpp","factCheckBy":[{"showSocialShare":null,"displayName":"Richard J. Gilfillan, MD","firstName":"Richard","lastName":"Gilfillan","url":{"current":"richard-j-gilfillan-md","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Donald","lastName":"Berwick","url":{"current":"donald-m-berwick-md-mpp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Donald M. Berwick, MD, MPP"}],"title":"Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP","thumbnail":{"alt":"AJMC","asset":{"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAKCAYAAAC0VX7mAAAACXBIWXMAABYlAAAWJQFJUiTwAAABxklEQVQoka2STW/aQBCG+f/qLZdeqkrpoQqpWiIlCk2BhKCEErAxRXGMnQ8wJoAxGMyX7fX6rWbSpqXnWlrN7M7sszPvOAMAaZrif32Z3zCySSKRSIlYJFhtQgTrLVbbCNsohpQSUqYIY8ErigU2YYxNGPGe7hHjFUiHjutj6C0w8ZfQLAeK0UPTtKF2bEwXK8yCNZ+3LAd6d4iOPcbjYIKB63MBO0BvvkSxYaDctHDvuCg0DJzd3OHsRsd+voaG0UP7YYAP+Rren1RxVGnxfjDxMZousN5GL0CCiSRhSLakIFtU0DT7DL9QTVy1HxiQLan4WtPxNlfBm48FHBQVPHtzloIkIvsLmMIP1tzWafUWh+cqCnUD+e+3KCkd1PQnfC5reHd8zRCye58u+IHucMoaU7ukP7EyJHR/PENd76J173CrhyUVuUsN52oH1fYjyk2TK6b1pazhqPKDH9OsPkx7zPfDKH6ZMpVK+tnjGVw/YGjusoVv9TsYvRG6Q48vTOZL1srqu1wZ+aQfDZKGRbJxhdS3SCSESFiL0TRgsZ+ePRaaziiZ8qgbyqP2yCdLMfIpvjPl139RSkRCcPK/sT/7v/3d+E98j+pE3hWucAAAAABJRU5ErkJggg==","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch"},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93}}},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh"},"_type":"mainImage"},"published":"2025-02-20T17:15:00.000Z","authorDetails":[{"url":{"current":"richard-j-gilfillan-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Richard J. Gilfillan, MD","firstName":"Richard","lastName":"Gilfillan"},{"showSocialShare":null,"displayName":"Donald M. Berwick, MD, MPP","firstName":"Donald","lastName":"Berwick","url":{"current":"donald-m-berwick-md-mpp","_type":"slug"},"profileImage":null,"biography":null}]},{"summary":null,"thumbnail":{"caption":"Ander Hertler, MD | Image credit: Evolent","asset":{"metadata":{"dimensions":{"height":1800,"_type":"sanity.imageDimensions","width":1800,"aspectRatio":1},"isOpaque":true,"blurHash":"eeJa{3juOskD$$~Tf6tlogRQS5a|RPj[kDS6ayadayt7odj[t7jsRj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"background":"#28385c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"background":"#d2b6af","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.54},"vibrant":{"title":"#fff","population":0,"background":"#7890c4","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#495c7e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":12.37},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":12.37,"background":"#495c7e","_type":"sanity.imagePaletteSwatch"},"muted":{"population":9.64,"background":"#5c759f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#f1cbc0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":3.86}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"},"sha1hash":"804cdb34aa88272063b6af54a7ef72eaf4f8fa92","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800.jpg","path":"images/0vv8moc6/ajmc/804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800.jpg","_createdAt":"2024-02-14T21:29:57Z","originalFilename":"Andrew Hertler Head Shot High Res.jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","assetId":"804cdb34aa88272063b6af54a7ef72eaf4f8fa92","_updatedAt":"2024-02-14T21:29:57Z","uploadId":"EmJHssAXy9Ob2FKR4o6xFVLIGtMA0NLu","_rev":"VsPixfEw6DNbTy7utCEJN0","size":2044952,"extension":"jpg","_id":"image-804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800-jpg"},"_type":"mainImage","alt":"Ander Hertler, MD | Image credit: Evolent"},"published":"2025-02-19T17:53:00.000Z","authorDetails":[{"displayName":"Andrew Hertler, MD, FACP","firstName":"Andrew","lastName":"Hertler","url":{"current":"andrew-hertler-md-facp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"lastName":"Hertler","url":{"current":"andrew-hertler-md-facp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Andrew Hertler, MD, FACP","firstName":"Andrew"}],"url":"clinical-trials-must-represent-those-who-will-receive-therapy","_id":"4032e831-2748-4d94-b3ba-10b9c74e53aa","issueGroup":{"_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68","_type":"reference"},"title":"Clinical Trials Must Represent Those Who Will Receive Therapy"},{"factCheckBy":[{"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"f73a10e9267d","markDefs":[],"children":[{"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span","marks":[]}]},{"_key":"95aad26356ef","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null}],"issueGroup":{"_type":"reference","_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68"},"summary":null,"thumbnail":{"_type":"mainImage","alt":"Tampa city scene | Image: Getty Images","asset":{"extension":"jpg","_rev":"qHhNQIW6XHipcCVoq0ny6L","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844.jpg","size":142962,"originalFilename":"Tampa Getty images.jpg","metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#e69f81","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.31},"darkVibrant":{"title":"#fff","population":1.7,"background":"#6a5b06","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"background":"#aab8d3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.3},"vibrant":{"population":1.26,"background":"#d7822e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#e69f81","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.31},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.89,"background":"#504f31"},"muted":{"background":"#81629b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.83}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"aspectRatio":1.7772511848341233,"height":844,"_type":"sanity.imageDimensions","width":1500},"isOpaque":true,"blurHash":"MZI4^%%MXUnMXRgladNGsAs.IyV@Wraeod"},"_type":"sanity.imageAsset","_createdAt":"2025-02-19T15:13:04Z","mimeType":"image/jpeg","sha1hash":"c48a99a97eeca7818a5d28fa95603c5fecc29285","path":"images/0vv8moc6/ajmc/c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844.jpg","assetId":"c48a99a97eeca7818a5d28fa95603c5fecc29285","_id":"image-c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844-jpg","uploadId":"pWFsyFLETHHSrtJzCJTHxmWraWX5bKRu","_updatedAt":"2025-02-19T15:13:04Z"}},"url":"a-new-horizon-precision-medicine-and-value-based-care-in-lung-gastric-and-sarcoma-cancers","_id":"071d815c-00f4-43f8-a143-a5179ccc1ffb","title":"A New Horizon: Precision Medicine and Value-Based Care in Lung, Gastric, and Sarcoma Cancers","published":"2025-02-19T14:07:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0"}],"_type":"block","style":"normal","_key":"f73a10e9267d","markDefs":[]},{"style":"normal","_key":"95aad26356ef","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"text":"LinkedIn","_key":"6fba991875ae1","_type":"span","marks":["510f2efa56c7"]},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block"}]}]},{"_id":"e4a32dfb-8008-41b9-82e8-569d97a87e7f","issueGroup":{"_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68","_type":"reference"},"url":"what-recent-evidence-is-telling-us-about-alcohol-and-cancer","published":"2025-02-19T03:49:00.000Z","factCheckBy":[{"url":{"current":"produced-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Produced by Mary Caffrey","firstName":"Mary ","lastName":"Caffrey"}],"title":"What Recent Evidence Is Telling Us About Alcohol and Cancer","summary":"Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.","thumbnail":{"caption":"Noelle LoConte, MD | Image credit: University of Wisconsin","asset":{"metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"height":118,"_type":"sanity.imageDimensions","width":141,"aspectRatio":1.194915254237288},"isOpaque":true,"blurHash":"eGD[@GkD0h-p}@bws:s.NGNF57t7={RjIptRoft7s.RkNHs:xZWCNG","_type":"sanity.imageMetadata","palette":{"darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.39,"background":"#51382f"},"muted":{"title":"#fff","population":6.74,"background":"#9b7161","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":1.3,"background":"#edb8a5","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"population":0,"background":"#602424","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#d9c3ba","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":2.31},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01,"background":"#b44444"},"dominant":{"title":"#fff","population":6.74,"background":"#9b7161","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette"}},"mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c0ffc966125542010d43006654c25de2d5a8b433-141x118.jpg","_id":"image-c0ffc966125542010d43006654c25de2d5a8b433-141x118-jpg","_createdAt":"2025-02-19T11:50:21Z","_updatedAt":"2025-02-19T11:50:21Z","originalFilename":"LoConte.jpg","_rev":"itvkhwxEA2FOFySb8jc0KF","_type":"sanity.imageAsset","sha1hash":"c0ffc966125542010d43006654c25de2d5a8b433","assetId":"c0ffc966125542010d43006654c25de2d5a8b433","extension":"jpg","uploadId":"zaGG18ur2Y8oBLhkaUfqqJLNWVWbGZUE","path":"images/0vv8moc6/ajmc/c0ffc966125542010d43006654c25de2d5a8b433-141x118.jpg","size":5645},"crop":{"left":0,"bottom":0,"_type":"sanity.imageCrop","right":0,"top":0.05084745762711864},"hotspot":{"_type":"sanity.imageHotspot","width":1,"x":0.5,"y":0.5254237288135594,"height":0.9491525423728814},"_type":"mainImage","alt":"Noelle LoConte, MD | Image credit: University of Wisconsin"},"authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Produced by Mary Caffrey","firstName":"Mary ","lastName":"Caffrey","url":{"current":"produced-by-mary-caffrey","_type":"slug"}}]},{"_id":"029c0e16-5487-4d46-8669-9c80e6c775d2","title":"KAP Regarding ChatGPT Among Health Care Professionals: Correspondence","summary":"This letter discusses previously published research that paves the way for deeper exploration of the ethical and human aspects of artificial intelligence in health care.","url":"kap-regarding-chatgpt-among-health-care-professionals-correspondence","authorDetails":[{"lastName":"Daungsupawong","url":{"current":"hinpetch-daungsupawong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Hinpetch Daungsupawong, PhD","firstName":"Hinpetch"},{"lastName":"Wiwanitkit","url":{"current":"viroj-wiwanitkit-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj"}],"issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6"}},"published":"2025-02-11T14:00:00.000Z","factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Hinpetch Daungsupawong, PhD","firstName":"Hinpetch","lastName":"Daungsupawong","url":{"_type":"slug","current":"hinpetch-daungsupawong-phd"}},{"biography":null,"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj","lastName":"Wiwanitkit","url":{"current":"viroj-wiwanitkit-md","_type":"slug"},"profileImage":null}]},{"_id":"90b5927a-b28a-40cd-a19e-2ad54b3a4de3","thumbnail":{"asset":{"size":203185,"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","originalFilename":"AJMC_logo_NEW.png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":778,"aspectRatio":2.0366492146596857,"height":382,"_type":"sanity.imageDimensions"},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93}}},"mimeType":"image/png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"},"_type":"mainImage","alt":"AJMC"},"url":"medical-policy-determinations-for-pharmacogenetic-tests-among-us-health-plans","published":"2025-02-10T14:00:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Jai N. Patel, PharmD","firstName":"Jai","lastName":"Patel","url":{"current":"jai-n-patel-pharmd","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Lena Chaihorsky, BS","firstName":"Lena","lastName":"Chaihorsky","url":{"current":"lena-chaihorsky-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Olivia","lastName":"Dong","url":{"current":"olivia-m-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Olivia M. Dong, PhD"},{"displayName":"Christine Y. Lu, PhD","firstName":"Christine","lastName":"Lu","url":{"current":"christine-y-lu-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz","url":{"current":"chad-moretz-scd","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Emily Reese, PhD, MPH","firstName":"Emily","lastName":"Reese","url":{"current":"emily-reese-phd-mph","_type":"slug"},"profileImage":null},{"lastName":"Teeple","url":{"current":"wrenda-teeple-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Wrenda Teeple, PharmD","firstName":"Wrenda"},{"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"current":"benjamin-brown-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Sara Rogers, PharmD","firstName":"Sara","lastName":"Rogers","url":{"current":"sara-rogers-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"displayName":"Jai N. Patel, PharmD","firstName":"Jai","lastName":"Patel","url":{"current":"jai-n-patel-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"lena-chaihorsky-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Lena Chaihorsky, BS","firstName":"Lena","lastName":"Chaihorsky"},{"displayName":"Olivia M. Dong, PhD","firstName":"Olivia","lastName":"Dong","url":{"_type":"slug","current":"olivia-m-dong-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Lu","url":{"current":"christine-y-lu-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Christine Y. Lu, PhD","firstName":"Christine"},{"url":{"current":"chad-moretz-scd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz"},{"displayName":"Emily Reese, PhD, MPH","firstName":"Emily","lastName":"Reese","url":{"current":"emily-reese-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Wrenda Teeple, PharmD","firstName":"Wrenda","lastName":"Teeple","url":{"_type":"slug","current":"wrenda-teeple-pharmd"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"current":"benjamin-brown-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Sara Rogers, PharmD","firstName":"Sara","lastName":"Rogers","url":{"current":"sara-rogers-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"title":"Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans","summary":"This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers."},{"thumbnail":{"caption":"Elias Jabbour, MD | Image credit: MD Anderson","asset":{"_rev":"03H5IWZJxxErG40FSFrSh1","assetId":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","_createdAt":"2025-01-22T01:39:28Z","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAYHBAX/xAAjEAABBAIBAwUAAAAAAAAAAAABAAIDBAURBhITIjEyQXGR/8QAFQEBAQAAAAAAAAAAAAAAAAAAAAH/xAAZEQACAwEAAAAAAAAAAAAAAAAAAQIREjL/2gAMAwEAAhEDEQA/AKrfz9jIYi9Xp9feMTg0s9QuJxKTKYziUZtwvY17yQCdkLThR2pnGPxJ0Dr7TFaAdMyIjcfT7fhXC6G6TiJsj7Uzy8MdooVHr1YBEAImfiFAf//Z","dimensions":{"_type":"sanity.imageDimensions","width":360,"aspectRatio":1.7821782178217822,"height":202},"isOpaque":true,"blurHash":"MKL;jYxvNZ%MMw%0?a%g-;IA~qWBs:aeWB","_type":"sanity.imageMetadata","palette":{"muted":{"background":"#8d624f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.13},"lightVibrant":{"background":"#ececfc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.02},"darkVibrant":{"title":"#fff","population":0,"background":"#5d3626","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":0.2,"background":"#c6b8b8","_type":"sanity.imagePaletteSwatch"},"vibrant":{"title":"#fff","population":0.25,"background":"#c78e77","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"dominant":{"background":"#563d35","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.59},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":5.59,"background":"#563d35","_type":"sanity.imagePaletteSwatch"}}},"_id":"image-d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202-jpg","mimeType":"image/jpeg","sha1hash":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","originalFilename":"Elias Jabbour MD.jpg","extension":"jpg","uploadId":"AI9UWYzlKUzpNZoSkOg0eaGj37ri4uGg","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","size":8344,"_updatedAt":"2025-01-22T01:39:28Z"},"_type":"mainImage","alt":"Elias Jabbour, MD | Image credit: MD Anderson"},"url":"mrd-and-other-predictors-from-felix-for-obe-cel-success-in-r-r-b-all","published":"2025-01-22T01:20:00.000Z","authorDetails":[{"biography":[{"markDefs":[],"children":[{"marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862","_type":"span"},{"_key":"953d8c643cce","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elias J. Jabbour, MD","firstName":null,"lastName":null,"url":{"_type":"slug","current":"elias-j-jabbour-md"}}],"factCheckBy":[{"biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}]},{"_key":"a03d32973d6e","markDefs":[{"href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_key":"9737335da1ed1","_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Elias J. Jabbour, MD","firstName":null,"lastName":null,"url":{"current":"elias-j-jabbour-md","_type":"slug"},"profileImage":null,"biography":null}],"_id":"a74e0c61-1db8-4176-a3ff-356818f8f1bc","issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"title":"MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL"},{"_id":"de999a47-35fe-4e8d-8527-755d8e08ce93","issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"title":"Spotlight on Access and Equity: Bispecifics for Multiple Myeloma in the Community Setting","url":"spotlight-on-access-and-equity-bispecifics-for-multiple-myeloma-in-the-community-setting","published":"2025-01-11T17:28:00.000Z","authorDetails":[{"firstName":null,"lastName":null,"url":{"current":"luke-halpern","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Luke Halpern"},{"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[],"children":[{"marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00","_type":"span"},{"_key":"3e92e7080a4e","_type":"span","marks":["em"],"text":"The American Journal of Managed Care"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"_type":"span","marks":[],"text":" (","_key":"4fcef11aec7b"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"083d2efe5747"},{"_type":"span","marks":["sup"],"text":"®","_key":"04c0192c7b85"},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_type":"span","marks":["sup"],"text":"®","_key":"5d07912e2fa4"},{"text":". She has been working on ","_key":"f8966f9273cf","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"ad2148a7aae1"},{"marks":[],"text":" since 2014 and has been with ","_key":"60560b0a7800","_type":"span"},{"text":"AJMC","_key":"3193684b48c2","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50"},{"_key":"f08f3edc84e9","_type":"span","marks":["sup"],"text":"®"},{"_type":"span","marks":[],"text":", since 2011.","_key":"641e0208eef5"}]},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_key":"67a67d3764f04","_type":"span","marks":[],"text":"."}],"_type":"block"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"}}],"summary":null,"thumbnail":{"_type":"mainImage","asset":{"_rev":"z05Cxco1bGw7CBDJOjIZyP","path":"images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg","uploadId":"AJOmAkothnE9756fQQSjcbTCOOjl6EfV","_type":"sanity.imageAsset","sha1hash":"d24a7ae4df61f95992f74a25b4d5666da68a6206","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg","_createdAt":"2025-01-22T17:37:51Z","originalFilename":"ontada_logo.jpg","mimeType":"image/jpeg","assetId":"d24a7ae4df61f95992f74a25b4d5666da68a6206","_updatedAt":"2025-01-22T17:37:51Z","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAUABQDASIAAhEBAxEB/8QAGAABAAMBAAAAAAAAAAAAAAAAAAEEBgf/xAAgEAACAQQDAAMAAAAAAAAAAAAAAQIDBAUREiExE1Fh/8QAGAEBAAMBAAAAAAAAAAAAAAAAAAEDBAX/xAAZEQEBAQADAAAAAAAAAAAAAAAAAhEBElH/2gAMAwEAAhEDEQA/AOBpN+EpN+Jmgo562pW8IQx1LnFLc2TSz9tDTdhBy72+u/w3xdVvacc7OPWfSf0wXchexua6nSp/FHilxQLEKOhoACUgAB//2Q==","dimensions":{"_type":"sanity.imageDimensions","width":200,"aspectRatio":1,"height":200},"isOpaque":true,"blurHash":"e96IKkfxRiogRTWCf8fRayfP02e]t8WAt4t7fhfioeju_Lk6R$ogRn","_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":79.02,"background":"#0c2c44","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":0.14,"background":"#334961","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"population":0.44,"background":"#697988","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#c4dc54","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0},"darkVibrant":{"background":"#0c2c44","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":79.02},"lightMuted":{"title":"#000","population":0.14,"background":"#c5d0da","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"title":"#fff","population":0.02,"background":"#bde428","_type":"sanity.imagePaletteSwatch","foreground":"#000"}}},"size":4528,"_id":"image-d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200-jpg","extension":"jpg"}},"factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Luke Halpern","firstName":null,"lastName":null,"url":{"current":"luke-halpern","_type":"slug"}},{"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"alt":"Laura Joszt headshot","asset":{"_type":"reference","_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg"},"_type":"mainImage"},"biography":[{"_key":"4a950aea97b3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"3e92e7080a4e"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"text":" (","_key":"4fcef11aec7b","_type":"span","marks":[]},{"marks":["em"],"text":"AJMC","_key":"083d2efe5747","_type":"span"},{"_type":"span","marks":["sup"],"text":"®","_key":"04c0192c7b85"},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_key":"5d07912e2fa4","_type":"span","marks":["sup"],"text":"®"},{"_type":"span","marks":[],"text":". She has been working on ","_key":"f8966f9273cf"},{"marks":["em"],"text":"AJMC","_key":"ad2148a7aae1","_type":"span"},{"text":" since 2014 and has been with ","_key":"60560b0a7800","_type":"span","marks":[]},{"marks":["em"],"text":"AJMC","_key":"3193684b48c2","_type":"span"},{"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50","_type":"span","marks":[]},{"_type":"span","marks":["sup"],"text":"®","_key":"f08f3edc84e9"},{"_type":"span","marks":[],"text":", since 2011.","_key":"641e0208eef5"}],"_type":"block","style":"normal"},{"children":[{"marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5","_type":"span"},{"marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01","_type":"span"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt"}]}]}]},{"issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"url":"spotlight-cilta-cel-shows-sustained-mrd-negativity-leads-to-prolonged-pfs-in-multiple-myeloma","published":"2025-01-09T00:20:00.000Z","_id":"e7f1792f-598b-4b39-a6aa-40177d13717c","title":"SPOTLIGHT: Cilta-Cel Shows Sustained MRD Negativity; Leads to Prolonged PFS in Multiple Myeloma","thumbnail":{"asset":{"_updatedAt":"2025-01-22T00:31:10Z","metadata":{"isOpaque":true,"blurHash":"eAEoV-x^0#Iq=F~CX9.7xuNG0gxt=FV?Eg.8n~D%WqWA-UWCS2s:V[","_type":"sanity.imageMetadata","palette":{"dominant":{"population":6.83,"background":"#d5a18e","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.02,"background":"#50343d"},"muted":{"population":0.01,"background":"#a4505c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"population":0,"background":"#dbae9e","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"population":2.18,"background":"#532f27","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#a9b5b9","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.92},"vibrant":{"population":6.83,"background":"#d5a18e","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAYABQDASIAAhEBAxEB/8QAGAABAQEBAQAAAAAAAAAAAAAAAAUGAgP/xAAiEAACAQQCAgMBAAAAAAAAAAABAgMABAURBhIiQSExYTL/xAAYAQACAwAAAAAAAAAAAAAAAAABAwACBP/EABsRAAICAwEAAAAAAAAAAAAAAAABAhEDEiEx/9oADAMBAAIRAxEAPwDwy+VTD4Nrsr2k31RT7NZXHcrzJv4Y87YmO2uj1hYLrVXb2FcpFaRuFdIZllZT7Aqzm44r+S3iaMFYyHQqP516pM5tSSRrxQi8bk34TJIB3OxSu7y6VJyoA+KVOlOGO4fk5EzsBlcujnqwP1o1Y5jzOW5uHtcdqC2j8S6jybX7SlO1V2I2damHlzN2H8Zm1+0pSiA//9k=","dimensions":{"_type":"sanity.imageDimensions","width":205,"aspectRatio":0.8333333333333334,"height":246}},"_rev":"0atQJUC04BTO87jLlB2QZm","_type":"sanity.imageAsset","size":4599,"originalFilename":"Yi Lin MD PhD.jpg","sha1hash":"74682bc40139d223bd547d491e60f19bbf4a7a89","_id":"image-74682bc40139d223bd547d491e60f19bbf4a7a89-205x246-jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","path":"images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","_createdAt":"2025-01-22T00:31:10Z","extension":"jpg","uploadId":"ow8Gv8Np3Nj1GOIUCHMbYvdmmOqXIgMk","mimeType":"image/jpeg","assetId":"74682bc40139d223bd547d491e60f19bbf4a7a89"},"_type":"mainImage","alt":"Yi Lin, MD, PhD "},"authorDetails":[{"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null}],"factCheckBy":[{"url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor"}]},{"thumbnail":{"alt":"chemotherapy | Image credit: Penn Medicine","asset":{"_rev":"bAl93RvH29PY4NpeP8EuRS","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png","_id":"image-fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658-png","uploadId":"eCMXCsgcAvTQfUHoAFR5Dl14CWyEWapm","assetId":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","_updatedAt":"2024-12-19T20:25:38Z","extension":"png","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png","originalFilename":"CHEMO PENN MEDICINE.png","metadata":{"dimensions":{"aspectRatio":1.5197568389057752,"height":658,"_type":"sanity.imageDimensions","width":1000},"isOpaque":true,"blurHash":"VIKnbqx^%M%Mx]_4?b%MIV-=tRogNGxtxaxst7kDozt6","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"background":"#3c3f48","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26},"muted":{"title":"#fff","population":0.63,"background":"#a98a6a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#c8b386","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#84723e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.52},"lightMuted":{"background":"#ccc3af","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.08,"background":"#cdbb65"},"dominant":{"background":"#3c3f48","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26}},"hasAlpha":false,"lqip":"data:image/png;base64,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"},"mimeType":"image/png","sha1hash":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","size":600696,"_createdAt":"2024-12-19T20:25:38Z"},"_type":"mainImage"},"url":"the-high-cost-of-shortages-of-low-cost-chemotherapy","authorDetails":[{"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"interview-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"interview-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"261d60f2-d321-4f0c-b80a-b02f3f9da3ba","issueGroup":{"_ref":"020f348b-83bc-4402-8a0e-56dfd206392b","_type":"reference"},"title":"The High Cost of Shortages of Low-Cost Chemotherapy","summary":null,"published":"2024-12-19T15:00:00.000Z"},{"title":"Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models","thumbnail":{"_type":"mainImage","alt":"Park City Utah | Image Credit: © SeanPavonePhoto - stock.adobe.com","asset":{"_rev":"NpDlOLwo2XgOWDaMKGnmaJ","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","size":684667,"extension":"jpg","metadata":{"exif":{"FocalLengthIn35mmFormat":70,"ColorSpace":1,"MeteringMode":5,"ExposureMode":1,"GainControl":0,"FocalLength":70,"SubSecTimeDigitized":"72","FNumber":11,"DateTimeDigitized":"2019-09-30T07:53:48.000Z","PixelYDimension":800,"LensSpecification":[70,200,2.8,2.8],"SensingMethod":2,"SensitivityType":2,"LightSource":9,"ExposureTime":72,"SubSecTimeOriginal":"72","ISO":64,"Sharpness":1,"Contrast":0,"ShutterSpeedValue":-6.169924996926103,"DateTimeOriginal":"2019-09-30T07:53:48.000Z","MaxApertureValue":2.9708536585365852,"ExposureProgram":1,"_type":"sanity.imageExifMetadata","RecommendedExposureIndex":64,"WhiteBalance":1,"FocalPlaneXResolution":2301.324607329843,"FocalPlaneResolutionUnit":3,"ApertureValue":6.9188632619439865,"SceneCaptureType":0,"Saturation":0,"ExposureBiasValue":0,"BodySerialNumber":"3009697","SubjectDistanceRange":0,"LensModel":"70.0-200.0 mm f/2.8","PixelXDimension":1200,"FocalPlaneYResolution":2301.324607329843,"CustomRendered":0},"isOpaque":true,"blurHash":"VbGt,K%NbvogW;-@o~s;xFofxbSiR*s9jvRjNIR*R*bI","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#55402b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.52},"_type":"sanity.imagePalette","darkMuted":{"population":6.52,"background":"#55402b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#8c7298","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.15},"lightVibrant":{"title":"#fff","population":5.57,"background":"#db8a8b","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#531914","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"foreground":"#000","title":"#fff","population":1.88,"background":"#baacda","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.86,"background":"#ce742b","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"aspectRatio":1.5,"height":800,"_type":"sanity.imageDimensions","width":1200}},"uploadId":"HbuqVrHWM61ym51aODEQvln7RdZOo3Y9","assetId":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","_id":"image-d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800-jpg","originalFilename":"Park City Utah - SeanPavonePhoto - stock.adobe.com.jpeg","_type":"sanity.imageAsset","sha1hash":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","path":"images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","_createdAt":"2024-12-09T16:14:43Z","_updatedAt":"2024-12-09T16:14:43Z"}},"factCheckBy":[{"url":{"current":"kyle-munz","_type":"slug"},"profileImage":{"asset":{"_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Kyle Munz"},"biography":null,"showSocialShare":null,"displayName":"Kyle Munz","firstName":"Kyle","lastName":"Munz"}],"_id":"1b2f775c-eb1e-4c9d-aab4-b9c0796cb0e2","summary":"Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes. ","url":"transforming-kidney-care-policy-risk-stratification-and-collaborative-models","published":"2024-12-12T18:00:00.000Z","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Kyle Munz","asset":{"_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Kyle Munz","firstName":"Kyle","lastName":"Munz","url":{"current":"kyle-munz","_type":"slug"}}],"issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"}},{"issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"summary":"Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.","published":"2024-12-12T17:00:00.000Z","authorDetails":[{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0"}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"text":"LinkedIn","_key":"6fba991875ae1","_type":"span","marks":["510f2efa56c7"]},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal","_key":"95aad26356ef"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}}}],"factCheckBy":[{"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal","_key":"95aad26356ef","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7"}]}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"}}],"_id":"f802c956-5821-427f-8529-cd5ac1bf6b46","title":"From Approval to Practice: Addressing the Hurdles in Biosimilar Integration","thumbnail":{"_type":"mainImage","alt":"Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com","asset":{"uploadId":"720OvtZqjd5bfGGG0HMUoxl39Z5gnaIE","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","size":691007,"_updatedAt":"2024-12-09T16:08:58Z","_rev":"Wk5bXdTaWvRA2U061yIUpH","sha1hash":"50d700b88aa9af2c75864177d43c5651d055284b","assetId":"50d700b88aa9af2c75864177d43c5651d055284b","_createdAt":"2024-12-09T16:08:58Z","extension":"jpg","path":"images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"width":1200,"aspectRatio":1.721664275466284,"height":697,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"M%DAo?fkWBofWBTOj]j?WWj?IXa~oKayj[","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.59,"background":"#53590e"},"lightMuted":{"background":"#d1c4b3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":8.22},"vibrant":{"background":"#1775d9","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.04},"dominant":{"background":"#565e2e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.35},"_type":"sanity.imagePalette","darkMuted":{"background":"#565e2e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.35},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04,"background":"#92ac4f"},"lightVibrant":{"title":"#fff","population":0.07,"background":"#8fb9e4","_type":"sanity.imagePaletteSwatch","foreground":"#000"}}},"_type":"sanity.imageAsset","_id":"image-50d700b88aa9af2c75864177d43c5651d055284b-1200x697-jpg","originalFilename":"Seattle Washington skyline - espiegle - stock.adobe.com.jpeg"}},"url":"from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration"},{"title":"Navigating the Complexities of Neurological Drug Access","summary":"At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases. ","url":"navigating-the-complexities-of-neurological-drug-access","published":"2024-12-12T16:00:00.000Z","authorDetails":[{"lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl "}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"}}],"_id":"07739c7a-2ab2-4136-9387-b461d01ee7d6","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"Aurora Colorado aerial | Image Credit: © Jacob - stock.adobe.com","asset":{"uploadId":"hDCo0dHvoUsJtwqc6XFChcP57mr0GYWo","_type":"sanity.imageAsset","extension":"jpg","_rev":"Wk5bXdTaWvRA2U061yEwr7","mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","size":792084,"assetId":"e795e86678821e21c6aef5cf087bc961b2661488","_id":"image-e795e86678821e21c6aef5cf087bc961b2661488-1200x799-jpg","originalFilename":"Aurora Colorado aerial - Jacob - stock.adobe.com.jpeg","metadata":{"isOpaque":true,"exif":{"DateTimeDigitized":"2021-10-22T12:38:25.000Z","DigitalZoomRatio":1,"FocalLengthIn35mmFormat":28,"Flash":0,"Saturation":0,"FocalLength":10.3,"MeteringMode":2,"ApertureValue":6.9188632619439865,"BodySerialNumber":"0K8TFB50024243","Contrast":0,"SceneCaptureType":0,"DateTimeOriginal":"2021-10-22T12:38:25.000Z","WhiteBalance":0,"ExposureProgram":1,"FNumber":11,"ExposureBiasValue":0,"LightSource":1,"Sharpness":0,"MaxApertureValue":2.9708536585365852,"PixelYDimension":799,"ColorSpace":1,"LensSpecification":[28,28,2.8,11],"ExposureTime":0.01,"_type":"sanity.imageExifMetadata","GainControl":0,"ExposureMode":1,"ISO":100,"PixelXDimension":1200,"ShutterSpeedValue":6.643856143856143},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAQGBf/EACIQAAIBBAEEAwAAAAAAAAAAAAECAAMEBREhBhIUMUFRYv/EABYBAQEBAAAAAAAAAAAAAAAAAAMAAv/EABwRAAEFAAMAAAAAAAAAAAAAAAEAAgQFIRVRUv/aAAwDAQACEQMRAD8AWt+ocWQKb4s7+uIvd5XC1A2scQR+pBWV1UYM5PK+o75BentlBJ59ydcSmnChFfGcNat0nHVj3pbKoPwX1CStdy9ViCVA40DCMLmZ2scXG8r/2Q==","location":{"lng":-104.88007777777777,"_type":"geopoint","alt":1846,"lat":39.63568055555555},"dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5018773466833542,"height":799},"blurHash":"VtBzqmogR*a}aypMofaxa#ayS+j[jZj[ayRkfkj?fPjs","_type":"sanity.imageMetadata","palette":{"muted":{"population":5.03,"background":"#938a66","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#fff","population":0.11,"background":"#7da9ec","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"title":"#fff","population":0.03,"background":"#054cac","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":0.11,"background":"#ada8bc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#0a71c4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.59},"dominant":{"title":"#fff","population":5.03,"background":"#938a66","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":0.95,"background":"#343f53","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}}},"sha1hash":"e795e86678821e21c6aef5cf087bc961b2661488","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","_createdAt":"2024-12-09T16:01:02Z","_updatedAt":"2024-12-09T16:01:02Z"}}},{"_id":"04159ba8-44f9-40b5-b25f-0ae627881e39","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"New Orleans Bourbon Street | Image Credit: © f11photo - stock.adobe.com","asset":{"size":4265557,"uploadId":"kH1bS8OTS7iWFNmOt3qixxFUDmuSmj11","sha1hash":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","path":"images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","_createdAt":"2024-08-28T16:07:24Z","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","opt":{"media":{"tags":null}},"originalFilename":"New Orleans Bourbon Street - f11photo - AdobeStock_169182961.jpeg","extension":"jpg","metadata":{"palette":{"vibrant":{"title":"#fff","population":5.95,"background":"#efa11f","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"dominant":{"population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#2e3d58","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.99},"muted":{"foreground":"#fff","title":"#fff","population":5.22,"background":"#976e64","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#935917","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.13},"lightMuted":{"foreground":"#000","title":"#fff","population":0.06,"background":"#b6a9cd","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2800,"aspectRatio":1.4997321906802357,"height":1867},"exif":{"ExposureBiasValue":0,"MaxApertureValue":4,"WhiteBalance":0,"FocalPlaneXResolution":2164.4328018223237,"SceneCaptureType":0,"DateTimeOriginal":"2016-11-15T06:32:19.000Z","FNumber":5.6,"FocalPlaneResolutionUnit":3,"FocalLength":28,"ShutterSpeedValue":-1,"ApertureValue":4.970853658536585,"ExposureMode":1,"CustomRendered":0,"LensSpecification":[16,35,4,4],"Sharpness":0,"_type":"sanity.imageExifMetadata","Contrast":0,"DigitalZoomRatio":1,"LightSource":0,"ISO":100,"RecommendedExposureIndex":100,"PixelXDimension":2800,"ColorSpace":1,"PixelYDimension":1867,"MeteringMode":5,"SensitivityType":2,"Saturation":2,"BrightnessValue":-0.89296875,"LensModel":"16-35mm F4 G SSM OSS","FocalLengthIn35mmFormat":42,"DateTimeDigitized":null,"FocalPlaneYResolution":2164.4328018223237,"ExposureProgram":1,"ExposureTime":2},"isOpaque":true,"blurHash":"VLKJoRB?^vPDoi765Ev|$*$x~W-poztRR-%#x]SxNyt7","_type":"sanity.imageMetadata"},"altText":null,"description":null,"mimeType":"image/jpeg","assetId":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","_updatedAt":"2024-08-28T16:07:46Z","_rev":"LtkInV1jlQdtEIFjVqjDMg","title":null,"_id":"image-29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867-jpg"}},"url":"healthy-state-practicing-what-they-preach-in-louisiana","published":"2024-09-16T16:31:55.211Z","authorDetails":[{"firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_type":"reference","_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png"}},"biography":null,"showSocialShare":null,"displayName":"Mary K. Caffrey"}],"factCheckBy":[{"url":{"_type":"slug","current":"mary-k-caffrey"},"profileImage":{"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"},"default":false},"biography":null,"showSocialShare":null,"displayName":"Mary K. Caffrey","firstName":null,"lastName":null}],"title":"Healthy State: Practicing What They Preach in Louisiana","summary":"An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings."},{"_id":"2a95bae0-0c9f-4bc1-8e7d-3602ac803646","title":"Institute for Value-Based Medicine®: Multifaceted Approach Can Help Patients Benefit From the Expanded Lipid-Lowering Toolbox","summary":"Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.","published":"2024-09-16T16:31:18.436Z","factCheckBy":[{"biography":[{"style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_key":"b9461d308bc8","_type":"span","marks":[],"text":") and "},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block"},{"_key":"a90d7ab4c801","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}}}],"issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"thumbnail":{"asset":{"uploadId":"H7WTao1JKvhWv1JBicLCJENbGPV6jpQH","_rev":"WVB52uR738qojYGNKmrerb","originalFilename":"Denver Colorado - f11photo - stock.adobe.com.jpeg","_id":"image-c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700-jpg","_updatedAt":"2024-09-13T18:14:54Z","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7142857142857142,"height":700},"exif":{"PixelYDimension":700,"_type":"sanity.imageExifMetadata","DateTimeDigitized":"2014-09-12T07:37:33.000Z","ColorSpace":1,"PixelXDimension":1200},"isOpaque":true,"blurHash":"MjHx1~IoS$S4oL%QRijZWrbH9vocWAoffP","_type":"sanity.imageMetadata","palette":{"dominant":{"population":6.64,"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":6.64,"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#50659b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.67},"lightVibrant":{"foreground":"#000","title":"#000","population":0.31,"background":"#e9cf8d","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#544d07","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.56},"lightMuted":{"background":"#a2a7c8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17},"vibrant":{"population":1.42,"background":"#ca762d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAcCBAX/xAAfEAACAgICAwEAAAAAAAAAAAABAgADBBEGEiExYQX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAwT/xAAdEQABBAIDAAAAAAAAAAAAAAADAAECEQQxBRJB/9oADAMBAAIRAxEAPwCeBhfnUkd7arNe+reptUZ/HVcV2voiKx8m2mtTWQCfgly3NtZEdhWWHgHqJI3InaVstA4C6aTkqyOIJWvfKRSRvREImxc7gMx8n5CBs83qLxhel//Z"},"_type":"sanity.imageAsset","sha1hash":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","path":"images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","size":584915,"assetId":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","extension":"jpg","mimeType":"image/jpeg","_createdAt":"2024-09-13T18:14:54Z","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg"},"_type":"mainImage","alt":"Denver Colorado | Image Credit: © f11photo - stock.adobe.com"},"url":"multifaceted-approach-can-help-patients-benefit-from-the-expanded-lipid-lowering-toolbox","authorDetails":[{"firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"marks":["em"],"text":"AJMC","_key":"b773bee92455","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_key":"14118ee858d3","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" (","_key":"a25757970c62","_type":"span"},{"marks":["em"],"text":"AJAC","_key":"6353c3a02e0f","_type":"span"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45"},{"markDefs":[{"_key":"c281c6aba22d","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/"}],"children":[{"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span","marks":[]},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null,"displayName":"Christina Mattina"}]},{"_id":"336a74f6-937d-40c6-a94c-b14c26f025f6","title":"Telehealth Insights From an Integrated Care System","summary":"Experiences from a large, integrated, value-based health system suggest that telehealth can be an effective care delivery approach. Public policies can improve telehealth access and care.","thumbnail":{"_type":"mainImage","alt":"telemedicine | Image Credit: © rh2010 - stock.adobe.com","asset":{"_createdAt":"2023-12-05T16:28:07Z","_updatedAt":"2023-12-05T16:28:07Z","metadata":{"palette":{"darkMuted":{"background":"#61553c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.82},"muted":{"background":"#b4745c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightVibrant":{"background":"#e7d1c6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.05},"darkVibrant":{"foreground":"#fff","title":"#fff","population":6.07,"background":"#493a1a","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.95},"vibrant":{"foreground":"#fff","title":"#fff","population":0.01,"background":"#ba825c","_type":"sanity.imagePaletteSwatch"},"dominant":{"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.95},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":7360,"aspectRatio":1.498371335504886,"height":4912},"isOpaque":true,"blurHash":"VEDl=,D%4n?c-;_N%M-pD%xvM{-;_3DiWBt7xax]t7M{","_type":"sanity.imageMetadata"},"_type":"sanity.imageAsset","originalFilename":"telemedicine - rh2010.jpeg","extension":"jpg","mimeType":"image/jpeg","_id":"image-aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912-jpg","_rev":"yLkPQ1Yunv4gUqVh5QBQaa","sha1hash":"aa55cba013e542363db5e3021a7d049b005c0d44","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","size":10640408,"uploadId":"ueKegQc9OLg07IP1riXXhgBAywYfiVMU","path":"images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","assetId":"aa55cba013e542363db5e3021a7d049b005c0d44"}},"authorDetails":[{"lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca"},{"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia","lastName":"Oregón"}],"factCheckBy":[{"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"}},{"url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan"},{"lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia"}],"issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"url":"telehealth-insights-from-an-integrated-care-system","published":"2024-09-16T16:29:41.215Z"}],"isLiveSite":true,"host":"www.ajmc.com","settings":{"title":"AJMC","networkID":"4688","adUnit":"ajmc.com","liveDomain":"www.ajmc.com","publicationName":"AJMC","logo":"/ajmc_logo_inverted.png","white_logo":"/ajmc_logo_inverted.png","logoHeight":"50px","enableEdgeCache":true,"sMaxAge":300,"staleWhileRevalidate":359,"clinicalTopicTopLatestNews":true,"megaMenuTaxName":"topic","megaMenuChildren":true,"sharingImageUrl":"https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png","twitterHandle":"@AJMC_Journal","publicationMapping":"publications","useNewSubNavMegaMenu":true,"redesignDetail":true,"redesignSAP":true,"useNewFooter":true,"newFooterLogos":[{"img":"/CHA_Logo.png","alt":"CH Logo","mobileWidth":"158px","mobileHeight":"42px","link":"/topic/center-on-health-equity-and-access","target":"_self"},{"img":"/CB.png","alt":"Center for Biosimilars Logo","mobileWidth":"170px","mobileHeight":"42px","link":"https://www.centerforbiosimilars.com/","target":"_blank"}],"useV3Components":true,"useAuthorRedesign":true,"navigationOptions":{"version":"2","variant":"4","customSpecialtyText":"Speciality Area"},"gateEnabled":"modal"},"homepage_creative_layout":{"creativeLayout":null}},"targeting":{"content_placement":["compendium/cll"],"document_url":["compendium/cll"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"statusCode":200,"data":{"page":{"creativeLayout":null,"externalLinks":null,"relatedMegaMenu":null,"title":"Compendium","creativeLayoutDetail":null,"articleDetailConfig":{"brightcovePlayerID":"pbDmfQhRw","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/publications","enableSegmentRecommend":true,"brightcoveAccountID":"10203567001","disqusShortName":"www-ajmc-com","downloadCitation":true,"shareOptions":{"shareSubject":"Check out this article!","twitterHandle":"AJMC","siteName":"ajmc","hideFacebook":false,"SocialIconSize":32,"twitterSiteName":"@AJMC_Journal","hidePinterest":false}},"fixIdentifier":null,"cmeConfig":null,"pageType":"Clinical Topic","parent":null,"intro":null,"contentCategories":null,"contentCategory":null,"archived":false,"filters":null,"orderDesc":null,"filterRequired":false,"labelRequired":false,"franchise":null,"theme":"default","styling":{"useDefaultLayout":true,"border":{"borderType":"lines","borderRadius":{"topLeft":"0rem","topRight":"0rem","bottomLeft":"0rem","bottomRight":"0rem"},"_type":"border","borderSize":0},"contentControl":{"showAuthor":true,"showSummary":true,"_type":"contentControl","showPublished":true,"readMore":true},"imageControl":{"_type":"imageControl","showImage":true,"thumbnailRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"}},"divider":{"_type":"divider","dividerSize":1},"titleOptions":{"titleSize":"1rem","_type":"titleOptions"}},"gateCode":null,"docGroup":null,"taxonomy":{"_createdAt":"2020-03-30T18:16:46Z","name":"Compendium","_rev":"oruil6rlosjyltJbhrNMGF","_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_updatedAt":"2024-04-09T09:14:18Z","_type":"taxonomy","pixelTrackingCode":null,"identifier":"compendium","isMainTopic":true},"featureContent":null,"disableEpisode":null,"linkedPage":null,"isDsoGated":null,"pages":null,"identifier":null,"creativeLayoutLatestNews":null,"content":null,"label":null,"pageSliders":null,"url":{"current":"/compendium","_type":"slug"},"hasSubCategory":false,"searchConfig":{"baseUrl":"/view/"},"videoPlayerConfig":null,"useV3":true,"excludeFromSitemap":false},"pageData":{"totalCount":134,"pageSize":30,"pageNumber":1,"data":[{"updatedOn":null,"title":"Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk R/R CLL","url":"liso-cel-prolongs-responses-pfs-and-os-in-pretreated-high-risk-r-r-cll","summary":"Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.","contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Ashling Wahner","url":"ashling-wahner"}],"factCheckAuthors":null,"_id":"c6485fe1-714c-4b8c-b86b-2b7450d8018b","thumbnail":{"_type":"mainImage","alt":"CLL Cells | Image Credit: © Laszlo - stock.adobe.com","asset":{"_ref":"image-25522052a2c51d8713921072b1256a81c1576daf-1200x800-jpg","_type":"reference"}},"published":"2025-03-07T15:54:00.000Z"},{"_id":"f2ab95d9-7ca9-4125-97a7-6170e7743312","title":"Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better","url":"ibrutinib-benefits-r-r-cll-but-combo-therapy-works-better","published":"2025-03-05T16:08:41.915Z","updatedOn":null,"factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com","asset":{"_ref":"image-dcc970cc0e88a2d1082c03f90fffac7a882f7264-5139x3426-jpg","_type":"reference"}},"summary":"Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}]},{"thumbnail":{"alt":"Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com","asset":{"_ref":"image-c47d1001b06db553ad12b402fa8d787f080c3245-3600x2057-jpg","_type":"reference"},"_type":"mainImage"},"summary":"Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.","published":"2025-02-10T22:03:49.443Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"factCheckAuthors":null,"_id":"18c29f40-05a0-4840-8f8d-a8afa244a228","url":"academic-cancer-centers-see-longer-survival-in-cll-mcl-than-community-centers","updatedOn":null,"title":"Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers"},{"_id":"d0f8cca4-8c55-4147-8146-b827b5b5cb66","url":"personalized-cll-therapy-with-mrd-guidance-improves-survival-outcomes","summary":"A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.","authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"factCheckAuthors":null,"title":"Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes","thumbnail":{"_type":"mainImage","alt":"CLL | Image credit: Saiful52 – stock.adobe.com","asset":{"_ref":"image-cc6ced98d5b353302d9801257a99e66403d946f7-1200x738-jpg","_type":"reference"}},"published":"2025-02-06T20:34:37.603Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"thumbnail":{"alt":"Red blood cells | Image credit: wanchalerm – stock.adobe.com","asset":{"_ref":"image-b1ee2df4225a6664d5e63acaef1d16318eb00901-5093x2853-jpg","_type":"reference"},"_type":"mainImage"},"summary":"Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"title":"Targeted Therapy in CLL May Impact Blood Cell Behavior","published":"2025-01-31T15:58:04.045Z","updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"factCheckAuthors":null,"_id":"936fd014-5b1c-4abc-861f-ed3b38729167","url":"targeted-therapy-in-cll-may-impact-blood-cell-behavior"},{"published":"2025-01-22T17:52:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"},{"displayName":"John Burke, MD","url":"john-burke-md"}],"factCheckAuthors":null,"url":"john-burke-md-discusses-survey-on-venetoclax-uptake-among-community-physicians","thumbnail":{"_type":"mainImage","alt":"John Burke, MD | Image credit: Navigating Cancer","asset":{"_ref":"image-8109a01173520de1840d640d8e4837fe43f0883c-200x200-jpg","_type":"reference"}},"_id":"300bfc34-605b-40da-a04e-0e078abc6d80","title":"John Burke, MD, Discusses Survey on Venetoclax Uptake Among Community Physicians","summary":null},{"_id":"083a44fc-eb24-4ba5-a4a4-301abb0d8717","url":"venetoclax-shows-good-results-even-in-short-telomere-patients-with-cll","thumbnail":{"_type":"mainImage","alt":"Chromosomes with Telomere floating on blue background | Image credit: peterschreiber.media – stock.adobe.com","asset":{"_ref":"image-3515117e6a864d50d9bf5dbf07c655b884d50d06-6700x3300-jpg","_type":"reference"}},"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"title":"Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL","summary":"New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL).","published":"2025-01-21T17:31:00.000Z","updatedOn":null,"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}]},{"_id":"7dc99418-9b2d-4505-bc65-17dc50bc05e8","title":"BTKi Resistance Mechanisms, Solutions Probed at ASH","thumbnail":{"_type":"mainImage","alt":"chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com","asset":{"_ref":"image-e9cc14ef4e90a78e114b001df670a92229b0212e-1920x1267-jpg","_type":"reference"}},"summary":"One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.","published":"2025-01-15T15:47:00.000Z","url":"btki-resistance-mechanisms-solutions-probed-at-ash","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"factCheckAuthors":null},{"_id":"14133336-cdb3-4476-8c8e-ba71e7803499","url":"ibrutinib-safe-and-effective-in-patients-with-cll-sll-real-world-data-show","summary":"The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).","updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"factCheckAuthors":null,"title":"Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show","thumbnail":{"_type":"mainImage","alt":"Ibrutinib packaging | Image credit: CLShebley – stock.adobe.com","asset":{"_ref":"image-dcc970cc0e88a2d1082c03f90fffac7a882f7264-5139x3426-jpg","_type":"reference"}},"published":"2025-01-10T12:27:00.000Z"},{"factCheckAuthors":null,"_id":"662b89d1-1fee-4174-bf71-e16dfe32871e","title":"Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024","thumbnail":{"_type":"mainImage","alt":"Patient with leukemia receiving treatment | Image credit: tonefotografia – stock.adobe.com","asset":{"_ref":"image-2c0c80a8d8015483642cad22fa013c85973e6fcc-4000x2662-jpg","_type":"reference"}},"updatedOn":null,"url":"patient-reported-qol-outcomes-of-initial-cll-treatments-ash-2024","summary":"Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.","published":"2025-01-08T21:22:52.498Z","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}]},{"_id":"e20dc78f-0503-4909-a71a-0057333437a4","title":"New Generation of CAR T May Elicit Improved CR Rates in CLL","url":"new-generation-of-car-t-may-elicit-improved-cr-rates-in-cll","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-870dc4d0d66f515ef74ad8e359f869e372efda1d-5824x3264-jpg","_type":"reference"}},"published":"2025-01-03T17:08:06.850Z","updatedOn":null,"authors":[{"displayName":"AJMC Contributor","url":"ajmc-contributor"}],"factCheckAuthors":null,"summary":"A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL). ","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"}},{"_id":"21f8c2b8-f9e2-4533-93e6-a6be341cfee6","title":"BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024","url":"beigene-s-mehrdad-mobasher-md-mph-discusses-cll-data-pipeline-following-ash-2024","published":"2025-01-02T13:00:00.000Z","updatedOn":null,"factCheckAuthors":null,"thumbnail":{"alt":"Mehrdad Mobasher, MD, MPH | Image credit: BeiGene","caption":"Mehrdad Mobasher, MD, MPH, is the chief medical officer for hematology at BeiGene. | Image credit: BeiGene","asset":{"_ref":"image-22e60e3b550af9c763788aaa1a5bbe0cdbbdfbcd-1200x1200-png","_type":"reference"},"_type":"mainImage"},"summary":"This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change January 2, 2025.","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}]},{"_id":"eef33dd1-bdf1-463d-9196-79c9e7d51a52","title":"Top 5 Most-Read CLL/SLL Articles of 2024","thumbnail":{"_type":"mainImage","alt":"Top 5 CLL of 2024","asset":{"_ref":"image-cc853809632b92ceefafe62b7af787d6451fb5fd-3187x1625-png","_type":"reference"}},"summary":"This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.","published":"2024-12-26T14:17:00.000Z","authors":[{"displayName":"Christina Mattina","url":"christina-mattina"}],"url":"top-5-most-read-cll-sll-articles-of-2024","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"_id":"da6a05e4-7ba4-46f8-9c7c-19336059c220","thumbnail":{"_type":"mainImage","alt":"A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com ","caption":"A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com ","asset":{"_ref":"image-f0c5d4ea0717f266f567a6a19f049cf7ff272c85-7500x4076-jpg","_type":"reference"}},"summary":"Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). ","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"factCheckAuthors":null,"title":"Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease","url":"infection-rate-more-than-double-in-cll-sll-accompanied-by-secondary-immunodeficiency-disease","published":"2024-12-19T17:35:00.000Z","updatedOn":null},{"url":"different-btk-inhibitors-bring-distinct-changes-to-full-length-btk","published":"2024-12-16T19:41:00.000Z","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"thumbnail":{"_type":"mainImage","alt":"doctor and patient - Sebra - stock.adobe.com.jpg","asset":{"_ref":"image-baa43745aa5408bc2ee3f75b86c2aab17c718dbe-1200x675-jpg","_type":"reference"}},"summary":"The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.","updatedOn":null,"factCheckAuthors":null,"_id":"c8820964-232e-456e-9384-e79610d0ecde","title":"Different Bruton Tyrosine Kinase Inhibitors Bring Distinct Changes to Full-Length BTK"},{"thumbnail":{"alt":"CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com ","caption":"CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com ","asset":{"_ref":"image-8b532ed92234b55d19339ba1cd96b319212188cf-6000x4000-jpg","_type":"reference"},"_type":"mainImage"},"summary":"Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen. ","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"published":"2024-12-10T14:42:00.000Z","factCheckAuthors":null,"_id":"fd779bf6-a693-4718-95df-be98d3f0766b","title":"6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL ","url":"6-year-data-support-fixed-duration-ven-obi-for-untreated-cll"},{"_id":"559b15e6-5ba9-45b4-a714-46231329f64b","url":"new-guidelines-clarify-eortc-quality-of-life-scores-for-chronic-lymphocytic-leukemia","thumbnail":{"_type":"mainImage","alt":"Guidelines folder-tashatuvango-stock.adobe.com.jpeg","asset":{"_type":"reference","_ref":"image-29f50a50749d5b42870bfbf652a620b3fce97dcb-1200x738-jpg"}},"summary":"Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.","published":"2024-12-02T17:36:13.598Z","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"title":"New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia","factCheckAuthors":null},{"url":"tattoos-may-be-associated-with-increased-risk-of-rare-nhls","thumbnail":{"asset":{"_ref":"image-d68a0ae1f89cececa803c05ff5632ab318098f1c-5472x3648-jpg","_type":"reference"},"_type":"mainImage","alt":"New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com","caption":"New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com"},"published":"2024-11-29T15:39:00.000Z","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"AJMC Contributor","url":"ajmc-contributor"}],"title":"Tattoos May Be Associated With Increased Risk of Rare NHLs ","summary":"Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution. ","factCheckAuthors":null,"_id":"958b07d0-dc82-4b3c-9194-1487ad0614d2"},{"url":"real-world-data-confirm-ibrutinib-s-role-in-relapsed-cll","thumbnail":{"_type":"mainImage","alt":"Big Data | Image Credit: © Friends Stock-stock.adobe.com","asset":{"_ref":"image-fd617092164d84c81add47518d2c67d8dc91de53-1200x738-jpg","_type":"reference"}},"summary":"This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.","published":"2024-11-26T13:00:00.000Z","updatedOn":null,"_id":"1b4c97e5-1e4a-4581-9298-f9d5fcaf46ec","title":"Real-World Data Confirm Ibrutinib's Role in Relapsed CLL","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null},{"published":"2024-11-23T13:16:00.000Z","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"_id":"1fdd2f09-9d9d-4679-8c5c-64fee40e632c","title":"Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles","thumbnail":{"_type":"mainImage","alt":"Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com","asset":{"_type":"reference","_ref":"image-b276506cb9fe42e52165074a6e038a4b99789dcb-5622x3622-jpg"}},"summary":"The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).","updatedOn":null,"factCheckAuthors":null,"url":"novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles"},{"updatedOn":null,"summary":"For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps ","published":"2024-11-21T16:53:08.498Z","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"_id":"6eb0a677-bc78-4bcb-ba17-a55e2bc97750","title":"Treating Double-Exposed Patients With CLL: A Continued Unmet Need","url":"treating-double-exposed-patients-with-cll-a-continued-unmet-need","thumbnail":{"_type":"mainImage","alt":"CLL over the image of a stethoscope and red blood cells | Image credit: Saiful52 - stock.adobe.com","asset":{"_ref":"image-cc6ced98d5b353302d9801257a99e66403d946f7-1200x738-jpg","_type":"reference"}}},{"thumbnail":{"_type":"mainImage","alt":"Health care costs and fees | Image Credit: © everythingpossible - stock.adobe.com","asset":{"_ref":"image-386a8d9de05e073b8c8e281bd8b54ba21d2c0fc4-6000x4000-jpg","_type":"reference"}},"authors":[{"displayName":"AJMC Contributor","url":"ajmc-contributor"}],"_id":"60da886f-166f-4a05-ae2b-55cd377e0197","url":"fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world","summary":"The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.","published":"2024-11-09T13:15:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"title":"Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World "},{"url":"kir2ds2-nk-cells-show-potential-in-hcc-and-leukemia-treatment","thumbnail":{"_type":"mainImage","alt":"NK Cell test | Image Credit: © jarun011-stock.adobe.com","asset":{"_ref":"image-8eccbe2e0fbcb0daf334fb38c368a1a559ae8af0-1200x738-jpg","_type":"reference"}},"summary":"These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment.\n","updatedOn":null,"factCheckAuthors":null,"_id":"8a600615-c322-4caa-9481-831cd5a46f92","published":"2024-11-06T20:15:55.278Z","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"AJMC Contributor","url":"ajmc-contributor"}],"title":"KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment"},{"url":"review-emphasizes-potential-infection-risks-with-btk-inhibitors","published":"2024-11-02T13:52:00.000Z","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"thumbnail":{"_type":"mainImage","alt":"Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com","caption":"Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com","asset":{"_ref":"image-962ea5111c87d03bf0c9862e1749ebeecd4f5905-5376x3584-jpg","_type":"reference"}},"summary":"Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract. ","updatedOn":null,"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"_id":"5d6e1d9b-7549-48d7-8de6-26e26e543532","title":"Review Emphasizes Potential Infection Risks With BTK Inhibitors "},{"published":"2024-10-30T14:49:27.498Z","updatedOn":null,"factCheckAuthors":null,"_id":"e6c11a6b-98bd-4d35-8b4c-c19853c2c9ad","title":"Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL","url":"zanubrutinib-more-effective-than-ibrutinib-in-treating-patients-with-relapsed-refractory-cll-sll","thumbnail":{"_type":"mainImage","alt":"Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com","asset":{"_ref":"image-e825022f10d04a8c8b873d06455d4327ec5a3449-1200x800-jpg","_type":"reference"}},"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"summary":"The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). "},{"title":"Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients ","url":"understanding-ibrutinib-relapse-in-cll-immune-profiles-of-responders-vs-relapsing-patients","thumbnail":{"_type":"mainImage","alt":"Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com","caption":"Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com","asset":{"_type":"reference","_ref":"image-9d0d21b5e56292278fdfee526605374241258910-6000x5248-jpg"}},"published":"2024-10-23T16:46:00.000Z","updatedOn":null,"_id":"73bb034b-d77a-40fd-abfd-6524ce1b00ce","summary":"A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. ","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"factCheckAuthors":null},{"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"AJMC Contributor","url":"ajmc-contributor"}],"factCheckAuthors":null,"summary":"The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.","published":"2024-10-17T20:47:28.256Z","updatedOn":null,"_id":"b15ef89e-f4ff-4990-b42e-db632a88b09a","title":"Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL","url":"zanubrutinib-not-cost-effective-in-china-against-fixed-duration-r-bendamustine-in-1l-cll","thumbnail":{"_type":"mainImage","alt":"money and stethoscope | Image Credit: © pla2na - stock.adobe.com","asset":{"_ref":"image-4964e17cc7785a4c0fc3b158e3dadf41c44b050a-6016x4016-jpg","_type":"reference"}}},{"published":"2024-10-16T16:36:22.265Z","updatedOn":null,"_id":"d331d995-b404-423a-bb7b-7adb441ba751","title":"Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis","summary":"Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.\n","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"factCheckAuthors":null,"url":"melanoma-risk-doubled-for-monoclonal-b-cell-lymphocytosis","thumbnail":{"_type":"mainImage","alt":"Skin Cancer Potential | Image Credit: © Monstar Studio-stock.adobe.com","asset":{"_ref":"image-739c7a6180c80ee48c24f41b112dab5177075f4e-5184x3456-jpg","_type":"reference"}}},{"url":"real-world-data-acalabrutinib-safety-profile-superior-in-cll-sll","thumbnail":{"asset":{"_ref":"image-89ce8146b16a95750ea182db263745b7a16b6ec5-8064x5376-jpg","_type":"reference"},"_type":"mainImage","alt":"Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com","caption":"Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"_id":"af181c88-3b3a-4b97-9544-9fa154a5dd49","title":"Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL ","summary":"A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.","published":"2024-10-09T13:41:00.000Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"_id":"7edd50a0-44ac-4194-8957-813870bcf431","url":"real-world-data-support-tki-discontinuation-after-cp-cml-remission","thumbnail":{"_type":"mainImage","alt":"diagnosis leukemia | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com","asset":{"_ref":"image-00f63d1a9fdd06b3f99a5e908a01ac22ec5b25ea-1200x728-jpg","_type":"reference"}},"summary":"Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.","published":"2024-10-04T15:25:26.840Z","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"factCheckAuthors":null,"title":"Real-World Data Support TKI Discontinuation After CP-CML Remission","authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}]}],"targeting":{"content_placement":["compendium/cll"],"document_url":["compendium/cll"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"currentTopic":{"pixelTrackingCode":null,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","thumbnail":null,"cmeType":null,"perKeywordMapping":null,"summary":null,"url":"cll","ptceKeywordMapping":null,"parent":{"_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","url":"compendium","parent":null}},"filterData":[],"relatedTopics":null,"podcastsData":[{"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-4d74ae04b0508977864936ec08f2aaa199758e5c-1000x563-jpg","_type":"reference"}},"is_visible":true,"ExcludeFromPubMedXML":false,"url":{"current":"diving-into-patient-preferences-for-blood-cancer-treatments-with-dr-sikander-ailawadhi","_type":"slug"},"_rev":"bAl93RvH29PY4NpeQjvRfS","articleType":"Commentary","contentCategory":{"_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z"},"documentGroup":null,"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.ajmc.com/2ca4f0a6-ffe3-4657-aa4a-75d067184301_1734458799952.4987c70d-c890-44a5-ba41-39dce9ac752f.mp3","_createdAt":"2024-12-17T16:00:21Z","documentGroupMapping":[{"_ref":"conference_ash","_type":"reference","_key":"06f77dd6c4b8"}],"title":"Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi","_id":"2ca4f0a6-ffe3-4657-aa4a-75d067184301","taxonomyMapping":[{"_ref":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_type":"reference","_key":"3d0f90bbc529"},{"_key":"bf6bc0c66ab0","_ref":"topic_clinical","_type":"reference"},{"_type":"reference","_key":"a1db339fec0b","_ref":"4ee49086-e720-4a65-883e-4efc24de53bb"},{"_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference","_key":"96edaca80301"},{"_ref":"22582798-e9d8-4c8b-bae3-787c9f45236f","_type":"reference","_key":"9934e9983d6e"}],"link":"/view/diving-into-patient-preferences-for-blood-cancer-treatments-with-dr-sikander-ailawadhi","_updatedAt":"2025-01-02T21:38:46Z","body":[{"children":[{"text":"Among the latest data being presented at the ","_key":"6821580195040","_type":"span","marks":[]},{"text":"American Society of Hematology Annual Meeting and Exposition","_key":"8af29deb9ddf","_type":"span","marks":["827e7a61788f"]},{"text":", held December 7-10, 2024, in San Diego, California, were 3 abstracts that focused on patient preferences and treatment choices.","_key":"23229718e17d","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"9e6b353a00b8","markDefs":[{"href":"https://www.ajmc.com/conference/ash","_key":"827e7a61788f","nofollow":false,"blank":true,"_type":"link"}]},{"_key":"26f7a0cc67cd","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"1fce38f8d6440"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"3d69b62126f1","markDefs":[],"children":[{"_key":"bca00b5afc600","_type":"span","marks":[],"text":"Sikander Ailawadhi, MD, professor of medicine in the Division of Hematology/Oncology at the Mayo Clinic, Florida, was a coauthor on all 3 abstracts, covering patient preferences for Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma, survivorship burden and patient preferences affecting treatment choices in multiple myeloma, and race/ethnicity-specific sociodemographic and economic factors driving refusal of treatment in multiple myeloma."}]},{"_type":"block","style":"normal","_key":"07aac058b37e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b38350fcb871"}]},{"_type":"iframe","_key":"301a11a897d6","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/1988030703%3Fsecret_token%3Ds-3pP4JrMWQCs\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true\u0026visual=true"},{"_key":"aa9bde059f76","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Listen above or through one of these podcast services:","_key":"313166ec3278"}],"_type":"block","style":"normal"},{"markDefs":[{"href":"https://podcasts.apple.com/us/podcast/managed-care-cast/id1177540313","_key":"f648f6948185","blank":true,"_type":"link"},{"blank":true,"_type":"link","href":"https://tunein.com/podcasts/Health--Wellness-Podcasts/Managed-Care-Cast-p937637/","_key":"04647613372f"},{"blank":true,"_type":"link","href":"https://www.stitcher.com/podcast/managed-care-cast","_key":"a17af5d21f01"},{"_type":"link","href":"https://open.spotify.com/show/7JQZGTuflqnkt8wjfX238y","_key":"0bef995e21b3","blank":true}],"children":[{"text":"iTunes","_key":"4641ea8b0221","_type":"span","marks":["f648f6948185"]},{"text":"\n","_key":"c6b87819732d","_type":"span","marks":[]},{"marks":["04647613372f"],"text":"TuneIn","_key":"40c28bc41cad","_type":"span"},{"_type":"span","marks":[],"text":"\n","_key":"800ba0e7a517"},{"_key":"ee02e221a465","_type":"span","marks":["a17af5d21f01"],"text":"Stitcher"},{"_type":"span","marks":[],"text":"\n","_key":"c76c8a530a7e"},{"_type":"span","marks":["0bef995e21b3"],"text":"Spotify","_key":"714e10ac8b61"}],"_type":"block","style":"normal","_key":"b128a5b803db"}],"updatedOn":null,"published":"2024-12-17T18:00:24.389Z","summary":"Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.","_type":"article"}],"videoSeriesData":[{"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"a269ca90f909"}],"published":"2024-08-19T17:37:15.208Z","summary":"Experts discuss future directions of BTK inhibitors.","authorMapping":[{"_updatedAt":"2024-08-02T15:09:20Z","url":{"current":"ryan-haumschild-pharmd-ms-mba-cpel","_type":"slug"},"firstName":"Ryan","displayName":"Ryan Haumschild, PharmD, MS, MBA, CPEL","_createdAt":"2024-08-02T15:09:20Z","_id":"c3086c92-aac8-4cfd-8790-ab82f09e5bc9","lastName":"Haumschild","_rev":"ELFKWX5zlCikAqlfg38IU3","_type":"author"},{"_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW"},{"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"}},{"_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z"}],"title":"Future Directions of BTK Inhibitors in Leukemia and Lymphoma","factCheckAuthorMapping":null,"is_visible":true,"_type":"article","_rev":"dX4KUm4JwEeojJupkPB6sh","url":{"current":"future-directions-of-btk-inhibitors-in-leukemia-and-lymphoma","_type":"slug"},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"link":"/view/future-directions-of-btk-inhibitors-in-leukemia-and-lymphoma","_createdAt":"2024-08-19T17:36:58Z","thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"lightMuted":{"population":0.3,"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":6.45,"background":"#363333","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#dc9880","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.07},"darkVibrant":{"foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch"}}},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"body":[{"disableAutoPlayVideo":false,"source":"brightcove","_key":"f2f6004e3d27","videoObject":{"videoTitle":"Future Directions of BTK Inhibitors in Leukemia and Lymphoma","thumbnail":{"asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"},"_type":"image"},"videoDuration":"PT12M31S","videoDescription":"Experts discuss future directions of BTK inhibitors.","_type":"videoDetails"},"_type":"video","videoID":"6355243870112"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"71719aa396f5"}],"_type":"block","style":"normal","_key":"538c812bb790"},{"_key":"a4450affdcda","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following:","_key":"6e96649d948c"}],"_type":"block","style":"normal"},{"listItem":"bullet","markDefs":[],"children":[{"_key":"377b142c71200","_type":"span","marks":[],"text":"Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?"}],"level":1,"_type":"block","style":"normal","_key":"d8339e7e1ed8"},{"_key":"7b375f6b39c8","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?","_key":"84ca843cdedd"}],"level":1,"_type":"block","style":"normal"}],"_updatedAt":"2024-08-19T17:39:47Z","articleType":"Opinion","seoTag":["CLL","chronic lymphocytic leukemia","CLL treatment","chronic lymphocytic leukemia treatment","BTKi","BTK inhibitors","BTK inhibition","BTK","future directions","leukemia","lymphoma"],"ExcludeFromPubMedXML":false,"documentGroup":{"_type":"reference","_ref":"27313d96-782a-4c0f-9250-13302fab3687"},"showSocialShare":true,"updatedOn":null,"taxonomyMapping":[{"identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z"},{"name":"Peer Exchange","summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1}],"_id":"99685758-e942-42a9-98d8-1710d630b529"},{"showSocialShare":true,"_createdAt":"2024-08-19T17:30:34Z","seoTag":["CLL","chronic lymphocytic leukemia","CLL treatment","chronic lymphocytic leukemia treatment","patient access","BTKi","BTK inhibitors","BTK inhibition","BTK","patient out of pocket costs"],"published":"2024-08-19T17:30:45.278Z","authorMapping":[{"_id":"c3086c92-aac8-4cfd-8790-ab82f09e5bc9","lastName":"Haumschild","_rev":"ELFKWX5zlCikAqlfg38IU3","_type":"author","_updatedAt":"2024-08-02T15:09:20Z","url":{"current":"ryan-haumschild-pharmd-ms-mba-cpel","_type":"slug"},"firstName":"Ryan","displayName":"Ryan Haumschild, PharmD, MS, MBA, CPEL","_createdAt":"2024-08-02T15:09:20Z"},{"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"}},{"firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z"},{"_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z"}],"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"a269ca90f909"}],"_rev":"9hnAaALbXCiJBiJomle7wi","documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"articleType":"Opinion","summary":"A panel of specialists discuss patient access advocacy for BTK inhibitors.","is_visible":true,"taxonomyMapping":[{"usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"},{"_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange","summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z"}],"body":[{"disableAutoPlayVideo":false,"source":"brightcove","_key":"f2f6004e3d27","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"PT3M38S","videoDescription":"A panel of specialists discuss patient access advocacy for BTK inhibitors.","_type":"videoDetails","videoTitle":"Patient Access Advocacy for BTK Inhibitors"},"_type":"video","videoID":"6355245636112"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"71719aa396f5"}],"_type":"block","style":"normal","_key":"538c812bb790"},{"markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following:","_key":"6e96649d948c"}],"_type":"block","style":"normal","_key":"a4450affdcda"},{"level":1,"_type":"block","style":"normal","_key":"53893507cef1","listItem":"bullet","markDefs":[],"children":[{"marks":[],"text":"How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?","_key":"8b69eea9344c0","_type":"span"}]},{"_key":"57ad7fa29759","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?","_key":"fc1b552ec891"}],"level":1,"_type":"block","style":"normal"}],"_updatedAt":"2024-08-19T17:36:47Z","_type":"article","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_id":"3e753607-1aaf-4ce6-b0fa-e73541f5c9a4","ExcludeFromPubMedXML":false,"link":"/view/patient-access-advocacy-for-btk-inhibitors","url":{"current":"patient-access-advocacy-for-btk-inhibitors","_type":"slug"},"title":"Patient Access Advocacy for BTK Inhibitors","thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.3,"background":"#b1bac3"},"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45},"muted":{"background":"#a97960","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.86},"lightVibrant":{"population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"}},"hasAlpha":true},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"updatedOn":null,"factCheckAuthorMapping":null},{"published":"2024-08-12T14:54:18.332Z","documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"link":"/view/the-inflation-reduction-act-implications-for-patient-access-in-cl","updatedOn":null,"showSocialShare":true,"title":"The Inflation Reduction Act: Implications for Patient Access in CL ","_updatedAt":"2024-08-12T14:57:39Z","thumbnail":{"asset":{"uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"vibrant":{"foreground":"#fff","title":"#fff","population":0.08,"background":"#a9704c","_type":"sanity.imagePaletteSwatch"},"dominant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"_type":"sanity.imagePalette","darkMuted":{"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45},"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.3,"background":"#b1bac3"}}},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z"}},"is_visible":true,"_type":"article","factCheckAuthorMapping":null,"articleType":"Opinion","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_rev":"cCu1fGsfI4aKbZqD2MCqWH","url":{"current":"the-inflation-reduction-act-implications-for-patient-access-in-cl","_type":"slug"},"seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"summary":"A group of experts discuss implications for patient access in CLL. ","_id":"922b9400-bf8a-4e6d-9fec-47100b888e1e","authorMapping":[{"_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild","_type":"author"},{"_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z"},{"url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c"},{"_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3"}],"body":[{"videoID":"6355244853112","disableAutoPlayVideo":false,"source":"brightcove","_key":"81674264f174","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"PT8M22S","videoDescription":"The Inflation Reduction Act: Implications for Patient Access in CL ","_type":"videoDetails","videoTitle":"The Inflation Reduction Act: Implications for Patient Access in CL "},"_type":"video"},{"style":"normal","_key":"88cb7f5844b6","markDefs":[],"children":[{"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110","_type":"span","marks":["strong","em"]}],"_type":"block"},{"_type":"block","style":"normal","_key":"88b98b812665","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What efforts are being made to improve affordability and access to BTK inhibitors for all patients who could benefit from them?","_key":"1bb8a5e525e30"}],"level":1},{"style":"normal","_key":"55012600f695","markDefs":[],"children":[{"_type":"span","marks":[],"text":" ","_key":"41650f9aefc10"}],"_type":"block"},{"listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Ibrutinib was selected for the first round of Medicare drug price negotiations, a key component of the Inflation Reduction Act (IRA). How might this negotiation impact patient access to BTK inhibitor therapy?","_key":"86157780551f0"}],"level":1,"_type":"block","style":"normal","_key":"afe39613475e"}],"_createdAt":"2024-08-12T14:53:59Z","taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange","summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy"}],"ExcludeFromPubMedXML":false,"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}]},{"contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"link":"/view/navigating-access-challenges-in-cll-treatment-strategies-for-overcoming-barriers","ExcludeFromPubMedXML":false,"title":"Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers  ","authorMapping":[{"_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild"},{"url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z"},{"firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z"},{"lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z"}],"_rev":"cCu1fGsfI4aKbZqD2MCer3","taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"sortOrder":1,"name":"Peer Exchange","summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z"}],"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"body":[{"_type":"video","videoID":"6355243653112","disableAutoPlayVideo":false,"source":"brightcove","_key":"81674264f174","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"PT8M04S","videoDescription":"Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers  ","_type":"videoDetails","videoTitle":"Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers  "}},{"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110"}],"_type":"block","style":"normal","_key":"88cb7f5844b6","markDefs":[]},{"listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What are the major access challenges in CLL treatment, and how can they be overcome?","_key":"0af984ee46b40"}],"level":1,"_type":"block","style":"normal","_key":"ce51d637f01b"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"88b2924a97000"}],"_type":"block","style":"normal","_key":"cd3382f26157"},{"_key":"0a359e5f1d72","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How do payer policies and clinical pathways affect the clinical decision-making process for CLL treatments? ","_key":"f89969a690290"}],"level":1,"_type":"block","style":"normal"}],"updatedOn":null,"thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"palette":{"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08,"background":"#a9704c"},"dominant":{"title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45},"muted":{"background":"#a97960","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.86},"lightVibrant":{"population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"},"lightMuted":{"title":"#fff","population":0.3,"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAAPoAAAD6AG1e1JrAAADEElEQVQokSWO3U9bBQBHmwzHtm5LlrEa48N0JvNBY8wSoAJtb1taWtrSS1Za4FJqW/rB7b0dAg29QDew1kVN3AxDzdRExwZjkslHxrY4qiZzZmoYVIxuCQ/GB+dfcQz48EvOy+/k6KrMCtWCyl5LBr1NoaZ1kOea05xOjnOn/CN//vWU9e1/eLT9lCd//8vynR9whXMY7GmOtg5ywKpQbVHYK6jsuHQ7sCOsMmV4xixz0CpTY47TnhhncbXMz5XH3N94zE+VJ2z+sc3Cyrc4enIcMcU5ZMuwT9j5KewxZ3anqxay7BNU9ltkDlj60ZvTHGmM4otpXF9Y4eEv6/y68Rvrm1s82qhwbX4Ja+cgh9+IohdkDtoU9EJmN2iPaVeocsia4XhznBddKQyuLDXmGM6QyuVPPuP+d2UqmxW2tn7n4YMHTF/6lAZf326hwT3ASU8/J1sSHBbSVP1fqHDUHOWUI0idJ8xxV4pjxk5MLom3C2e5MfMla/fWKJe/Z/7qDNrQMLUWEUOjxEuefqz+ME5vByesEnpLGt1+c4pn6/w0WJyYmz28UO/B8IqdJpufQTXLB6Ui01OX+OjCRcZzQ8S6O6k12nj+dSevCSIBUaSrzcOpphaONXajO2GTeNVop8Vioq1ZoMHYRG2dCa/ThRyRGFOTaGqKM30RkqF2utvcOAQrRqOFFquNWLubsMdOU309Lxud6BJdHaQDXoZCbkYlD1qPl7zkQ+1wMyT5uZANMz0Q5v10EK3HhxL0kO89zbl4iHOxAMV4AE3ykRQd9Ppd6OZG+5jNR5kdiTA30ssNLcJMrodSzM9kVGROi3FrMsnC6JtMZYIU+wJc0RLcKqksFxWWSme4WXqLuQmFr/JxdLffkVmZSLJYiLE4HmWpEOXasMREr5eRbg8fZ7u4Mhzm84FOzsdFxiIiX+Ri3C6p3HtvgLWLGmtTZ7n7YZ6lYgbdalFmsRBnYTTCN2MRlgtRLqtBZNFGyGkiJTrIBpzI7XYirQJhr52JeID5sQR3z6usvpvl5qTM14UEs/kI/wFo3uWik0jZfQAAAABJRU5ErkJggg==","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata"},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"is_visible":true,"_type":"article","documentGroup":{"_type":"reference","_ref":"27313d96-782a-4c0f-9250-13302fab3687"},"_id":"4d370971-e354-4f3b-982c-c9c80c5eab47","_updatedAt":"2024-08-12T14:53:20Z","seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"factCheckAuthorMapping":null,"summary":"A panel of experts discuss navigating access challenges in CLL treatment. ","_createdAt":"2024-08-12T14:49:10Z","published":"2024-08-12T14:49:52.997Z","url":{"current":"navigating-access-challenges-in-cll-treatment-strategies-for-overcoming-barriers","_type":"slug"},"articleType":"Opinion","showSocialShare":true},{"authorMapping":[{"url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z"},{"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"}},{"_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD"},{"_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai"}],"ExcludeFromPubMedXML":false,"documentGroupMapping":[{"_type":"reference","_key":"450ad0b57b6f","_ref":"27313d96-782a-4c0f-9250-13302fab3687"}],"_type":"article","documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"showSocialShare":true,"updatedOn":null,"_rev":"6nISw5aZ4szN8tuPDioF6A","body":[{"_type":"video","videoID":"6355244463112","disableAutoPlayVideo":false,"source":"brightcove","_key":"81674264f174","videoObject":{"videoDescription":"Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization ","_type":"videoDetails","videoTitle":"Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization ","thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"PT5M43S"}},{"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110"}],"_type":"block","style":"normal","_key":"88cb7f5844b6","markDefs":[]},{"listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What are the financial burdens of BTK inhibitor therapy? How does the cost of BTK inhibitors impact access and utilization for patients with CLL?","_key":"e005a003f8030"}],"level":1,"_type":"block","style":"normal","_key":"a0c271926cdb"}],"articleType":"Opinion","seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"url":{"current":"financial-challenges-of-btk-inhibitor-therapy-in-cll-impact-on-access-and-utilization","_type":"slug"},"thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"title":"#fff","population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.3},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08,"background":"#a9704c"},"dominant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"_type":"sanity.imagePalette","darkMuted":{"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080}},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"_createdAt":"2024-08-05T21:27:34Z","factCheckAuthorMapping":null,"published":"2024-08-05T21:28:08.730Z","is_visible":true,"taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange","summary":[{"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8","markDefs":[]}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z"}],"title":"Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization ","contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"summary":"Experts discuss financial challenges of BTK inhibitor therapy. ","link":"/view/financial-challenges-of-btk-inhibitor-therapy-in-cll-impact-on-access-and-utilization","_id":"8e19be71-764b-47be-a95b-a1526372d584","_updatedAt":"2024-08-05T21:29:53Z"},{"articleType":"Opinion","_createdAt":"2024-08-05T21:23:50Z","title":"Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment ","taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"summary":[{"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8","markDefs":[]}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange"}],"ExcludeFromPubMedXML":false,"_rev":"mKdf7JXZ2wTMEukqTiqglJ","seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"link":"/view/combination-regimens-with-btk-inhibitors-new-frontiers-in-cll-treatment","is_visible":true,"documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"_id":"bd60ba63-74f7-4ae4-bd42-939c898b3b52","thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":6.45,"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"},"lightMuted":{"population":0.3,"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":true},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"_type":"article","_updatedAt":"2024-08-05T21:26:48Z","summary":"A panel of experts discuss combination regimens with BTK inhibitors. ","documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"authorMapping":[{"_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z"},{"url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z"},{"lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian"},{"url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn"}],"body":[{"source":"brightcove","_key":"81674264f174","videoObject":{"thumbnail":{"_type":"image","asset":{"_type":"reference","_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png"}},"videoDuration":"PT3M41S","videoDescription":"Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment ","_type":"videoDetails","videoTitle":"Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment "},"_type":"video","videoID":"6355243278112","disableAutoPlayVideo":false},{"_type":"block","style":"normal","_key":"88cb7f5844b6","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110"}]},{"style":"normal","_key":"1997ec8149ef","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL? ","_key":"b6bbe2f6621c0"}],"level":1,"_type":"block"}],"published":"2024-08-05T21:24:20.054Z","showSocialShare":true,"updatedOn":null,"factCheckAuthorMapping":null,"url":{"current":"combination-regimens-with-btk-inhibitors-new-frontiers-in-cll-treatment","_type":"slug"}},{"_type":"article","articleType":"Opinion","seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"taxonomyMapping":[{"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false},{"sortOrder":1,"name":"Peer Exchange","summary":[{"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8","markDefs":[]}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z"}],"authorMapping":[{"_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA"},{"_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW"},{"firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z"},{"displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam"}],"_updatedAt":"2024-07-29T20:28:10Z","link":"/view/decision-making-in-cll-the-role-of-real-world-evidence","updatedOn":null,"factCheckAuthorMapping":null,"documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"title":"Decision-Making in CLL: The Role of Real-World Evidence ","thumbnail":{"asset":{"extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"palette":{"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#fff","population":0.3,"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":6.45,"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata"},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png"}},"published":"2024-07-29T20:26:34.221Z","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_id":"6f5a1bb0-67d9-4fc0-8f74-708c8e18817b","url":{"current":"decision-making-in-cll-the-role-of-real-world-evidence","_type":"slug"},"ExcludeFromPubMedXML":false,"body":[{"source":"brightcove","_key":"81674264f174","videoObject":{"_type":"videoDetails","videoTitle":"Decision-Making in CLL: The Role of Real-World Evidence ","thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"PT3M58S","videoDescription":"Decision-Making in CLL: The Role of Real-World Evidence "},"_type":"video","videoID":"6355244368112","disableAutoPlayVideo":false},{"style":"normal","_key":"88cb7f5844b6","markDefs":[],"children":[{"_key":"734e69f0b2110","_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):"}],"_type":"block"},{"level":1,"_type":"block","style":"normal","_key":"80fc43a42809","listItem":"bullet","markDefs":[],"children":[{"text":"How do you integrate real-world evidence into your clinical decision-making process for BTK inhibitors in CLL?","_key":"a6af9c09a42a0","_type":"span","marks":[]}]}],"_rev":"oyIUHkUBdFuSXDBDnJrYsu","_createdAt":"2024-07-29T20:26:15Z","showSocialShare":true,"summary":"A discussion on therapeutic decision-making in CLL and the role of real-world evidence.","is_visible":true},{"seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"showSocialShare":true,"_type":"article","link":"/view/leveraging-maics-for-decision-making-in-cll-btk-inhibitor-selection","_id":"92eeb87d-dc1b-449b-b18f-e0b97e264679","taxonomyMapping":[{"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN"},{"summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange"}],"documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"articleType":"Opinion","_createdAt":"2024-07-29T20:22:40Z","_updatedAt":"2024-07-29T20:24:35Z","published":"2024-07-29T20:22:54.235Z","body":[{"_type":"video","videoID":"6355245251112","disableAutoPlayVideo":false,"source":"brightcove","_key":"81674264f174","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}},"videoDuration":"7:57","videoDescription":"Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection ","_type":"videoDetails","videoTitle":"Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection "}},{"markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110"}],"_type":"block","style":"normal","_key":"88cb7f5844b6"},{"style":"normal","_key":"59590bf6d50d","listItem":"bullet","markDefs":[],"children":[{"_key":"9b2365c4af900","_type":"span","marks":[],"text":"How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?"}],"level":1,"_type":"block"}],"summary":"Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor. ","thumbnail":{"asset":{"_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"},"lightMuted":{"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.3},"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"population":9.44,"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45},"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png"}},"ExcludeFromPubMedXML":false,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"is_visible":true,"updatedOn":null,"_rev":"oyIUHkUBdFuSXDBDnJqhTA","title":"Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection ","url":{"current":"leveraging-maics-for-decision-making-in-cll-btk-inhibitor-selection","_type":"slug"},"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"authorMapping":[{"firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc"},{"_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author"},{"url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c"},{"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"}}],"factCheckAuthorMapping":null},{"articleType":"Opinion","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_updatedAt":"2024-07-23T14:27:53Z","seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"_id":"1a747dd1-d872-44ae-94da-3b81b9f10314","showSocialShare":true,"link":"/view/optimizing-therapy-sequencing-in-cll","_type":"article","documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"factCheckAuthorMapping":null,"taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange"}],"authorMapping":[{"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc","firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"}},{"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW","_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"}},{"firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD","_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z"},{"_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z","lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z"}],"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"published":"2024-07-23T14:27:27.045Z","updatedOn":null,"thumbnail":{"asset":{"metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"},"lightMuted":{"title":"#fff","population":0.3,"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08,"background":"#a9704c"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44,"background":"#043c6c"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":6.45,"background":"#363333","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":6.86,"background":"#a97960","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.07,"background":"#dc9880"}},"hasAlpha":true},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z","uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png"}},"_createdAt":"2024-07-23T14:23:07Z","is_visible":true,"title":"Optimizing Therapy Sequencing in CLL ","url":{"current":"optimizing-therapy-sequencing-in-cll","_type":"slug"},"summary":"A panel of experts discuss optimizing therapy sequencing in CLL. ","_rev":"mQnYCYbyJQ5d5tNwMCsxOy","body":[{"source":"brightcove","_key":"81674264f174","videoObject":{"videoTitle":"Optimizing Therapy Sequencing in CLL ","thumbnail":{"asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"},"_type":"image"},"videoDuration":"PT4M52S","videoDescription":"Optimizing Therapy Sequencing in CLL ","_type":"videoDetails"},"_type":"video","videoID":"6355245829112","disableAutoPlayVideo":false},{"children":[{"_key":"734e69f0b2110","_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):"}],"_type":"block","style":"normal","_key":"88cb7f5844b6","markDefs":[]},{"markDefs":[],"children":[{"_key":"9c9ac60953f10","_type":"span","marks":[],"text":"How do you determine the optimal sequencing of therapies for patients with CLL?"}],"level":1,"_type":"block","style":"normal","_key":"a59096fe567b","listItem":"bullet"},{"_key":"19f0f3d66534","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How does prior therapy exposure influence your choice of subsequent treatments?","_key":"af3d069254c8"}],"level":1,"_type":"block","style":"normal"}],"ExcludeFromPubMedXML":false},{"_type":"article","taxonomyMapping":[{"_updatedAt":"2024-04-24T12:52:07Z","identifier":"cll","_rev":"4KNeooMEhkvpk2GRi3EMaN","_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","usedForRecommendations":false,"video":{"isTaxVideo":false}},{"_createdAt":"2020-03-30T20:08:04Z","sortOrder":1,"name":"Peer Exchange","summary":[{"markDefs":[],"children":[{"marks":["em"],"text":"AJMC","_key":"8f85c4bb6762","_type":"span"},{"_key":"10038819bd05","_type":"span","marks":[],"text":"® "},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block","style":"normal","_key":"b0f5dba695a8"}],"identifier":"peer-exchange","_rev":"XH8IynABFFUkUnvZmkb21z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14","_updatedAt":"2022-01-19T10:37:00Z"}],"body":[{"disableAutoPlayVideo":false,"source":"brightcove","_key":"81674264f174","videoObject":{"videoDuration":"PT3M58S","videoDescription":"Empowering Patients: Key Considerations for BTK Inhibitor Adherence ","_type":"videoDetails","videoTitle":"Empowering Patients: Key Considerations for BTK Inhibitor Adherence ","thumbnail":{"_type":"image","asset":{"_ref":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","_type":"reference"}}},"_type":"video","videoID":"6355243869112"},{"_key":"88cb7f5844b6","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following question(s):","_key":"734e69f0b2110"}],"_type":"block","style":"normal"},{"_key":"3862f3d6c5fe","listItem":"bullet","markDefs":[],"children":[{"text":"What are the key considerations for educating and empowering patients about BTK inhibitors to support adherence for the course of long-term treatment?","_key":"e82045c381300","_type":"span","marks":[]}],"level":1,"_type":"block","style":"normal"}],"_updatedAt":"2024-07-23T14:15:18Z","updatedOn":null,"_id":"860a86ca-2147-49cb-97fd-9eaba2597abe","documentGroup":{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference"},"title":"Empowering Patients: Key Considerations for BTK Inhibitor Adherence ","_createdAt":"2024-07-23T14:12:13Z","summary":"A conversation on how to empower patients and the considerations for BTK inhibitor adherence. ","factCheckAuthorMapping":null,"thumbnail":{"asset":{"uploadId":"ZbiNPNxUuvkoChYcCW7MluM1vw2QDxVm","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_updatedAt":"2024-06-27T19:17:35Z","originalFilename":"AJMC wide.png","extension":"png","_rev":"PwtudI1Atq8Z7xHPGxqEkK","sha1hash":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","size":2868666,"_id":"image-1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080-png","metadata":{"blurHash":"MNFrYOaz00af_2Gwof0KWB-;^jaxaKoLkC","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#dc9880","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"lightMuted":{"background":"#b1bac3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.3},"vibrant":{"background":"#a9704c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.08},"dominant":{"background":"#043c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.44},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.45,"background":"#363333"},"muted":{"background":"#a97960","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.86}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true},"path":"images/0vv8moc6/ajmc/1c824a015e5049e7fabc6851f109250ac0e2d7a8-1920x1080.png","_type":"sanity.imageAsset","assetId":"1c824a015e5049e7fabc6851f109250ac0e2d7a8","_createdAt":"2024-06-27T19:17:35Z"}},"seoTag":["chronic lymphocytic leukemia","CLL","CLL treatment","chronic lymphocytic leukemia treatment","CLL treatment landscape","BTK inhibitors","Bruton tyrosine kinase inhibitors","BTK inhibition","ibrutinib","acalabrutinib","Combination Therapies","MRD","treatment sequencing","Long-term Toxicity","Resistance Mechanisms","Access","Affordability","Chemoimmunotherapy"," Targeted Therapies"," Clinical Efficacy","Cost-Effectiveness"],"link":"/view/empowering-patients-key-considerations-for-btk-inhibitor-adherence","is_visible":true,"published":"2024-07-23T14:13:52.965Z","_rev":"mQnYCYbyJQ5d5tNwMCrofO","contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"showSocialShare":true,"documentGroupMapping":[{"_ref":"27313d96-782a-4c0f-9250-13302fab3687","_type":"reference","_key":"450ad0b57b6f"}],"url":{"current":"empowering-patients-key-considerations-for-btk-inhibitor-adherence","_type":"slug"},"authorMapping":[{"firstName":"Ryan","lastName":"Haumschild","_type":"author","_id":"811cc466-c9bb-40c7-be45-af18204b2e89","_updatedAt":"2021-11-01T13:41:17Z","url":{"current":"ryan-haumschild-pharmd-ms-mba","_type":"slug"},"displayName":"Ryan Haumschild, PharmD, MS, MBA","_createdAt":"2021-11-01T13:41:17Z","_rev":"N2C2AHA8iw8qNZFj8T7Mxc"},{"_type":"author","_id":"author_44c91d8b1cd2afefa81a2b95fbb6f66e","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"roy-beveridge-md","_type":"slug"},"displayName":"Roy Beveridge, MD","_createdAt":"2020-05-05T10:50:04Z","_rev":"NCRmx1hVt53BGtkLG1XuTW"},{"_createdAt":"2024-06-27T19:27:14Z","_rev":"Mydw5pPtm5cb2CbTfXDXdY","_updatedAt":"2024-06-27T19:27:14Z","firstName":"Brian","lastName":"Hill","_type":"author","_id":"3c9ee90c-6860-4b76-8d93-7febe3ceb44c","url":{"current":"brian-t-hill-md-phd","_type":"slug"},"displayName":"Brian T. Hill, MD, PhD"},{"lastName":"Kittai","_createdAt":"2024-06-27T19:27:36Z","_rev":"1HTMDxcyxKX1u0vOdGF7Tn","url":{"current":"adam-s-kittai-md","_type":"slug"},"firstName":"Adam","displayName":"Adam S. Kittai, MD","_type":"author","_id":"210d26e7-c1b9-4c8b-bccc-8011f38b86c3","_updatedAt":"2024-06-27T19:27:36Z"}],"ExcludeFromPubMedXML":false,"articleType":"Opinion"}],"videoNonSeriesData":[{"_id":"50b00b46-20ac-49f0-9dc3-5a43ef5a7573","documentGroup":{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"},"authorMapping":[{"displayName":"Sikander Ailawadhi, MD ","_rev":"bAl93RvH29PY4NpePFNt9S","_type":"author","_id":"ae79c2ef-5705-4f5b-a739-bb6827256c60","_updatedAt":"2024-12-20T15:20:24Z","url":{"current":"sikander-ailawadhi-md","_type":"slug"},"_createdAt":"2024-12-20T15:20:19Z","authorType":"expert"}],"body":[{"_key":"5f5f6e40f53a","videoObject":{"_type":"videoDetails","videoTitle":"Advancing Hematologic Care and the Future of Shared Decision-Making","thumbnail":{"_type":"image","asset":{"_ref":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","_type":"reference"}},"videoDuration":"pt5m21s","videoDescription":"Advancing Hematologic Care and the Future of Shared Decision-Making"},"_type":"video","videoID":"6366194662112","disableAutoPlayVideo":false,"source":"brightcove"},{"_key":"0bbf942355f6","markDefs":[],"children":[{"text":"Video content above is prompted by the following:","_key":"6e9cf9304ff00","_type":"span","marks":["em","strong"]}],"_type":"block","style":"normal"},{"style":"normal","_key":"a2e38774f1fa","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"In what ways do these studies’ data collectively advance our understanding of unmet needs in hematologic cancer management, and how can their findings shape future clinical practices?","_key":"a070a36f5be2"}],"level":1,"_type":"block"},{"listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How can the findings presented at ASH 2024 shape the next generation of shared decision-making models for patients with hematologic cancers?","_key":"f0dfe8a4cd2a"}],"level":1,"_type":"block","style":"normal","_key":"fcae5b696163"},{"level":1,"_type":"block","style":"normal","_key":"660fb5b2447f","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?","_key":"7bc0b7033061"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"50a86a452b2d"}],"_type":"block","style":"normal","_key":"5b99e066f3d7"}],"url":{"current":"advancing-hematologic-care-and-the-future-of-shared-decision-making","_type":"slug"},"thumbnail":{"asset":{"_rev":"bAl93RvH29PY4NpePFPBjS","_createdAt":"2024-12-20T15:24:36Z","_updatedAt":"2024-12-20T15:24:36Z","extension":"png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MCBzkI4T0f~o0U.9V=M}x^V?03.7={9F?Z","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.62,"background":"#5e363c"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86,"background":"#647097"},"lightVibrant":{"foreground":"#fff","title":"#fff","population":1.28,"background":"#658bc4","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22,"background":"#045482"},"lightMuted":{"foreground":"#000","title":"#000","population":1.81,"background":"#d8d9be","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#0c648f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.15},"dominant":{"population":9.22,"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"_id":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","uploadId":"EYqTkXRFu73mG361p7PeWZeyyO9buX29","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","path":"images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","size":1597095,"assetId":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","originalFilename":"marketing image (62).png","_type":"sanity.imageAsset","sha1hash":"65abf17ba3ef66810178d69b9b1b479fa2ce848d"}},"_rev":"iBzEylCaJfBlbg7ZelbVNb","source":null,"documentGroupMapping":[{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference","_key":"2f54738fc10b"}],"showSocialShare":true,"_createdAt":"2025-01-24T17:13:29Z","seoTag":["Hematologic cancers","ASH 2024","Patient preferences","Shared decision-making","Bruton tyrosine kinase inhibitors","BTKi treatment","Chronic lymphocytic leukemia","CLL","Small lymphocytic lymphoma","SLL","Patient-centered care","Survivorship burden","Multiple myeloma","MM treatment choices","Real-world data","Prospective studies","Hematopoietic cell transplantation","Allogeneic transplant","Older adult patients","Cancer management trends","Clinical decision-making","Emerging trends in hematologic oncology","Future of hematologic cancer care","Advances in hematologic cancer treatment","Survivorship in cancer care","Patient involvement in treatment decisions","Patient-reported outcomes","Hematologic treatment innovations","Hematologic cancer therapies","Unmet needs in oncology care"],"link":"/view/advancing-hematologic-care-and-the-future-of-shared-decision-making","updatedOn":null,"is_visible":true,"articleType":"Opinion","published":"2025-01-24T17:13:42.493Z","title":"Advancing Hematologic Care and the Future of Shared Decision-Making","_updatedAt":"2025-01-24T17:14:54Z","factCheckAuthorMapping":null,"summary":"Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"taxonomyMapping":[{"_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ"},{"_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","name":"Post Conference Perspectives","identifier":"post-conference-perspectives"},{"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"}}],"_type":"article","ExcludeFromPubMedXML":false},{"is_visible":true,"_rev":"wsljz10lCZachwUMK34bdI","_id":"d5e942fc-0924-4805-bce7-60e1fdcce0a1","showSocialShare":true,"updatedOn":null,"taxonomyMapping":[{"_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series"},{"identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","name":"Post Conference Perspectives"},{"identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"}],"body":[{"_type":"video","videoID":"6366195346112","disableAutoPlayVideo":false,"source":"brightcove","_key":"5f5f6e40f53a","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","_type":"reference"}},"videoDuration":"pt6m14s","videoDescription":"Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients","_type":"videoDetails","videoTitle":"Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients"}},{"_key":"0bbf942355f6","markDefs":[],"children":[{"text":"Video content above is prompted by the following:","_key":"6e9cf9304ff00","_type":"span","marks":["em","strong"]}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"cf40a0b7ce860","_type":"span","marks":[],"text":"Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Hematologists’ Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation.”"}],"level":1,"_type":"block","style":"normal","_key":"4a13a67639c3","listItem":"bullet"},{"style":"normal","_key":"290fb9f6474b","listItem":"bullet","markDefs":[],"children":[{"text":"What was the objective of the study?","_key":"0cc2b23389930","_type":"span","marks":[]}],"level":1,"_type":"block"},{"style":"normal","_key":"31bb0f8c2be8","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How was this study designed/what methodology was used?","_key":"eb50d4ef45a50"}],"level":1,"_type":"block"},{"_key":"c5252abc9c88","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What results were presented?","_key":"27bf786aaf270"}],"level":1,"_type":"block","style":"normal"}],"url":{"current":"insights-on-allogeneic-hematopoietic-cell-transplantation-values-of-older-adult-patients","_type":"slug"},"thumbnail":{"asset":{"uploadId":"EYqTkXRFu73mG361p7PeWZeyyO9buX29","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","path":"images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","size":1597095,"assetId":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","originalFilename":"marketing image (62).png","_type":"sanity.imageAsset","sha1hash":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","_rev":"bAl93RvH29PY4NpePFPBjS","_createdAt":"2024-12-20T15:24:36Z","_updatedAt":"2024-12-20T15:24:36Z","extension":"png","metadata":{"blurHash":"MCBzkI4T0f~o0U.9V=M}x^V?03.7={9F?Z","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"foreground":"#fff","title":"#fff","population":1.28,"background":"#658bc4","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":9.22,"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#d8d9be","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.81},"vibrant":{"title":"#fff","population":0.15,"background":"#0c648f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"title":"#fff","population":9.22,"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":0.62,"background":"#5e363c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86,"background":"#647097"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true},"_id":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png"}},"published":"2025-01-17T15:57:30.733Z","title":"Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients","contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"link":"/view/insights-on-allogeneic-hematopoietic-cell-transplantation-values-of-older-adult-patients","articleType":"Opinion","seoTag":["Hematologic cancers","ASH 2024","Patient preferences","Shared decision-making","Bruton tyrosine kinase inhibitors","BTKi treatment","Chronic lymphocytic leukemia","CLL","Small lymphocytic lymphoma","SLL","Patient-centered care","Survivorship burden","Multiple myeloma","MM treatment choices","Real-world data","Prospective studies","Hematopoietic cell transplantation","Allogeneic transplant","Older adult patients","Cancer management trends","Clinical decision-making","Emerging trends in hematologic oncology","Future of hematologic cancer care","Advances in hematologic cancer treatment","Survivorship in cancer care","Patient involvement in treatment decisions","Patient-reported outcomes","Hematologic treatment innovations","Hematologic cancer therapies","Unmet needs in oncology care"],"documentGroupMapping":[{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference","_key":"2f54738fc10b"}],"_createdAt":"2025-01-17T15:56:23Z","documentGroup":{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"},"summary":"Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “\"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”\" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.","_updatedAt":"2025-01-17T15:58:33Z","source":null,"_type":"article","ExcludeFromPubMedXML":false,"factCheckAuthorMapping":null,"authorMapping":[{"authorType":"expert","displayName":"Sikander Ailawadhi, MD ","_rev":"bAl93RvH29PY4NpePFNt9S","_type":"author","_id":"ae79c2ef-5705-4f5b-a739-bb6827256c60","_updatedAt":"2024-12-20T15:20:24Z","url":{"current":"sikander-ailawadhi-md","_type":"slug"},"_createdAt":"2024-12-20T15:20:19Z"}]},{"_createdAt":"2025-01-10T16:05:25Z","contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"summary":"Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.","body":[{"videoObject":{"videoTitle":"Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences","thumbnail":{"_type":"image","asset":{"_ref":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","_type":"reference"}},"videoDuration":"pt5m48s","videoDescription":"Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.","_type":"videoDetails"},"_type":"video","videoID":"6366193610112","disableAutoPlayVideo":false,"source":"brightcove","_key":"5f5f6e40f53a"},{"markDefs":[],"children":[{"_type":"span","marks":["em","strong"],"text":"Video content above is prompted by the following:","_key":"6e9cf9304ff00"}],"_type":"block","style":"normal","_key":"0bbf942355f6"},{"_key":"65255b00cd79","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Discuss the data that were presented at the 2024 ASH Annual Meeting titled in “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study.”","_key":"08fa6dbcb2780"}],"level":1,"_type":"block","style":"normal"},{"style":"normal","_key":"e330fa5a3df1","listItem":"bullet","markDefs":[],"children":[{"marks":[],"text":"What was the objective of the study?","_key":"e3be9fb2570b0","_type":"span"}],"level":1,"_type":"block"},{"_key":"290bd17da95b","listItem":"bullet","markDefs":[],"children":[{"marks":[],"text":"How was this study designed/what methodology was used?","_key":"3c0a91b873350","_type":"span"}],"level":1,"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"What results were presented?","_key":"9101ebf3261f0"}],"level":1,"_type":"block","style":"normal","_key":"23735b8b52f5","listItem":"bullet","markDefs":[]},{"_key":"2b46c8c24312","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What are your key takeaways from this study, and how do these results impact how you manage patients with MM?","_key":"27572e96c8cf"}],"level":1,"_type":"block","style":"normal"}],"url":{"current":"insights-on-multiple-myeloma-treatment-real-world-data-on-survivorship-burden-and-patient-preferences","_type":"slug"},"is_visible":true,"_id":"414fb994-454b-456c-bc1d-08863e294779","link":"/view/insights-on-multiple-myeloma-treatment-real-world-data-on-survivorship-burden-and-patient-preferences","updatedOn":null,"factCheckAuthorMapping":null,"published":"2025-01-10T16:05:50.974Z","title":"Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences","articleType":"Opinion","thumbnail":{"asset":{"uploadId":"EYqTkXRFu73mG361p7PeWZeyyO9buX29","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","path":"images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","size":1597095,"assetId":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","originalFilename":"marketing image (62).png","_type":"sanity.imageAsset","sha1hash":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","_rev":"bAl93RvH29PY4NpePFPBjS","_createdAt":"2024-12-20T15:24:36Z","_updatedAt":"2024-12-20T15:24:36Z","extension":"png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MCBzkI4T0f~o0U.9V=M}x^V?03.7={9F?Z","_type":"sanity.imageMetadata","palette":{"lightMuted":{"title":"#000","population":1.81,"background":"#d8d9be","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#0c648f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.15},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22,"background":"#045482"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.62,"background":"#5e363c","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86,"background":"#647097"},"lightVibrant":{"foreground":"#fff","title":"#fff","population":1.28,"background":"#658bc4","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAFHRFWHRDcmVhdG9yAFByZW1pZXJlIFByb2l7TwQAAAMLSURBVHicTdJrT1sFAMbx7pxJcRMEZwjbIICLlg1wmMYY0wsdDNraUtrSy+npOaWHlrIWKQPtYFyGha63zSlzW6ZTY2a27IVu0RlfSJYYdWjUOJNFp/GNlw/yN8M3foFfnifPo2v3zWDUlumS56kfTCFa44hWDfHIBOLwPIJURpDPIoZKiN4VRM8ion8VIbCOGDqNGCoihIroQiV0oTK6ZncGQ3iOrtA0T3s0Otxx2l1j7LNH2etK0CrlaJGXaFNO0ZlYoztVwJAq0JHIY0iv05kp0qSVeCRSQSdV0T1qi7NnUOOwV8EXV9FeThJNjWEfdTMw8hJBJYqsxFFT0yy/cZFzV6+Rf/cDZjfOs3y5yqtvlTDnitQpVQTpLDrBpLDbImMcCZOZ0ThTPsHaapZxzUNMcrKYjLIekylMT/HZp7f45cFPfHf/R774/kvu3L3B1Zsb+FbLNMb+D1qj2+DUbII3z61QKZ0gcyxAenyUwmSCoqzw+swcX93Z5K9/fufB339w78/f+PnXTT7+/AqB/Bka1QpCuIpO3AZleoeDaCmZ5cUM87kkMXUYNezh5JjGmhSnkD7OjWsfsrW1yTf3tvj6/rfc/eEm129dwP8woVJCeDiKaFLZZZHpsnsJSG4mk36UqAdLnxWj0UzErZBTZoh7Y0SkKAsLc1x6b4OPbl/h9idVLr2/inshT4N8GiFY/K9yrSnCgT4nLo8NTXHgcvbT1n6YpuZeBocmOJaqYh9QaG0xYDB0I8mjnK+kub4xTqWcYiA7T72U377SNqg3RWizuHCOOIipPixWGw2NT1Hf2IlpaAol8zbWI3Eer29FX7uH7p5nSceGKB63k5sdxTyRpS64guB/DZ1oVtGbo7TYwpi8MQaCCZ55wUltk4Fd+56jxzGHY/IdevuTPNZkQKjbz5NtnbzYbyIYGSSYDNI7lmW3fwnBu4Jup0WlxqLyhE2hw5GgfShBw/M+dh46So0xwF7vKQ5qF2ixZ9EfOsqOAyb0Xf00941w0B+lJzrJfukVarwn2eFZ4l9nXcE/WHYT4AAAAABJRU5ErkJggg=="},"_id":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png"}},"showSocialShare":true,"documentGroupMapping":[{"_key":"2f54738fc10b","_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"}],"authorMapping":[{"authorType":"expert","displayName":"Sikander Ailawadhi, MD ","_rev":"bAl93RvH29PY4NpePFNt9S","_type":"author","_id":"ae79c2ef-5705-4f5b-a739-bb6827256c60","_updatedAt":"2024-12-20T15:20:24Z","url":{"current":"sikander-ailawadhi-md","_type":"slug"},"_createdAt":"2024-12-20T15:20:19Z"}],"taxonomyMapping":[{"_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z"},{"identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","name":"Post Conference Perspectives"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll"}],"source":null,"ExcludeFromPubMedXML":false,"_rev":"94AxnTZUIgBouxL1OMZxlJ","_updatedAt":"2025-01-10T16:10:50Z","seoTag":["Hematologic cancers","ASH 2024","Patient preferences","Shared decision-making","Bruton tyrosine kinase inhibitors","BTKi treatment","Chronic lymphocytic leukemia","CLL","Small lymphocytic lymphoma","SLL","Patient-centered care","Survivorship burden","Multiple myeloma","MM treatment choices","Real-world data","Prospective studies","Hematopoietic cell transplantation","Allogeneic transplant","Older adult patients","Cancer management trends","Clinical decision-making","Emerging trends in hematologic oncology","Future of hematologic cancer care","Advances in hematologic cancer treatment","Survivorship in cancer care","Patient involvement in treatment decisions","Patient-reported outcomes","Hematologic treatment innovations","Hematologic cancer therapies","Unmet needs in oncology care"],"documentGroup":{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"},"_type":"article"},{"taxonomyMapping":[{"_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series"},{"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","name":"Post Conference Perspectives","identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4},{"identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"}],"_type":"article","url":{"current":"insights-on-cll-and-sll-treatment-with-btk-inhibitors-patient-preferences-and-shared-decision-making","_type":"slug"},"articleType":"Opinion","_createdAt":"2025-01-03T14:06:26Z","summary":"Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.","showSocialShare":true,"is_visible":true,"documentGroup":{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"},"published":"2025-01-03T14:06:39.231Z","link":"/view/insights-on-cll-and-sll-treatment-with-btk-inhibitors-patient-preferences-and-shared-decision-making","source":null,"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"title":"Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making","updatedOn":null,"factCheckAuthorMapping":null,"ExcludeFromPubMedXML":false,"documentGroupMapping":[{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference","_key":"2f54738fc10b"}],"_updatedAt":"2025-01-03T20:28:19Z","_rev":"nSiylLUa1wQabitQUy4ueo","authorMapping":[{"_id":"ae79c2ef-5705-4f5b-a739-bb6827256c60","_updatedAt":"2024-12-20T15:20:24Z","url":{"current":"sikander-ailawadhi-md","_type":"slug"},"_createdAt":"2024-12-20T15:20:19Z","authorType":"expert","displayName":"Sikander Ailawadhi, MD ","_rev":"bAl93RvH29PY4NpePFNt9S","_type":"author"}],"thumbnail":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","path":"images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","size":1597095,"assetId":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","originalFilename":"marketing image (62).png","_type":"sanity.imageAsset","sha1hash":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","_rev":"bAl93RvH29PY4NpePFPBjS","_createdAt":"2024-12-20T15:24:36Z","_updatedAt":"2024-12-20T15:24:36Z","extension":"png","metadata":{"_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.62,"background":"#5e363c","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86,"background":"#647097"},"lightVibrant":{"title":"#fff","population":1.28,"background":"#658bc4","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"darkVibrant":{"population":9.22,"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#d8d9be","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.81},"vibrant":{"title":"#fff","population":0.15,"background":"#0c648f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22,"background":"#045482"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MCBzkI4T0f~o0U.9V=M}x^V?03.7={9F?Z"},"_id":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","uploadId":"EYqTkXRFu73mG361p7PeWZeyyO9buX29","mimeType":"image/png"}},"body":[{"videoID":"6366193410112","disableAutoPlayVideo":false,"source":"brightcove","_key":"5f5f6e40f53a","videoObject":{"videoDuration":"pt6m36s","videoDescription":"Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making","_type":"videoDetails","videoTitle":"Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making","thumbnail":{"_type":"image","asset":{"_ref":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","_type":"reference"}}},"_type":"video"},{"children":[{"text":"Video content above is prompted by the following:","_key":"6e9cf9304ff00","_type":"span","marks":["em","strong"]}],"_type":"block","style":"normal","_key":"0bbf942355f6","markDefs":[]},{"_key":"a58195e8dc39","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA).”","_key":"97ac51b895d80"}],"level":1,"_type":"block","style":"normal"},{"listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What was the objective of the study?","_key":"8381ef82c5990"}],"level":1,"_type":"block","style":"normal","_key":"fc8a56dfd995"},{"_type":"block","style":"normal","_key":"e9ff828b52c0","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How was this study designed/what methodology was used?","_key":"9cc9c4a2735f0"}],"level":1},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"What results were presented?","_key":"6747a2b4a4cb0"}],"level":1,"_type":"block","style":"normal","_key":"4047a0fb3752","listItem":"bullet"},{"children":[{"text":"What are your key takeaways from this study, and how does it change your perspective as a clinician when deciding between BTKis for patients with CLL or SLL?","_key":"a9dd37c6b12b0","_type":"span","marks":[]}],"level":1,"_type":"block","style":"normal","_key":"6115b6015ff2","listItem":"bullet","markDefs":[]}],"seoTag":["Hematologic cancers","ASH 2024","Patient preferences","Shared decision-making","Bruton tyrosine kinase inhibitors","BTKi treatment","Chronic lymphocytic leukemia","CLL","Small lymphocytic lymphoma","SLL","Patient-centered care","Survivorship burden","Multiple myeloma","MM treatment choices","Real-world data","Prospective studies","Hematopoietic cell transplantation","Allogeneic transplant","Older adult patients","Cancer management trends","Clinical decision-making","Emerging trends in hematologic oncology","Future of hematologic cancer care","Advances in hematologic cancer treatment","Survivorship in cancer care","Patient involvement in treatment decisions","Patient-reported outcomes","Hematologic treatment innovations","Hematologic cancer therapies","Unmet needs in oncology care"],"_id":"8c32c593-37e6-49d2-8cbe-4046fbeb1bf3"},{"is_visible":true,"contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"thumbnail":{"asset":{"_rev":"bAl93RvH29PY4NpePFPBjS","_createdAt":"2024-12-20T15:24:36Z","_updatedAt":"2024-12-20T15:24:36Z","extension":"png","metadata":{"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAFHRFWHRDcmVhdG9yAFByZW1pZXJlIFByb2l7TwQAAAMLSURBVHicTdJrT1sFAMbx7pxJcRMEZwjbIICLlg1wmMYY0wsdDNraUtrSy+npOaWHlrIWKQPtYFyGha63zSlzW6ZTY2a27IVu0RlfSJYYdWjUOJNFp/GNlw/yN8M3foFfnifPo2v3zWDUlumS56kfTCFa44hWDfHIBOLwPIJURpDPIoZKiN4VRM8ion8VIbCOGDqNGCoihIroQiV0oTK6ZncGQ3iOrtA0T3s0Otxx2l1j7LNH2etK0CrlaJGXaFNO0ZlYoztVwJAq0JHIY0iv05kp0qSVeCRSQSdV0T1qi7NnUOOwV8EXV9FeThJNjWEfdTMw8hJBJYqsxFFT0yy/cZFzV6+Rf/cDZjfOs3y5yqtvlTDnitQpVQTpLDrBpLDbImMcCZOZ0ThTPsHaapZxzUNMcrKYjLIekylMT/HZp7f45cFPfHf/R774/kvu3L3B1Zsb+FbLNMb+D1qj2+DUbII3z61QKZ0gcyxAenyUwmSCoqzw+swcX93Z5K9/fufB339w78/f+PnXTT7+/AqB/Bka1QpCuIpO3AZleoeDaCmZ5cUM87kkMXUYNezh5JjGmhSnkD7OjWsfsrW1yTf3tvj6/rfc/eEm129dwP8woVJCeDiKaFLZZZHpsnsJSG4mk36UqAdLnxWj0UzErZBTZoh7Y0SkKAsLc1x6b4OPbl/h9idVLr2/inshT4N8GiFY/K9yrSnCgT4nLo8NTXHgcvbT1n6YpuZeBocmOJaqYh9QaG0xYDB0I8mjnK+kub4xTqWcYiA7T72U377SNqg3RWizuHCOOIipPixWGw2NT1Hf2IlpaAol8zbWI3Eer29FX7uH7p5nSceGKB63k5sdxTyRpS64guB/DZ1oVtGbo7TYwpi8MQaCCZ55wUltk4Fd+56jxzGHY/IdevuTPNZkQKjbz5NtnbzYbyIYGSSYDNI7lmW3fwnBu4Jup0WlxqLyhE2hw5GgfShBw/M+dh46So0xwF7vKQ5qF2ixZ9EfOsqOAyb0Xf00941w0B+lJzrJfukVarwn2eFZ4l9nXcE/WHYT4AAAAABJRU5ErkJggg==","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MCBzkI4T0f~o0U.9V=M}x^V?03.7={9F?Z","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#045482","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.62,"background":"#5e363c"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86,"background":"#647097"},"lightVibrant":{"foreground":"#fff","title":"#fff","population":1.28,"background":"#658bc4","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":9.22,"background":"#045482"},"lightMuted":{"background":"#d8d9be","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.81},"vibrant":{"foreground":"#fff","title":"#fff","population":0.15,"background":"#0c648f","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true},"_id":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png","uploadId":"EYqTkXRFu73mG361p7PeWZeyyO9buX29","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","path":"images/0vv8moc6/ajmc/65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080.png","size":1597095,"assetId":"65abf17ba3ef66810178d69b9b1b479fa2ce848d","originalFilename":"marketing image (62).png","_type":"sanity.imageAsset","sha1hash":"65abf17ba3ef66810178d69b9b1b479fa2ce848d"}},"ExcludeFromPubMedXML":false,"body":[{"_type":"video","videoID":"6366194475112","disableAutoPlayVideo":false,"source":"brightcove","_key":"5f5f6e40f53a","videoObject":{"videoDescription":"Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024","_type":"videoDetails","videoTitle":"Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024","thumbnail":{"_type":"image","asset":{"_type":"reference","_ref":"image-65abf17ba3ef66810178d69b9b1b479fa2ce848d-1920x1080-png"}},"videoDuration":"pt4m28s"}},{"markDefs":[],"children":[{"_type":"span","marks":["em","strong"],"text":"Video content above is prompted by the following:","_key":"6e9cf9304ff00"}],"_type":"block","style":"normal","_key":"0bbf942355f6"},{"_type":"block","style":"normal","_key":"501bf8cf0608","listItem":"number","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Coming into ASH 2024, what would you consider to be the largest unmet needs in the management of hematologic cancers?","_key":"36b7f54985610"}],"level":1},{"_key":"a81deff79e15","listItem":"number","markDefs":[],"children":[{"_key":"041e9f8c57b4","_type":"span","marks":[],"text":"What are the latest trends and innovations you have observed in the treatment and management of hematologic cancers leading up to and coming out of ASH 2024?"}],"level":1,"_type":"block","style":"normal"}],"title":"Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024","url":{"current":"unmet-needs-and-emerging-trends-in-hematologic-cancer-management-around-ash-2024","_type":"slug"},"summary":"Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.","documentGroup":{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference"},"_type":"article","seoTag":["Hematologic cancers","ASH 2024","Patient preferences","Shared decision-making","Bruton tyrosine kinase inhibitors","BTKi treatment","Chronic lymphocytic leukemia","CLL","Small lymphocytic lymphoma","SLL","Patient-centered care","Survivorship burden","Multiple myeloma","MM treatment choices","Real-world data","Prospective studies","Hematopoietic cell transplantation","Allogeneic transplant","Older adult patients","Cancer management trends","Clinical decision-making","Emerging trends in hematologic oncology","Future of hematologic cancer care","Advances in hematologic cancer treatment","Survivorship in cancer care","Patient involvement in treatment decisions","Patient-reported outcomes","Hematologic treatment innovations","Hematologic cancer therapies","Unmet needs in oncology care"],"taxonomyMapping":[{"_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e"},{"identifier":"post-conference-perspectives","_createdAt":"2020-03-30T20:09:58Z","sortOrder":4,"_rev":"qSdU4wnaaJBFavo8Te0VMX","_type":"taxonomy","_id":"33811d15-ebf7-41f3-a9b5-e5811542a40e","_updatedAt":"2021-05-14T15:31:15Z","name":"Post Conference Perspectives"},{"_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z"}],"_id":"488f4e0f-a20f-4dbe-88a6-3235c2ec258b","link":"/view/unmet-needs-and-emerging-trends-in-hematologic-cancer-management-around-ash-2024","updatedOn":null,"_rev":"bAl93RvH29PY4NpeQs279S","showSocialShare":true,"_createdAt":"2024-12-20T15:19:53Z","articleType":"Opinion","_updatedAt":"2025-01-03T20:26:23Z","authorMapping":[{"_rev":"bAl93RvH29PY4NpePFNt9S","_type":"author","_id":"ae79c2ef-5705-4f5b-a739-bb6827256c60","_updatedAt":"2024-12-20T15:20:24Z","url":{"current":"sikander-ailawadhi-md","_type":"slug"},"_createdAt":"2024-12-20T15:20:19Z","authorType":"expert","displayName":"Sikander Ailawadhi, MD "}],"published":"2024-12-20T15:20:04.966Z","source":null,"factCheckAuthorMapping":null,"documentGroupMapping":[{"_ref":"b0bcace2-6d1b-4f1c-b6b9-279dc80ccf62","_type":"reference","_key":"2f54738fc10b"}]},{"is_visible":true,"body":[{"source":"brightcove","_key":"c4df04ec797e","videoObject":{"videoDuration":"PT2M11S","videoDescription":"interview with Ryan Jacobs, MD, Atrium Health Levine Cancer Institute","_type":"videoDetails","videoTitle":"Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL","thumbnail":{"_type":"image","asset":{"_ref":"image-8975edd8363de3a38e61e71410852276c595a645-1200x728-jpg","_type":"reference"}}},"_type":"video","caption":"Ryan Jacobs, MD, Atrium Health Levine Cancer Institute","videoID":"6358992215112","disableAutoPlayVideo":false},{"children":[{"_type":"span","marks":[],"text":"At the recent ","_key":"c273a58eacd80"},{"_type":"span","marks":["437252032d33"],"text":"European Hematology Association 2024 Congress","_key":"c273a58eacd81"},{"marks":[],"text":", Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, presented updated data from ","_key":"c273a58eacd82","_type":"span"},{"marks":["b62fba6f1791"],"text":"CAPTIVATE, a multicenter, phase 2 study","_key":"c273a58eacd83","_type":"span"},{"_type":"span","marks":[],"text":" with 2 patient cohorts that assessed outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).","_key":"c273a58eacd84"}],"_type":"block","style":"normal","_key":"4c89f241aa34","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/eha","_key":"437252032d33"},{"nofollow":true,"blank":true,"_type":"link","href":"https://www.clinicaltrials.gov/study/NCT02910583","_key":"b62fba6f1791"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"2b4015263fa60"}],"_type":"block","style":"normal","_key":"77ff1a4bb55c"},{"children":[{"_key":"9cbf105480c70","_type":"span","marks":[],"text":"In "},{"text":"part 1","_key":"9cbf105480c71","_type":"span","marks":["ee716024644f"]},{"marks":[],"text":" of our interview with him, he explained how these long-term data show that a majority of patients with CLL had stable disease after 4.5 years of follow-up. These data were presented in ","_key":"9cbf105480c72","_type":"span"},{"_key":"9cbf105480c73","_type":"span","marks":["59ee48d55ba7"],"text":"the abstract"},{"_type":"span","marks":[],"text":" “Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 years of Follow-Up in the Phase 2 CAPTIVATE Study.”","_key":"9cbf105480c74"}],"_type":"block","style":"normal","_key":"25584fd43e9f","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/dr-ryan-jacobs-highlights-sustained-success-in-patients-with-cll-through-1-year-treatment-plan","_key":"ee716024644f"},{"_type":"link","href":"https://www.ajmc.com/view/treatment-strategies-including-venetoclax-effective-against-cll-in-real-world-long-term-data","_key":"59ee48d55ba7","blank":true}]},{"style":"normal","_key":"0a362c67f5ba","markDefs":[],"children":[{"text":"","_key":"8a0f402fc04a0","_type":"span","marks":[]}],"_type":"block"},{"children":[{"text":"Here in part 2, he explains the importance of CAPTIVATE’s design and the primary goals of the investigation.","_key":"e5ccc22d44fd0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"a3ef3497a41d","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"2a501f36bad10","_type":"span"}],"_type":"block","style":"normal","_key":"8c19eead6e98"},{"style":"normal","_key":"a66e97b66d7b","markDefs":[],"children":[{"text":"Transcript","_key":"57dc9c4d915c0","_type":"span","marks":["strong","underline"]}],"_type":"block"},{"_type":"block","style":"normal","_key":"6d856164e78e","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Can you discuss the design and the objectives of the phase 2 CAPTIVATE study?","_key":"28c0dd850d300"}]},{"_type":"block","style":"normal","_key":"2e4f9aec853f","markDefs":[],"children":[{"text":"","_key":"b868a113533e0","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_key":"eae65433dc0a0","_type":"span","marks":[],"text":"CAPTIVATE was a study that began several years ago. It was a phase 2 study with an interest in exploring the efficacy and safety of putting the 2 most commonly used targeted treatments with small molecule inhibitors together, and that would be ibrutinib and venetoclax. At the time, ibrutinib was the only BTK [Bruton tyrosine kinase] inhibitor available. Of course, now there are additional BTK inhibitors. Venetoclax remains the only BCL2 inhibitor."}],"_type":"block","style":"normal","_key":"a5c814fcca41"},{"_type":"block","style":"normal","_key":"ee942b65ab57","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"17f41f6a4f4b0"}]},{"style":"normal","_key":"7b121855e90e","markDefs":[{"blank":true,"_type":"link","href":"https://www.clinicaltrials.gov/study/NCT01722487","_key":"1e950da20239","nofollow":true}],"children":[{"marks":[],"text":"We have been using BTK inhibitors a lot in treating CLL patients. They are wonderful in how effective they are. There’s a presentation at this meeting of using a BTK inhibitor as a first-line treatment with ibrutinib, ","_key":"bea2fd710a710","_type":"span"},{"_type":"span","marks":["1e950da20239"],"text":"the RESONATE-2","_key":"0645b49e5e80"},{"_key":"65fe5928beef","_type":"span","marks":[],"text":" 10-plus year follow-up. The majority of patients still have not progressed even 10 years in, so this is an incredibly effective way to treat CLL patients. But with the indefinite treatment is a potential for toxicity. We are becoming more informed on ibrutinib’s toxicities specifically. And then there’s obviously the financial toxicity of having to take a treatment for years."}],"_type":"block"},{"style":"normal","_key":"3d2e667b4e8e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"61ebac64db260"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"So, this study [CAPTIVATE] was interested in harnessing the deep responses seen by venetoclax and still involving BTK inhibition and its positive, long-term effects on controlling CLL using the 2 agents together in an all-oral combination that’s given over a defined treatment timeline over the course of 1 year after a 3-month single-agent ibrutinib lead-in.","_key":"0d46f97b1f220"}],"_type":"block","style":"normal","_key":"b4d822650e46","markDefs":[]}],"articleType":"Commentary","_updatedAt":"2024-07-23T21:49:26Z","summary":"Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). ","_createdAt":"2024-07-23T19:21:08Z","link":"/view/exploring-the-efficacy-and-safety-of-ibrutinib-and-venetoclax-in-cll","factCheckAuthorMapping":null,"_rev":"hS25uTmEvsaaDM5BOqS9Ap","thumbnail":{"asset":{"assetId":"8975edd8363de3a38e61e71410852276c595a645","_type":"sanity.imageAsset","size":255037,"_updatedAt":"2024-07-23T19:25:20Z","metadata":{"isOpaque":true,"blurHash":"VFIr7wm6I95c$v}NKSIvv{g4N|RPs:xuNLtlVsj]bwVs","_type":"sanity.imageMetadata","palette":{"lightMuted":{"background":"#a4c8d2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.21},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#1474bc"},"dominant":{"population":8.1,"background":"#a59250","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":1.32,"background":"#365565","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":8.1,"background":"#a59250","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#8fe3f7","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":2.1},"darkVibrant":{"population":0.48,"background":"#8e7a2a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAFwABAQEBAAAAAAAAAAAAAAAABQACBv/EAB0QAAICAwEBAQAAAAAAAAAAAAECAAMEESEFMVH/xAAWAQEBAQAAAAAAAAAAAAAAAAADAQX/xAAeEQACAgEFAQAAAAAAAAAAAAABAgADBAUTFDFRQf/aAAwDAQACEQMRAD8AU8KtBavdbjPr5T42fiUY2nW3hnMYdjJWpU6MYpsY4yOTtvoP52ZWmUDJtIb5EzbuOgKjuI5FjCwhlOxKY9GxjepJ6UG5QrkNVjJ4Zan3ED+z/9k=","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.6483516483516483,"height":728}},"mimeType":"image/jpeg","sha1hash":"8975edd8363de3a38e61e71410852276c595a645","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg","path":"images/0vv8moc6/ajmc/8975edd8363de3a38e61e71410852276c595a645-1200x728.jpg","_createdAt":"2024-07-23T19:25:20Z","originalFilename":"CLL Video - Ryan Jacobs - TN.jpg","extension":"jpg","uploadId":"csg0V0vaabwLugVlYDyVAVBtro02bu2l","_rev":"hS25uTmEvsaaDM5BOqOuNJ","_id":"image-8975edd8363de3a38e61e71410852276c595a645-1200x728-jpg"}},"title":"Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_id":"2c4dd404-60be-4e2f-b632-b67bdefe0523","taxonomyMapping":[{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll"},{"summary":[{"markDefs":[],"children":[{"text":"The ","_key":"e80c79954e08","_type":"span","marks":[]},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"f7d4dddf7edd","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"_createdAt":"2020-05-04T23:46:13Z","_type":"taxonomy","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","_rev":"HexDiduX8d6Nqnq1ECriVF","name":"Clinical"},{"identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_type":"taxonomy","_rev":"xqhc4WIQcOa1P2rns6bqkh","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z"},{"_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy","name":"News"},{"_rev":"52vAUxG62nnEnK65ZDo5dG","_type":"taxonomy","name":"Health Care Delivery","_id":"topic_healthcare-delivery","_updatedAt":"2022-11-29T18:34:57Z","identifier":"healthcare-delivery","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z"},{"identifier":"conference","_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z"},{"identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","_type":"taxonomy","name":"Hematology","_updatedAt":"2020-07-30T14:48:10Z","_createdAt":"2020-04-14T15:02:13Z","_id":"compendium_hematology"}],"documentGroupMapping":[{"_ref":"c8290b53-9d62-43a0-8676-937e2332b940","_type":"reference","_key":"bbde48431e70"}],"seoTag":["ibrutinib","venetoclax","CAPTIVATE study","RESONATE-2 "],"url":{"current":"exploring-the-efficacy-and-safety-of-ibrutinib-and-venetoclax-in-cll","_type":"slug"},"ExcludeFromPubMedXML":false,"authorMapping":[{"_type":"author","profileImage":{"_type":"mainImage","alt":"Brooke McCormick","asset":{"_ref":"image-1fe4e81696463cdd9c1d6b62a2e47c2228d7df99-430x430-png","_type":"reference"}},"lastName":"McCormick","authorType":"author","_createdAt":"2023-06-21T17:59:19Z","_rev":"A9UM2QVfJg2GpKiBNGLBGh","_id":"00af9d05-a2c4-4451-a6d1-0e28b08cbb65","biography":[{"_key":"936ecf4b7f0c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Brooke is an associate editor for ","_key":"8d68730a8da0"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"730c46c984c9"},{"marks":[],"text":"® (","_key":"0b218fbaa571","_type":"span"},{"_key":"b1b5b3d9cff0","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined ","_key":"7de919198f04"},{"marks":["em"],"text":"AJMC","_key":"f31a60d737e2","_type":"span"},{"text":" in 2023, where she produces written content covering multiple disease states.","_key":"df11193684f8","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"","_key":"5731fbb8e0ae","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"9af540ce04de"},{"style":"normal","_key":"98aee68dab9d","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/brooke-mccormick-1a254b1b6/","_key":"80a1c1a9d7cd"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism from Seton Hall University. You can connect with Brooke on ","_key":"bb68b5e8ee83"},{"_type":"span","marks":["80a1c1a9d7cd"],"text":"LinkedIn","_key":"4bb222fe2840"},{"_type":"span","marks":[],"text":".","_key":"c87621477700"}],"_type":"block"}],"_updatedAt":"2025-01-08T16:42:13Z","url":{"_type":"slug","current":"brooke-mccormick"},"firstName":"Brooke","displayName":"Brooke McCormick"},{"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"lastName":"Shaw","displayName":"Maggie L. Shaw","_createdAt":"2020-05-05T10:50:09Z","_updatedAt":"2025-04-02T21:44:43Z","url":{"current":"maggie-l-shaw","_type":"slug"},"firstName":"Maggie","authorType":"author","_rev":"0Bu8bP1wGAOjvJjEMH3pxd","_type":"author","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","biography":[{"style":"normal","_key":"643be033259e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}],"_type":"block"},{"_key":"f4070c315fab","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}],"_type":"block","style":"normal"}]}],"_type":"article","published":"2024-07-23T19:59:00.000Z","updatedOn":null,"source":null},{"published":"2024-02-11T13:00:00.000Z","_updatedAt":"2024-02-12T16:17:10Z","taxonomyMapping":[{"usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN"},{"_type":"taxonomy","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","_rev":"HexDiduX8d6Nqnq1ECriVF","name":"Clinical","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"e80c79954e08","_type":"span","marks":[]},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"f7d4dddf7edd","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"_createdAt":"2020-05-04T23:46:13Z"},{"identifier":"providers","_createdAt":"2020-04-14T19:37:19Z","_rev":"sBk7YzjWMuBuhiatU3dlrp","name":"Providers","_id":"e6d00060-6fac-4bf6-9b44-4be71a23cb38","_updatedAt":"2020-04-14T19:37:19Z","parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},"_type":"taxonomy"},{"_type":"taxonomy","_rev":"xqhc4WIQcOa1P2rns6bqkh","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3}],"body":[{"_type":"video","videoID":"6346433359112","disableAutoPlayVideo":false,"source":"brightcove","_key":"9d8e75fc0c7a","videoObject":{"_type":"videoDetails","videoTitle":"TKTK","thumbnail":{"_type":"image","asset":{"_ref":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","_type":"reference"}},"videoDuration":"PT2M50S","videoDescription":"TKTK"}},{"children":[{"_type":"span","marks":[],"text":"","_key":"8336eb7eb0b5"}],"_type":"block","style":"normal","_key":"eeca39a52bb5","markDefs":[]},{"_type":"block","style":"normal","_key":"a3971712bc30","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments. ","_key":"bd5d479f0bcc0"}]},{"style":"normal","_key":"53622320dd30","markDefs":[],"children":[{"_key":"eb9b7726052d","_type":"span","marks":[],"text":""}],"_type":"block"},{"style":"normal","_key":"29a405257e17","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"c83d48c82ca6"}],"_type":"block"},{"_key":"cf421b0dc23c","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Immunotherapies have been moving to earlier lines of therapy, both alone and in combination with chemotherapy. How might these treatment options and sequencing for lymphomas evolve in the near future based on the current landscape and pipeline?","_key":"48acaebefd8f0"}],"_type":"block","style":"normal"},{"_key":"d0230e8ab9c1","markDefs":[{"blank":true,"_type":"link","href":"https://www.swog.org/clinical-trials/s1826","_key":"9f0d703e4008","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"I think we know that these—the bispecifics in particular—are very combinable, and they're very active. So I think we will begin to see these being used more and more in clinical trials upfront in indolent lymphomas and then combining them with chemoimmunotherapy in aggressive lymphomas. I think that in Hodgkin lymphoma, we are likely, I didn't mention that before, but I think we're likely to see hopefully a publication from the ","_key":"5044705e7e400"},{"text":"S1826 trial","_key":"35414754055b","_type":"span","marks":["9f0d703e4008"]},{"_type":"span","marks":[],"text":" comparing brentuximab plus AVD [doxorubicin, vinblastine, and dacarbazine] to nivolumab plus AVD, and I think this is going to be a major game changer and change how we initially treat patients. So I think, you know, the goal here is to have long-term remissions in as many patients as possible up front, and then continue to develop drugs for those patients who fail, but it's really a very exciting space.","_key":"a84f2fac91bd"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"0998d797c01b","markDefs":[],"children":[{"text":"","_key":"605fddf13dcb","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"As we begin to see more longer-term data on newer generation BTK inhibitors, including data in CLL presented at ASH 2023, how do you see this area evolving in the near future?","_key":"2d2d35bf8c0b0"}],"_type":"block","style":"normal","_key":"e013c80c7bbf"},{"markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/cll","_key":"e08d593af00d"}],"children":[{"_type":"span","marks":[],"text":"We've really seen in the past year or 2, particularly in the US, we're not really using ibrutinib anymore. I mean, this was a real game changing drug that changed the prognosis of ","_key":"6c3fe93d5dcc0"},{"text":"CLL","_key":"16c8c9424ab4","_type":"span","marks":["e08d593af00d"]},{"_type":"span","marks":[],"text":". It was really dramatic when we first started using this drug, but we now know the next generations are better tolerated and very active. So now I think the question is the noncovalent BTK inhibitors like pirtobrutinib, which have even more favorable toxicity profiles than the the approved BTK inhibitors. So I think it's going to be very interesting to see how they compare in previously untreated patients, to know whether maybe we're going to be going to these noncovalent ones, as our initial frontline therapy—but we have some work to do is to compare those and really look at the data. But I think, overall, there's just been such incredible changes in how we manage this disease, I think maybe of any of the diseases we treat from when I started as a fellow and we were using chemoimmunotherapy and patients really didn't do well and had a lot of toxicity. And now, I think chemoimmunotherapy is very rarely even considered in CLL, even in our most favorable young patients who are mutated.","_key":"a99b2d4453a1"}],"_type":"block","style":"normal","_key":"2720c46da1a2"}],"contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"link":"/view/dr-ann-lacasce-discusses-potentially-game-changing-treatments-for-lymphoma","source":null,"title":"Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma","_id":"d32a4980-72bd-4a17-92d2-cef4c504d1c1","seoTag":["chronic lymphocytic leukemia","CLL"],"authorMapping":[{"url":{"current":"rose-mcnulty","_type":"slug"},"firstName":"Rose","_createdAt":"2020-10-06T12:46:55Z","_rev":"N7mKycgLbGtEq6btkTWlrd","_type":"author","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d","lastName":"McNulty","displayName":"Rose McNulty","biography":[{"style":"normal","_key":"3a2b873558e3","markDefs":[],"children":[{"_key":"123612bd9b2b0","_type":"span","marks":[],"text":"Rose is an associate editorial director at "},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"032c8e723210"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}],"_type":"block"},{"_key":"3a18842aed2b","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span","marks":["a1a427c7e90e"]},{"marks":[],"text":".","_key":"123612bd9b2b2","_type":"span"}],"_type":"block","style":"normal"}],"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"_updatedAt":"2024-06-13T13:26:39Z"}],"summary":"Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments. ","factCheckAuthorMapping":null,"_type":"article","thumbnail":{"asset":{"uploadId":"2ZKuk0RRNWrOqNOI7zJh7CkUYVgrd5Rc","_rev":"HQBcDLuXZwx0xKDEZjcIDm","sha1hash":"b3cf913180d16149af8afb7d582c55f389b097f4","path":"images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png","_createdAt":"2024-02-02T21:44:23Z","_updatedAt":"2024-02-02T21:44:23Z","assetId":"b3cf913180d16149af8afb7d582c55f389b097f4","_id":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","originalFilename":"Screen Shot 2024-02-02 at 4.33.23 PM.png","metadata":{"isOpaque":true,"blurHash":"McKK+it8~ptRwH_MWXjZj?M{t6ayV@oKbb","_type":"sanity.imageMetadata","palette":{"lightMuted":{"population":0.35,"background":"#ccc2ab","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"foreground":"#fff","title":"#fff","population":0,"background":"#e14b1e","_type":"sanity.imagePaletteSwatch"},"dominant":{"background":"#a57b67","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.29},"_type":"sanity.imagePalette","darkMuted":{"background":"#4e3e2b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.89},"muted":{"population":2.29,"background":"#a57b67","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#fcccb1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.01},"darkVibrant":{"title":"#fff","population":0.18,"background":"#1e0a04","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":882,"aspectRatio":1.764,"height":500}},"_type":"sanity.imageAsset","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png","size":635609,"extension":"png"}},"is_visible":true,"url":{"current":"dr-ann-lacasce-discusses-potentially-game-changing-treatments-for-lymphoma","_type":"slug"},"_createdAt":"2024-02-07T22:26:42Z","articleType":"Commentary","ExcludeFromPubMedXML":false,"_rev":"SQWl37udcADFBD7Ypg0seA","updatedOn":null},{"factCheckAuthorMapping":null,"_createdAt":"2024-02-02T21:44:51Z","ExcludeFromPubMedXML":false,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_id":"6b119582-0188-4c67-b70b-278a3e8b2cf9","link":"/view/dr-ann-lacasce-looks-to-the-year-ahead-in-the-lymphoma-treatment-landscape","_type":"article","_rev":"HQBcDLuXZwx0xKDEZjeUIh","_updatedAt":"2024-02-02T22:16:03Z","summary":"Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.","articleType":"Commentary","published":"2024-02-02T22:15:58.778Z","taxonomyMapping":[{"identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_type":"taxonomy","_rev":"xqhc4WIQcOa1P2rns6bqkh","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z"},{"video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z","_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f"},{"_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","_rev":"HexDiduX8d6Nqnq1ECriVF","name":"Clinical","summary":[{"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"text":"The ","_key":"e80c79954e08","_type":"span","marks":[]},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"f7d4dddf7edd","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}]}],"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"_createdAt":"2020-05-04T23:46:13Z","_type":"taxonomy","_id":"topic_clinical"},{"parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},"_type":"taxonomy","identifier":"providers","_createdAt":"2020-04-14T19:37:19Z","_rev":"sBk7YzjWMuBuhiatU3dlrp","name":"Providers","_id":"e6d00060-6fac-4bf6-9b44-4be71a23cb38","_updatedAt":"2020-04-14T19:37:19Z"}],"thumbnail":{"asset":{"_createdAt":"2024-02-02T21:44:23Z","_updatedAt":"2024-02-02T21:44:23Z","assetId":"b3cf913180d16149af8afb7d582c55f389b097f4","_id":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","originalFilename":"Screen Shot 2024-02-02 at 4.33.23 PM.png","metadata":{"isOpaque":true,"blurHash":"McKK+it8~ptRwH_MWXjZj?M{t6ayV@oKbb","_type":"sanity.imageMetadata","palette":{"vibrant":{"foreground":"#fff","title":"#fff","population":0,"background":"#e14b1e","_type":"sanity.imagePaletteSwatch"},"dominant":{"title":"#fff","population":2.29,"background":"#a57b67","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.89,"background":"#4e3e2b"},"muted":{"title":"#fff","population":2.29,"background":"#a57b67","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.01,"background":"#fcccb1"},"darkVibrant":{"title":"#fff","population":0.18,"background":"#1e0a04","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":0.35,"background":"#ccc2ab","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":882,"aspectRatio":1.764,"height":500}},"_type":"sanity.imageAsset","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png","size":635609,"extension":"png","uploadId":"2ZKuk0RRNWrOqNOI7zJh7CkUYVgrd5Rc","_rev":"HQBcDLuXZwx0xKDEZjcIDm","sha1hash":"b3cf913180d16149af8afb7d582c55f389b097f4","path":"images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png"}},"url":{"current":"dr-ann-lacasce-looks-to-the-year-ahead-in-the-lymphoma-treatment-landscape","_type":"slug"},"seoTag":["Ann LaCasce","lymphoma ","CLL","MZL","chronic lymphocytic leukemia","leukemia"],"is_visible":true,"authorMapping":[{"biography":[{"_key":"3a2b873558e3","markDefs":[],"children":[{"_key":"123612bd9b2b0","_type":"span","marks":[],"text":"Rose is an associate editorial director at "},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"032c8e723210"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span","marks":["a1a427c7e90e"]},{"marks":[],"text":".","_key":"123612bd9b2b2","_type":"span"}],"_type":"block","style":"normal","_key":"3a18842aed2b","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e"}]}],"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"_updatedAt":"2024-06-13T13:26:39Z","url":{"current":"rose-mcnulty","_type":"slug"},"firstName":"Rose","_createdAt":"2020-10-06T12:46:55Z","_rev":"N7mKycgLbGtEq6btkTWlrd","_type":"author","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d","lastName":"McNulty","displayName":"Rose McNulty"}],"body":[{"_type":"video","caption":"Ann LaCasce, MD, MMSc","videoID":"6346087277112","disableAutoPlayVideo":false,"source":"brightcove","_key":"72be2c25209d","videoObject":{"videoDuration":"PT2M02S","videoDescription":"Dr Ann LaCasce on the Year Ahead in Lymphoma Treatment","_type":"videoDetails","videoTitle":"Dr Ann LaCasce on the Year Ahead in Lymphoma Treatment","thumbnail":{"_type":"image","asset":{"_ref":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","_type":"reference"}}}},{"_key":"1fbc7fbbecf4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead. With novel therapies moving into earlier lines of therapy and additional potential approvals on the horizon, the future looks exciting in this dynamic space.","_key":"eaaa188d26710"}],"_type":"block","style":"normal"},{"style":"normal","_key":"e31c2a1fc632","markDefs":[],"children":[{"text":"","_key":"3bdcec4edca50","_type":"span","marks":[]}],"_type":"block"},{"style":"normal","_key":"29e628ce05aa","markDefs":[],"children":[{"text":"Transcript","_key":"4bd2a282e0890","_type":"span","marks":["strong","underline"]}],"_type":"block"},{"_type":"block","style":"normal","_key":"5c11c3d7f668","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Looking to the year ahead, what do you foresee shifting—or staying the same—in the lymphoma space?","_key":"1fccb5c1f198"}]},{"children":[{"_type":"span","marks":[],"text":"Last year was a very exciting year. The last couple of years, we've seen CAR [chimeric antigen receptor] T come into second line, and now we're seeing the bispecifics, which I think are a real game changer, both looking at clinical trials in frontline indolent lymphomas like follicular lymphoma and hopefully marginal zone lymphoma. I think we'll see clinical trials, I think you'll see in clinical practice that we're going to be using these very frequently in relapsed and refractory patients. For aggressive lymphomas, for patients who have recurred after CAR T, I think, again, we'll be seeing bispecifics, they will be incorporated upfront. There are a number of trials ongoing to try to improve on polatuzumab–R-CHP [cyclophosphamide, doxorubicin, and prednisone], which has become a standard therapy for patients with aggressive lymphoma, so I think that is exciting. [In] mantle cell lymphoma, we have pirtobrutinib now in the third line—again, waiting for the bispecifics to be approved in that setting. There's some ongoing trials testing that against standard of care. In CLL [","_key":"0698e18cc6490"},{"text":"chronic lymphocytic leukemia","_key":"346f936e2dc7","_type":"span","marks":["520cdc5dae79"]},{"_type":"span","marks":[],"text":"], we have lots of options, and I think now the real challenge in that field is to define which patients benefit from which therapy. Should we be combining multiple agents and doing time-limited, MRD [minimal residual disease]–driven therapy, or should we sequence things? Because we know these patients typically live a very long time. So I think more of the same, but very exciting. More of the same in terms of bispecifics and these novel agents, and just really trying to define and move them forward.","_key":"0331ae346a30"}],"_type":"block","style":"normal","_key":"0354b603a990","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/cll","_key":"520cdc5dae79"}]}],"title":"Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape","updatedOn":null,"source":null},{"taxonomyMapping":[{"_rev":"4KNeooMEhkvpk2GRi3EMaN","usedForRecommendations":false,"_id":"22582798-e9d8-4c8b-bae3-787c9f45236f","video":{"isTaxVideo":false},"_updatedAt":"2024-04-24T12:52:07Z","_type":"taxonomy","name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","identifier":"cll","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2023-12-14T19:13:51Z"},{"_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","_rev":"HexDiduX8d6Nqnq1ECriVF","name":"Clinical","summary":[{"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"text":"The ","_key":"e80c79954e08","_type":"span","marks":[]},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"f7d4dddf7edd","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}]}],"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"_createdAt":"2020-05-04T23:46:13Z","_type":"taxonomy","_id":"topic_clinical"},{"identifier":"providers","_createdAt":"2020-04-14T19:37:19Z","_rev":"sBk7YzjWMuBuhiatU3dlrp","name":"Providers","_id":"e6d00060-6fac-4bf6-9b44-4be71a23cb38","_updatedAt":"2020-04-14T19:37:19Z","parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},"_type":"taxonomy"},{"_rev":"xqhc4WIQcOa1P2rns6bqkh","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_type":"taxonomy"}],"title":"Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL","_type":"article","link":"/view/dr-jennifer-brown-discusses-zanubrutinib-uptake-in-cll-sll","thumbnail":{"asset":{"uploadId":"u2IHden3gI0uMGYltJeNowl87I2jG6td","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/ecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png","size":5376725,"assetId":"ecb06c2560fa1130e5deca7f85f8dc903e1c3136","originalFilename":"Screen Shot 2023-06-09 at 6.06.50 PM.png","_type":"sanity.imageAsset","_id":"image-ecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623-png","_updatedAt":"2023-06-09T22:52:13Z","extension":"png","_rev":"TMxEdWkpP22cqhfBO3ZXdN","_createdAt":"2023-06-09T22:52:13Z","metadata":{"isOpaque":true,"blurHash":"MQJvjMB@o~q?lB~C-hoIIptR^hRQaebvr=","_type":"sanity.imageMetadata","palette":{"darkMuted":{"population":0.04,"background":"#6e6a7a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"population":6.94,"background":"#7a6654","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"foreground":"#000","title":"#fff","population":8.66,"background":"#90d3ef","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":1.12,"background":"#2d535f","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#a4c7ce","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.15},"vibrant":{"foreground":"#000","title":"#fff","population":9.6,"background":"#5fc0e9","_type":"sanity.imagePaletteSwatch"},"dominant":{"population":9.6,"background":"#5fc0e9","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7744916820702403,"height":1623,"_type":"sanity.imageDimensions","width":2880}},"sha1hash":"ecb06c2560fa1130e5deca7f85f8dc903e1c3136","path":"images/0vv8moc6/ajmc/ecb06c2560fa1130e5deca7f85f8dc903e1c3136-2880x1623.png"}},"is_visible":true,"_rev":"NuKmNEJEtqI7CGtQXpZnMH","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"articleType":"Commentary","body":[{"_key":"454c6f548325","videoObject":{"videoDescription":"Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL","_type":"videoDetails","videoTitle":"Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL","thumbnail":{"_type":"image","asset":{"_ref":"image-be1f640c159ae63f0352b4b8ab41c35de15fd2dd-2880x1623-jpg","_type":"reference"}},"videoDuration":"PT1M33S"},"_type":"video","videoID":"6335446005112","disableAutoPlayVideo":false,"source":"brightcove"},{"markDefs":[{"_key":"36a4a798d32f","nofollow":true,"blank":true,"_type":"link","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma"},{"nofollow":true,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/leukemia-lymphoma","_key":"5979d47d7ad2"}],"children":[{"text":"Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center and an institute physician at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib in chronic lymphocytic ","_key":"7d039b77d3060","_type":"span","marks":[]},{"_type":"span","marks":["5979d47d7ad2"],"text":"leukemia","_key":"1a0e9ba5d000"},{"_type":"span","marks":[],"text":" (CLL) and small lymphocytic leukemia (SLL) following positive ALPINE trial (NCT03734016) results and the drug's ","_key":"e02bc0ab818e"},{"_type":"span","marks":["36a4a798d32f"],"text":"full FDA approval ","_key":"b61bcf5fb2d4"},{"text":"for CLL and SLL in January 2023.","_key":"fce5a34657f9","_type":"span","marks":[]},{"_type":"span","marks":["superscript"],"text":"1,2","_key":"c2384f1f7907"}],"_type":"block","style":"normal","_key":"839d95972028"},{"children":[{"_type":"span","marks":[],"text":"","_key":"3d56018899cd"}],"_type":"block","style":"normal","_key":"d8b2c3bf3fb0","markDefs":[]},{"_key":"f472557eada2","markDefs":[],"children":[{"_key":"5c04d3e7d3db","_type":"span","marks":["strong","underline"],"text":"Transcript "}],"_type":"block","style":"normal"},{"children":[{"text":"Since the presentation of the ALPINE trial results in December 2023, what is your sense of uptake of zanubrutinib in first-line CLL/SLL? ","_key":"7b69bda7512f0","_type":"span","marks":["strong"]}],"_type":"block","style":"normal","_key":"c5a5e5f39e57","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think it's slow but gradual and increasing, has been my experience, at least amongst academics and people who attend talks or who I interact with around the country. There has been less experience with zanubrutinib to date compared to acalabrutinib, and so many people are still using acalabrutinib and starting to dabble in zanubrutinib and moving over gradually.","_key":"5bd656463d750"}],"_type":"block","style":"normal","_key":"ff8f4493b4aa"},{"_type":"block","style":"normal","_key":"a58f1ef304fa","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"42b2cc380ecd0"}]},{"style":"normal","_key":"2abbb567fded","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Are patients encountering any barriers to testing needed for TP53 or 17p deletion? ","_key":"be95a9ecd60c"}],"_type":"block"},{"style":"normal","_key":"97cd91b1c586","markDefs":[],"children":[{"text":"No, I haven't really experienced any cost-related barriers, for example. We've been working on this for 15 years, and I think we have largely now reached a point where most patients in the community are at least getting their fish testing, [and] that includes 17p. There's still some lack of full awareness about doing TP53 mutation testing, as well. But we continue to discuss that, and it's certainly available.","_key":"a26eb9440f730","_type":"span","marks":[]}],"_type":"block"},{"markDefs":[],"children":[{"text":"","_key":"73b319685e8b0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"83bc6148ef9f"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"In December, you said you didn’t see a reason to start patients on ibrutinib given the benefits seen in zanubrutinib. Do you hear from clinicians who have any issues access to zanubrutinib?","_key":"d83804c306ea"}],"_type":"block","style":"normal","_key":"16ca091ec95b"},{"children":[{"_type":"span","marks":[],"text":"No, I haven't heard about any issues with accessing zanubrutinib. It is now fully approved in the United States for CLL in any line of therapy, and so we haven't had trouble getting it. Similarly, we don't have trouble getting acalabrutinib.","_key":"98ca7451a8af0"}],"_type":"block","style":"normal","_key":"dfc098a716f1","markDefs":[]},{"children":[{"_key":"aca7f8140121","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"42a35b8b6e67","markDefs":[]},{"_key":"8f6fdf7427ac","markDefs":[],"children":[{"marks":["strong"],"text":"References","_key":"b43f16c80b27","_type":"span"}],"_type":"block","style":"normal"},{"style":"normal","_key":"78584e4d6831","markDefs":[],"children":[{"marks":[],"text":"1. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. ","_key":"310e65c7df0f","_type":"span"},{"_type":"span","marks":["em"],"text":"N Eng J Med.","_key":"d550fbae5364"},{"_type":"span","marks":[],"text":" 2023; 388:319-332. doi:10.1056/NEJMoa2211582\n","_key":"5e42ab3499e0"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"2. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. News release. FDA. January 19, 2023. Accessed August 23, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma ","_key":"b56527beb375"}],"_type":"block","style":"normal","_key":"281ad863e8a7","markDefs":[]}],"factCheckAuthorMapping":null,"url":{"current":"dr-jennifer-brown-discusses-zanubrutinib-uptake-in-cll-sll","_type":"slug"},"published":"2023-08-23T19:42:53.787Z","seoTag":["CLL","SLL","leukemia","zanubrutinib"],"updatedOn":null,"summary":"Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).","_createdAt":"2023-08-23T19:41:49Z","_id":"9393f661-72c7-41e6-be93-8216015525a1","authorMapping":[{"_id":"author_23eb58ee573d6006f4342daadc88b50b","_updatedAt":"2024-08-07T15:46:57Z","url":{"current":"skylar-jeremias","_type":"slug"},"profileThumbnail":{"_type":"mainImage","asset":{"_ref":"image-1c1b3fe8f75d7099cec82cef128b20d15b4a4497-849x755-jpg","_type":"reference"}},"displayName":"Skylar Jeremias","_createdAt":"2020-05-05T10:50:10Z","_type":"author","biography":[{"style":"normal","_key":"f73a10e9267d","markDefs":[],"children":[{"_key":"6fba991875ae0","_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders."}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_key":"6fba991875ae1","_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal","_key":"95aad26356ef","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true}]}],"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"_rev":"4vyIlJfwMwqB8NbLEufc9y"},{"lastName":"McNulty","displayName":"Rose McNulty","biography":[{"_type":"block","style":"normal","_key":"3a2b873558e3","markDefs":[],"children":[{"_key":"123612bd9b2b0","_type":"span","marks":[],"text":"Rose is an associate editorial director at "},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"032c8e723210"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}]},{"style":"normal","_key":"3a18842aed2b","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span","marks":["a1a427c7e90e"]},{"marks":[],"text":".","_key":"123612bd9b2b2","_type":"span"}],"_type":"block"}],"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"_updatedAt":"2024-06-13T13:26:39Z","url":{"current":"rose-mcnulty","_type":"slug"},"firstName":"Rose","_createdAt":"2020-10-06T12:46:55Z","_rev":"N7mKycgLbGtEq6btkTWlrd","_type":"author","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d"}],"source":null,"_updatedAt":"2024-01-02T15:50:01Z","ExcludeFromPubMedXML":false}],"topArticlesData":[{"_id":"7212808d-ba80-4a75-bf96-138f9453d147","title":"Immune Microenvironment a Key Target in CLL","published":"2025-04-08T14:19:10.471Z","updatedOn":null,"source":null,"url":"immune-microenvironment-a-key-target-in-cll","thumbnail":{"_type":"mainImage","alt":"Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com","caption":"Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com","asset":{"_ref":"image-7b9dd275b35617925e2b92ad55dfd2cf3877df7c-1920x1280-jpg","_type":"reference"}},"summary":"A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). ","authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"factCheckAuthors":null},{"_id":"b909d9d6-68de-498d-b031-25c4f645c729","title":"Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy","thumbnail":{"_type":"mainImage","alt":"Patient visit with pharmacist | Image credit : Chinnapong – stock.adobe.com","asset":{"_ref":"image-e7e3790d75cf4ac814dcc6a9237c379fd03100b4-4766x2681-jpg","_type":"reference"}},"summary":"New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.","published":"2025-04-03T19:15:53.110Z","source":null,"factCheckAuthors":null,"url":"pharmacist-led-model-reduces-tumor-lysis-risk-in-cll-venetoclax-therapy","updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}]},{"title":"In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib","url":"in-cll-zanubrutinib-shows-better-safety-profile-than-ibrutinib","summary":"A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.","published":"2025-03-20T12:57:00.000Z","source":null,"factCheckAuthors":null,"_id":"31e40aed-b164-4a53-8caf-acb52fea89a7","thumbnail":{"_type":"mainImage","alt":"Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com","asset":{"_ref":"image-de33354bfc2652c55294b5567eaeb5f1e32dad12-5000x3337-jpg","_type":"reference"}},"updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}]},{"published":"2025-03-19T15:04:00.000Z","updatedOn":null,"source":null,"factCheckAuthors":null,"_id":"0a04a08f-b7b2-467d-8d7d-7cda6c6c0d96","thumbnail":{"_type":"mainImage","alt":"CLL | Image credit: jarun011 – stock.adobe.com","asset":{"_ref":"image-93a174337b137846bb88ca7522afba78209a16dd-6000x4000-jpg","_type":"reference"}},"summary":"Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes. ","authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"title":"Newer CLL Therapies Show Superior Long-Term Disease Control","url":"newer-cll-therapies-show-superior-long-term-disease-control"},{"title":"Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL","url":"modulating-cholesterol-metabolism-could-open-therapeutic-pathways-in-cll","summary":"Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.","published":"2025-03-11T21:18:44.401Z","factCheckAuthors":null,"_id":"771849c8-7864-44ff-bb7b-0edc7299b6be","thumbnail":{"_type":"mainImage","alt":"Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com","caption":"Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com","asset":{"_ref":"image-e83905430236d6800bb84d2a61fb00c3bf27af05-1037x673-jpg","_type":"reference"}},"updatedOn":null,"source":null,"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}]}],"features":[],"cmeData":{"msg":"Missing Keywords","fail":true},"videoData":{}},"queryString":{"slug":["compendium","cll"]}},"host":"www.ajmc.com"},"__N_SSP":true},"page":"/[...slug]","query":{"slug":["compendium","cll"]},"buildId":"br828rKgKfSPtzyqAf35K","isFallback":false,"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>